Hi team FDA-

Sorry for the late email. From my conversations with FDA officials, it seems like [b](5) [b]

Thanks for all your hard work!!

Devin

Exclusive: U.S. coronavirus testing threatened by shortage of critical lab materials

By David Lim, Brianna Ehley

03/10/2020 06:46 PM EDT

A looming shortage in lab materials is threatening to delay coronavirus test results and cause officials to undercount the number of Americans with the virus.

The slow pace of coronavirus testing has created a major gap in the U.S. public health response. The latest problem involves an inability to prepare samples for testing, creating uncertainties in how long it will take to get results.

CDC Director Robert Redfield told POLITICO on Tuesday that he is not confident that U.S. labs have an adequate stock of the supplies used to extract genetic material from any virus in a patient’s sample — a critical step in coronavirus testing.

“The availability of those reagents is obviously being looked at,” he said, referring to the chemicals used for preparing samples. “I’m confident of the actual test that we have, but as people begin to operationalize the test, they realize there’s other things they need to do the test.”

The coronavirus task force convened by the White House is also aware of the shortages, and one official said members are working on it.

The growing scarcity of these “RNA extraction” kits is the latest trouble for U.S. labs, which have struggled to implement widespread coronavirus testing in the seven weeks since the country diagnosed its first case. Epidemiologists and public health officials say that the delayed rollout, caused in part by a botched CDC test, has masked the scope of the U.S. outbreak and hobbled efforts to limit it.

If enough processing kits aren’t available, the risk that testing will be disrupted is “huge,” said Michael Mina, associate medical director of molecular diagnostics at
Brigham and Women's Hospital in Boston.

“RNA extraction is the first step in being able to perform” a coronavirus test, he said. “If we cannot perform this step, the [coronavirus] test cannot be performed.”

Qiagen, a major supplier of the kits, confirmed that its product is backordered due to “the extraordinary pace” at which the world has increased coronavirus testing over the last few weeks.

Public health labs across the U.S. have tested more than 5,000 people, according to the Trump administration. HHS Secretary Alex Azar told lawmakers on Tuesday that U.S. labs’ capacity could grow to 10,000-20,000 people per day by the end of the week.

“Increased demand for testing has the potential to exhaust supplies needed to perform the test itself,” said Robin Patel, president of the American Society for Microbiology. That would limit the testing capacity of public health, hospital and commercial labs alike, she added.

Complicating the situation, most labs have been running at least two tests per patient — although that could soon change. The CDC issued interim guidelines on Monday that minimize the number of tests required for a diagnosis. The agency says labs can combine a patient’s nose and throat samples into one test, a move experts say will cut in half the amount of supplies used to test each person.

But Redfield said he doesn’t know how the agency would deal with any scarcity of RNA extraction kits and reagents that arise. “I don’t know the answer to that question,” he said when asked how the CDC would handle such a situation — adding that he is hopeful “there will be mechanisms between multiple manufacturers to correct” it.

Mandy Cohen, North Carolina’s secretary of health, said that a shortage of extraction kits and other chemicals had hampered testing in her state. “Folks were saying, ‘We are sending you the [test] kits,’ and I don’t think they understood at first what exact part of the supply chain we needed,” she said. “We needed extraction kits.”

An FDA spokesperson said that the agency is contacting labs that are testing for the coronavirus “to understand their supply issues and assist where we can.”

The FDA has also approved a change to the CDC diagnostic test that allows labs to switch from Qiagen’s RNA extraction method to another manufactured by Roche, says Denny Russell, who leads the coronavirus response at Washington state’s public health lab. But getting his lab ready to use the Roche method could take a week in part because technicians will need training to use it.

Commercial labs, which have recently started running coronavirus tests, have not experienced any supply shortages, according to a spokesperson for the American Clinical Laboratory Association.

In the meantime, Qiagen has told customers that it may not be able to fill large
standing orders, because it is trying to provide smaller numbers of kits to as many labs as possible, said spokesperson Robert Reitze. The company is ramping up production of RNA extraction kits at manufacturing sites in Hilden, Germany; Barcelona, Spain; and Germantown, Md.

Nancy Cook and Dan Goldberg contributed to this report.

To view online:

You received this POLITICO Pro content because your customized settings include: Alex Azar. To change your alert settings, please go to

This email alert has been sent for the exclusive use of POLITICO Pro subscriber, judy.stecker@hhs.gov. Forwarding or reproducing the alert without the express, written permission of POLITICO Pro is a violation of copyright law and the POLITICO Pro subscription agreement.

Copyright © 2020 by POLITICO LLC. To subscribe to Pro, please go to politicopro.com.
Hi everyone-

It's been a busy week, especially the last couple of days. We appreciate everyone's patience, especially [REDACTED]. I also want to thank everyone for (b)(5).

On a related note, starting on Monday, the schedule for Task Force related meetings is shifting a bit. This means that Katie and I, and other members of the team, will be harder to get ahold of from the hours of 9:00 am – 11:30 am (instead of 4:00 pm – 6:30 pm). Please consider this when thinking about reviews/clearances. We will also adjust the morning call to a time TBD.

As always, please feel free to call me whenever you have an issue, think something can be done better, or have an idea. We appreciate hearing from you.

Thank you for all you are doing!

Devin

Devin M. O'Malley
202-881-8964
From today’s NICCL call (full notes attached):

(b)(5)

From: April Brubach <April.Brubach@fda.hhs.gov>
Sent: Friday, March 27, 2020 1:22 PM
To: 2019-nCoV FDA IMG JIC Leadership <2019-nCoV-FDA-IMG-JIC-Leadership@fda.hhs.gov>
Subject: NICCL Meeting Call-Out 3.27.2020

(b)(5)

From: FEMA-ESF15-Coordination <FEMA-ESF15-Coordination@fema.dhs.gov>
Sent: Friday, March 27, 2020 1:07 PM
To: 2019-nCoV FDA IMG JIC Leadership <2019-nCoV-FDA-IMG-JIC-Leadership@fda.hhs.gov>; Clark, Alaina <alaina.clark@csa.dhs.gov>; Glenn, Amanda <Amanda.Glenn@csa.dhs.gov>; Palczewski, Andrew (OS) <Andrew.Palczewski@hhs.gov>; ALFONSO-ROYALS, ANGELICA <ANGELICA.ALFONSO-ROYALS@hhs.dhs.gov>; Trevino, Anna <anna.trevino@fema.dhs.gov>; Tatem, Anne (OS) <Anne.Tatem@hhs.gov>; CERAOL, ANTHONY <ANTHONY.CERAOL@hhs.dhs.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; BOZA-HOLMAN, SOFIA <SOFIA.BOZA-HOLMAN@hhs.dhs.gov>; McPherson, Brendan <Brendan.McPherson@hhs.dhs.gov>; Glauser, Brittany (OS) <Brittany.Glauser@hhs.gov>; Brown, Lynn <lynn.brown@fema.dhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; Daniels,
Good afternoon,

Attached is the NICCL Summary for today’s call. Thank you for your agency’s participation.

Best,

Alexa Fortuna
Emergency Management Specialist | FEMA ESF 15 Coordination | Office of External Affairs
Mobile: (6)
Hey guys-

(b)(5) - Dr. Hahn mentioned the name of a woman at FDA that would walk the reporter through some of the technical aspects, but I forget her name. Could you get this done tomorrow for online (and the Monday print)?

(b)(5)

Thanks!

Devin

Devin M. O’Malley
From: O'Malley, Devin M. EOP/OVP
To: Caccomo, Stephanie; Hall, Bill (OS); Miller, Katie R. EOP/OVP; Fetalvo, Ninio J. EOP/OVP
Cc: Murphy, Ryan (OS); Oakley, Caitlin B (OS); McKeogh, Katherine (OS); Caliguiri, Laura; Felberbaum, Michael
Subject: RE: FDA release on chloroquine
Date: Thursday, March 19, 2020 2:09:29 PM
Attachments: impoe01.pdf

(b)(5)

From: Caccomo, Stephanie <Stephanie.Caccomo@fda.hhs.gov>
Sent: Thursday, March 19, 2020 2:01 PM
To: O'Malley, Devin M. EOP/OVP (b) (6)@ovp.eop.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP ((b) (6)@ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP (b) (6)@ovp.eop.gov>
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>
Subject: RE: FDA release on chloroquine

(b)(5)

Stephanie Caccomo
Press Officer
Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.448.1956
Cell: 240.762.8873
stephanie.caccomo@fda.hhs.gov

From: O’Malley, Devin M. EOP/OVP (b) (6)@ovp.eop.gov>
Date: March 19, 2020 at 1:53:15 PM EDT
To: Caccomo, Stephanie <Stephanie.Caccomo@fda.hhs.gov>, Hall, Bill (OS) (b) (6)@hhs.gov, Miller, Katie R. EOP/OVP ((b) (6)@ovp.eop.gov), Fetalvo, Ninio J. EOP/OVP (b) (6)@ovp.eop.gov>
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>, Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>, McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>, Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>, Felberbaum, Michael
From: Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>
Sent: Thursday, March 19, 2020 1:37 PM
To: O'Malley, Devin M. EOP/OVP <b>(6) @ovp.eop.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP <b>(b) (6) ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP <b>(b) (6) @ovp.eop.gov>
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>

Subject: RE: FDA release on chloroquine

Will do. (b) (5) can we issue?

---

Stephanie Caccamo
Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.448.1056
Cell: 240.762.8873
stephanie.caccamo@fda.hhs.gov

---

From: O'Malley, Devin M. EOP/OVP <b>(6) @ovp.eop.gov>
Sent: Thursday, March 19, 2020 1:35 PM
To: Hall, Bill (OS) <b>(6) @hhs.gov>; Miller, Katie R. EOP/OVP <b>(b) (6) ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP <b>(b) (6) @ovp.eop.gov>
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>

Subject: RE: FDA release on chloroquine

---

From: Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>
Sent: Thursday, March 19, 2020 1:24 PM
To: O'Malley, Devin M. EOP/OVP <b>(6) @ovp.eop.gov>; Miller, Katie R. EOP/OVP <b>(b) (6) ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP <b>(b) (6) @ovp.eop.gov>
Cc: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B. (OS/ASPA)
All...FDA is ready to issue this. Please let us know if we have the green light. Bill
Sent from my iPhone

On Mar 29, 2020, at 1:34 PM, Caccomo, Stephanie
<Stephanie.Caccomo@fda.hhs.gov> wrote:

Hi folks—

Flagging for you (b) (5):

Response:

Stephanie Caccomo
Press Officer
Adding the appropriate hhs Comms components to make sure they follow up with policy offices to start promoting this

Sent from my iPhone

On Mar 21, 2020, at 2:44 PM, McGowan, Robert (Kyle) (CDC/OD/OCS) <omc2@cdc.gov> wrote:

Thank you. We will post it shortly.

Get Outlook for iOS

My understanding is that our approval was the final outstanding approval, so if that’s correct then yes.

Is the CDC cleared to post this on our website?
Get Outlook for iOS

From: O'Malley, Devin M. EOP/OVP (b) (6) ********@ovp.eop.gov
Sent: Saturday, March 21, 2020 2:38:18 PM
To: McGuffee, Tyler A. EOP/OVP (b) (6) ********@ovp.eop.gov; Hahn, Stephen (b) (6) fda.hhs.gov; Birx, Deborah L. EOP/NSC (b) (6) nsc.eop.gov; Fauci, Anthony (NIH/NIAID) (b) (6) niaid.nih.gov; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP (b) (6) ********@ovp.eop.gov
Cc: Rom, Colin (FDA/OC) <Colin.Rom@fda.hhs.gov>; McGowan, Robert (Kyle) (CDC/OD/OC) <omc2@cdc.gov>; Lane, Cliff (NIH/NIAID) [E] <CLANE@niaid.nih.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Good. Just want to make sure that the appropriate comms teams know that we want to see the content that promotes this before it goes out. Thanks!

From: McGuffee, Tyler A. EOP/OVP (b) (6) ********@ovp.eop.gov
Sent: Saturday, March 21, 2020 2:26 PM
To: O'Malley, Devin M. EOP/OVP (b) (6) ********@ovp.eop.gov; Hahn, Stephen (b) (6) fda.hhs.gov; Birx, Deborah L. EOP/NSC (b) (6) nsc.eop.gov; Fauci, Anthony S (NIH) (b) (6) niaid.nih.gov; Redfield, Robert R (CDC) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP (b) (6) ********@ovp.eop.gov
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>; McGowan, Robert K (CDC) <omc2@cdc.gov>; Lane, Henry C (NIH) <clane@niaid.nih.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Message from Dr. Stephen Hahn to all:

Attached is the FINAL v9. Dr. Hahn and Devin O’Malley just met in person and made the following changes:

(b) (5)

Pushing this back to OVP Comms for final affirmative clearance. Please advise when approved by OVP Comms we are ready for OVP comms to coordinate with Dr. Redfield, CDC communications and others on publication.
Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D.
Office of the White House Coronavirus Response Coordinator
Associate Advisor to the Office of the Vice President
C: (202) 881-8195 [no text]

---

From: O'Malley, Devin M. EOP/OVP <b>(6) **********@ovp.eop.gov>
Sent: Saturday, March 21, 2020 1:59 PM
To: McGuffee, Tyler A. EOP/OVP <b>(6) **********@ovp.eop.gov>; Hahn, Stephen <b>(6) fda.hhs.gov>; Birx, Deborah L. EOP/NSC <b>(6) nsc.eop.gov>; Fauci, Anthony S (NIH) <b>(6) niaid.nih.gov>; Redfield, Robert R (CDC) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP <b>(6)**********@ovp.eop.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>; McGowan, Robert K (CDC) <omc2@cdc.gov>; Lane, Henry C (NIH) <clane@niaid.nih.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Some thoughts attached <b>(5)

---

From: McGuffee, Tyler A. EOP/OVP <b>(6) **********@ovp.eop.gov>
Sent: Saturday, March 21, 2020 1:14 PM
To: Hahn, Stephen <b>(6) fda.hhs.gov>; Birx, Deborah L. EOP/NSC <b>(6) nsc.eop.gov>; Fauci, Anthony S (NIH) <b>(6) niaid.nih.gov>; Redfield, Robert R (CDC) <olx1@cdc.gov>; Miller, Katie R. EOP/OVP <b>(6)**********@ovp.eop.gov>; O'Malley, Devin M. EOP/OVP <b>(6)**********@ovp.eop.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>; McGowan, Robert K (CDC) <omc2@cdc.gov>; Lane, Henry C (NIH) <clane@niaid.nih.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: RE: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

Message from Dr. Stephen Hahn to OVP Comms:

Attached is the FINAL information for clinicians regarding treatment of COVID-19 patients. This has been reviewed and approved by the principals in the “To:” line. When approved by OVP Comms we are ready for you to coordinate with Dr. Redfield, CDC communications and others on publication.

Sincerely,
TAM
From: Hahn, Stephen <fda.hhs.gov>
Sent: Saturday, March 21, 2020 12:48 PM
To: Birx, Deborah L. EOP/NSC <Lane, Henry C (NIH)
clare@niaid.nih.gov>; McGuffee, Tyler A. EOP/OVP
<ovp.eop.gov>; Fauci, Anthony S (NIH) <naiad.nih.gov>; Redfield, Robert R (CDC) <olx1@cdc.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>; McGowan, Robert K (CDC) <omc2@cdc.gov>
Subject: Re: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

From: Birx, Deborah L. EOP/NSC
Date: March 21, 2020 at 12:40:16 PM EDT
To: Lane, Henry C (NIH) <clare@niaid.nih.gov>, McGuffee, Tyler A. EOP/OVP
<ovp.eop.gov>, Fauci, Anthony S (NIH) <naiad.nih.gov>, Hahn, Stephen <fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>, McGowan, Robert K (CDC) <omc2@cdc.gov>
Subject: Re: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

From: "Lane, Cliff [NIH/NIAID] [E]" <clare@niaid.nih.gov>
Date: Saturday, March 21, 2020 at 12:31 PM
Cc: "Rom, Colin (FDA/OC)" <Colin.Rom@fda.hhs.gov>, "McGowan, Robert (Kyle) (CDC/OD/OCS)" <omc2@cdc.gov>
Re: NEEDS FINAL AFFIRMATIVE CLEARANCE RE: Treatment Document

I realize I am on the cc line, however I have three comments and have tracked suggestions:

Cliff Lane

From: "McGuffee, Tyler A. EOP/OVP" <b>(6) ovp.eop.gov>
Date: Saturday, March 21, 2020 at 11:33 AM
To: Anthony Fauci <b>(6) niaid.nih.gov>, "Hahn, Stephen" <b>(6) fda.hhs.gov>, "Birx, Deborah L. EOP/NSC" <b>(6) hsc.eop.gov>, "Redfield, Robert R. (CDC/OD)" <olx1@cdc.gov>
Cc: "Lane, Cliff [NIH/NIAID] [E]" <clane@niaid.nih.gov>, "Rom, Colin (FDA/OC)" <Colin.Rom@fda.hhs.gov>, "McGowan, Robert (K) (CDC/OD/OC)
Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D.
Office of the White House Coronavirus Response Coordinator
Associate Advisor to the Office of the Vice President
C: (202) 881-8195 [no text]
Tony,

Looks like we - . The group wants to make some more edits and then send out this evening for review. We would like to meet up prior to or after the task force meeting tomorrow. Sound OK?

Steve

Sent from my iPad

---

On Mar 20, 2020, at 7:06 PM, Hahn, Stephen <fda.hhs.gov> wrote:

I have a couple of comments

I'll await for other comments.

Thanks

Steve

Sent from my iPad

---

On Mar 20, 2020, at 6:45 PM, Fauci, Anthony (NIH/NIAID) <niaid.nih.gov> wrote:

Team:
As per my discussion with Steve a few minutes ago, I have made some changes in the document. First, I stated what the purpose of the document is in the introduction. I have removed granular material that I do not feel contributes to our purpose. I addition, I have not checked out the references with the statements that were made. I am attaching a tracked version of the document that was your FINAL as well as a clean copy with all of the changes accepted. Please take a look and Steve said that he would like to set up a quick call to discuss after you have had a look. I am very sorry to come in with these changes at this late point, but I really did not get a chance to have a good look at the document as I was in a car.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

<dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked changes showing.docx>
<dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked Clean copy.docx>
From: Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>
Sent: Friday, March 13, 2020 7:48 AM
To: O'Malley, Devin M. EOP/OVP; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Cc: Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Oakley, Caitlin B. (OS/ASPA) <Caitlin.Oakley@HHS.GOV>; Miller, Katie R. EOP/OVP <Katie.R.Miller@EOP.OVP.GOV>; Love, Kelly A. EOP/OVP
Subject: Re: Releases

We are having a telebriefing at 1pm today — Undoubtedly we will be asked about this today and will be ready to respond on the telebriefing.

Take care,
Kate

Get Outlook for iOS

From: O'Malley, Devin M. EOP/OVP <Devin.O'Malley@EOP.OVP.GOV>
Sent: Friday, March 13, 2020 7:37:44 AM
To: Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>; Caliguiri, Laura (FDA/OC) <Laura.Caliguiri@fda.hhs.gov>; Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>
Cc: Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; Galatas, Kate (CDC/OD/OADC) <kkg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Oakley, Caitlin B. (OS/ASPA) <Caitlin.Oakley@HHS.GOV>; Miller, Katie R. EOP/OVP <Katie.R.Miller@EOP.OVP.GOV>; Love, Kelly A. EOP/OVP
Subject: RE: Releases

Is anyone from the CDC available to provide an update on their end? I can wait to send out our release if they have something to include.
Hi all-

Here is the plan:

(b) (5)

Thanks for your coordination on this; I think it will prove to be more effective.

Devin
(b) (5)
Hi Devin—
Attaching our draft release. These actions happened this evening (within the last hour), so they can be discussed in AM TV programs. Please feel free to call if you need any walk through on any of this.

Stephanie Caccomo
Press Officer
Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: 240.762.8873
stephanie.caccomo@fda.hhs.gov

From: O'Malley, Devin M. EOP/OVP <b>6</b> @ovp.eop.gov>
Sent: Thursday, March 12, 2020 10:56 PM
To: Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>
Cc: Hall, Bill (OS) <bill.hall@hhs.gov>; Galatas, Kate (CDC) <kkg2@cdc.gov>; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Caccomo, Stephanie <Stephanie.Caccomo@fda.hhs.gov>
Subject: RE: Releases

Checking in on where folks are at with their releases.

(b)(5)

From: Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>
Sent: Thursday, March 12, 2020 8:32 PM
To: O'Malley, Devin M. EOP/OVP <b>6</b> @ovp.eop.gov; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>
Cc: Hall, Bill (OS) <bill.hall@hhs.gov>; Galatas, Kate (CDC) <kkg2@cdc.gov>; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Caccomo, Stephanie <Stephanie.Caccomo@fda.hhs.gov>
Subject: RE: Releases

Here is where we are: We are buttoning up on our end, going through our clearance. (b)(5) ···

From: O'Malley, Devin M. EOP/OVP <b>6</b> @ovp.eop.gov
Sent: Thursday, March 12, 2020 8:27 PM
Thank you. Put NIH on by accident. Taking them off now.

On Mar 12, 2020, at 8:20 PM, O'Malley, Devin M. EOP/OVP ovp.eop.gov wrote:

Hi CDC and FDA-

I've heard from each of you separately that you will have testing-related press releases tomorrow.

Can you let me know how the drafting of materials is going?

Thanks!

Devin

Devin M. O’Malley
202-881-8964
Hi all-

You are receiving this email because you have a principal that is on the Task Force or frequently attends its meetings. [b] (5)

As you may know, we are working on meetings with nurses, physicians, and the tourism industry, so having a sense of what you all may be planning could help us build out a more robust communications plan around those meetings.

Thanks!

Devin

Devin M. O’Malley
202-881-8964
Hey Folks – I hope everyone is having a good Friday afternoon. I wanted to send a quick update on the process here. Below are updated lists of WH and OVP folks who need to be on the clearance emails you send up to the WH/OVP. Also, please make sure that you receive affirmative WH approval in addition to OVP approval before proceeding.

Appreciate everyone’s assistance and great work. Please let me know if you’ve any questions.

Thanks,

Ryan

For material and print interview clearances –

Devin O’Malley (@ovp.eop.gov)

Katie Miller (ovp.eop.gov)

Hannah MacInnis (@ovp.eop.gov)

Alyssa Farah (@who.eop.gov)

Kayleigh Gilmartin (@who.eop.gov)

Hogan Gidley (@who.eop.gov)

Brittany Yanick (@who.eop.gov)

Tori Syrek (@who.eop.gov)

Judd Deere (@who.eop.gov)

For broadcast interview clearances –

Devin O’Malley

Katie Miller

Hannah MacInnis

Alyssa Farah

Kayleigh Gilmartin
Just a quick follow-up here to clarify on this: there’s not been a change in the COVID-19
clearance process. Stuff still needs to be flagged for ASPA and/or approved by ASPA before going up to WH/OVP. The email below was simply to update you all on who at WH/OVP will need to receive the clearance emails when they go up to WH/OVP. The processes we’ve been following remain in place. Please call with any questions.

From: Murphy, Ryan (OS/ASPA)
Sent: Monday, May 11, 2020 12:42 PM
To: Lemar, Naweed (OS/ASPA) <Naweed.Lemar@hhs.gov>; Michael Robinson (michael.robinson@hhs.gov) <michael.robinson@hhs.gov>; Simone Myrie (Simone.Myrie@hhs.gov) <Simone.Myrie@hhs.gov>; Bradley, Tasha (OS/ASPA) <Tasha.Bradley@hhs.gov>; Formoso, Paula (HHS/ASPA) <Paula.Formoso@hhs.gov>; Daniels, Carla (HHS/ASPA) <Carla.Daniels@hhs.gov>; Felberbaum, Michael (FDA/OC) <Michael.Felberbaum@fda.hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Molly Block (Molly.Block@fda.hhs.gov) <Molly.Block@fda.hhs.gov>; Kate Galatas (CDC/OD/OADC) (kg2@cdc.gov) <kg2@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>; Oury, Rachael (CDC/OD) <OKC3@cdc.gov>; Courtney (NIH/NIAID) Billet [E] (billetc@niaid.nih.gov) <billetc@niaid.nih.gov>; Jennifer (NIH/NIAID) Routh [E] (jennifer.routh@nih.gov) <jennifer.routh@nih.gov>; Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Gretchen Michael (Gretchen.Michael@hhs.gov) <Gretchen.Michael@hhs.gov>; Elleen Kane (OS/ASPR/OEA) (Elleen.Kane@hhs.gov) <Elleen.Kane@hhs.gov>; Danko, Carol (OS/ASPR/OE) <Carol.Danko@hhs.gov>; Mia Heck (HHS/OASH) (Mia.Heck@hhs.gov) <Mia.Heck@hhs.gov>; Tara Broido (Tara.Broido@hhs.gov) <Tara.Broido@hhs.gov>; Jennifer Sherman (HHS/OASH) (Jennifer.Sherman@hhs.gov) <Jennifer.Sherman@hhs.gov>
Cc: Blakeman, Scott (OS/ASPA) <Scott.Blakeman@hhs.gov>; Brennan, Patrick (OS/ASPA) <Patrick.Brennan@hhs.gov>; Caputo, Michael (HHS/ASPA) <Michael.Caputo@hhs.gov>; Foster, Timothy (OS/ASPA) <Timothy.Foster@hhs.gov>; Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Oakley, Caitlin B. (OS/ASPA) <Caitlin.Oakley@HHS.GOV>; Pratt, Michael (OS/ASPA) <Michael.Pratt@hhs.gov>; Traverse, Brad (HHS/ASPA) <Brad.Traverse@hhs.gov>; Weber, Mark (HHS/ASPA) <Mark.Weber@hhs.gov>
Subject: for clearances

Hey Folks – we thought it might be helpful to send an update to what folks at WH/OVP should receive clearance emails. Below reflects our understanding of who has been routinely receiving clearance items and/or who WH/OVP has often added to a chain for review. I’ve bucketed the lists below. Please let me know if you have any questions.

- Ryan

For material and print interview clearances –
Devin O’Malley (b) (6) @ovp.eop.gov
Katie Miller (b) (6) @ovp.eop.gov
Hannah MacInnis (b) (6) @ovp.eop.gov
Meghan Burris (b) (6) @who.eop.gov
Brittany Yanick (b) (6) @who.eop.gov
Tori Syrek (b) (6) @who.eop.gov
Judd Deere (b) (6) @who.eop.gov
Alexa Henning (b) (6) @who.eop.gov
Roma Daravi (b) (6) @who.eop.gov
John Hortsman (b) (6) who.eop.gov

For broadcast interview clearances –

Devin O’Malley
Katie Miller
Hannah MacInnis
Meghan Burris
Brittany Yanick
Tori Syrek
Judd Deere
Alexa Henning
Roma Daravi
John Hortsman
From: Miller, Katie R. EOP/OVP [redacted]@oep.eop.gov
Sent: 5/29/2020 1:44:26 PM
To: Hahn, Stephen [redacted]ExchangeLabs/ou=Exchange Administrative Group
Subject: reporter contact

Sarah Owermohle <sowermohle@politico.com>
Sent from my iPhone

Begin forwarded message:

From: The Washington Post Live <washpostlive@washpost.com>
Date: April 15, 2020 at 4:41:32 PM EDT
To: "Miller, Katie R. EOP/OVP"@ovp.eop.gov>
Subject: Thurs at 11 am ET: FDA Commissioner Dr. Stephen Hahn, Steve Ballmer with Wash Post Live
SIGN UP FOR A LIVESTREAM REMINDER

Thursday, April 16th
Streaming will begin at 11:00 a.m. ET

This event will be streamed on The Washington Post Live’s Facebook, Twitter and YouTube pages, as well as The Washington Post homepage.

To sign up for email notifications for upcoming Washington Post Live virtual events, click here.

Presented by
This email contains news or other information about an event from Washington Post Live, the live journalism division of The Washington Post. If you no longer wish to receive these emails related to Washington Post Live events, please click the unsubscribe link below.

The Washington Post | 1301 K Street NW, Washington D.C., 20071
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
Operational Check-in

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy
Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (D) (G)
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Untitled Attachment; Operational Check-in
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy
Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:54:30 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0fa3c4b98913833e38a036e9f-Stephen.Hahn]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=f596362221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: Phone Call: Joe/ Dr. Hahn
Attachments: Untitled Attachment; Untitled Attachment; Canceled: Phone Call: Joe/ Dr. Hahn
Location: Joe will call Dr. Hahn

Start: 3/24/2020 7:45:00 AM
End: 3/24/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:54:30 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: Phone Call: Joe/ Dr. Hahn
Attachments: Untitled Attachment; Untitled Attachment
Location: Joe will call Dr. Hahn

Start: 3/24/2020 7:45:00 AM
End: 3/24/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)
Operational Check-in

Recurrence:
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Untitled Attachment; Operational Check-in
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy
Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [b] (6) [b] (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS](6); Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381fbb0349983490fcd-HHS-ol1-ccd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2b83b77989d40cc3-HHS-6]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0fac0cfa3cc4b98913833e38a036e9f-Stephen.Hah]

Subject: Operational Check-in
Location: Roosevelt Room
Start: 3/30/2020 2:00:00 PM
End: 3/30/2020 2:30:00 PM
Show Time As: Busy

Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDI0HF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]

Subject: Operational Check-in
Location: Dr. Birx Office
Start: 3/30/2020 2:00:00 PM
End: 3/30/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)
Subject: Call: (b)(5) - DPP

Location: (202) 395-6392, (b)(6) #

Start: 3/30/2020 8:00:00 PM
End: 3/30/2020 8:30:00 PM

Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b)(6)

Follow up from 2 pm meeting re: (b)(5)

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan
Subject: Operational Check-in
Attachments: Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
Subject: HOLD: ALS Meeting

Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

-----Original Appointment-----
From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Monday, April 13, 2020 8:21 AM
To: Grogan, Joseph J. EOP/WHO; Sheehy, Janice; Williams, James H. EOP/WHO; Merkel, Theo W. EOP/WHO; D'Angelo, Gregory B. EOP/OMB; Bruno, Grace A. EOP/OMB; Bonner, Maria K. EOP/WHO; Giuliani, Andrew H. EOP/WHO; Sugarman, AJ J. EOP/WHO
Subject: HOLD: ALS Meeting
When: Friday, April 17, 2020 9:30 AM-10:00 AM (UTC-05:00) Eastern Time (US & Canada).
Where:
Operational Check-in

Roosevelt Room

3/31/2020 2:30:00 PM
3/31/2020 3:00:00 PM

(none)
Operational Check-in

Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: Weekly

Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
Subject: Operational Check-in

Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
Subject: Operational Check-in

Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in;

Canceled: Operational Check-in

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: Weekly

Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
Operational Check-in

Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (6)
<table>
<thead>
<tr>
<th>From:</th>
<th>Grogan, Joseph J. EOP/WHO [<a href="mailto:Joseph.J.Grogan@who.eop.gov">Joseph.J.Grogan@who.eop.gov</a>]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sent:</td>
<td>3/23/2020 8:54:30 AM</td>
</tr>
<tr>
<td>To:</td>
<td>Grogan, Joseph J. EOP/WHO [<a href="mailto:Joseph.J.Grogan@who.eop.gov">Joseph.J.Grogan@who.eop.gov</a>]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0af0c0cfa3c4b968913833e38a036e9f-Stephen.Hahn]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f596367221f4340d697dbd43ee27255fb-Colin.Rom]</td>
</tr>
<tr>
<td>Subject:</td>
<td>Phone Call: Joe/ Dr. Hahn</td>
</tr>
<tr>
<td>Attachments:Untitled Attachment; Untitled Attachment</td>
<td></td>
</tr>
<tr>
<td>Location:</td>
<td>Joe will call Dr. Hahn</td>
</tr>
<tr>
<td>Start:</td>
<td>3/24/2020 7:45:00 AM</td>
</tr>
<tr>
<td>End:</td>
<td>3/24/2020 8:00:00 AM</td>
</tr>
<tr>
<td>Show Time As:</td>
<td>Busy</td>
</tr>
<tr>
<td>Recurrence:</td>
<td>(none)</td>
</tr>
</tbody>
</table>
Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:54:30 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f596362221f4340d6697dbd43ee27255fb-Colin.Rom]

Subject: Phone Call: Joe/ Dr. Hahn
Attachments: Untitled Attachment
Location: Joe will call Dr. Hahn

Start: 3/24/2020 7:45:00 AM
End: 3/24/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@(6)]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381fbbdd983419fcdf-HHS-olx1-cd]; (6) cms.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- (6)]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]

Subject: Operational Check-in  

Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Operational Check-in  

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM  
End: 3/31/2020 3:00:00 PM  

Show Time As: Busy

Recurrence: Weekly  
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392  
Participant Code: (b) (6)
Subject: Operational Check-in

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
Subject: Operational Check-in

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code (b) (6)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@b]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbbdd983419fcd-HHS-oix1-cd]; Hahn, Stephen (ems.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-b]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)
Operational Check-in

Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@(b) (6) cms.hhs.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fc4d-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-0(b) (6)]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01b16905e1300-HHS-Meredith]
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@[b] (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbbd983419fcd-HHS-oli1-ccd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-([b] (6) Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [b] (6)
Subject: Operational Check-in

Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Canceled: Operational Check-in

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (B) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Bix, Deborah L. EOP/NSC [Deborah.L.Bix@(b)(6)]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650995f424381ffbd983419fcd-HHS-o1x1-cd]; cms.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- (b)(6)]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Operational Check-in
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b)(6)
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (6) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS.GOV]; Redfield, Robert R (CDC) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f42381ffbd983419fcd-HHS-olx1-cd); Fauci, Anthony S (NIH) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-olx1-cd; Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah); Good-Cohn, Meredith (CMS) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Operational Check-in
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@[b](6)]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; [b](6) cms.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- [b](6)]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [b](6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NNSC [Deborah.L.Birx@(6) (6) cms.hhs.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-o1x1-cd]; Hahn, Stephen (6) (6) Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah];

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Untitled Attachment

Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code (6) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@DOD]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd9834319fcd-HHS-oli1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS;]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [666]
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Brix, Deborah L. EOP/NSC [Deborah.L.Brix@b]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd9b83419fcd-HHS-olx1-cd]; cms.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-oix1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b4772b83b77989d40ccc3-HHS-cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [D] [O].
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:54:30 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f596362221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Phone Call: Joe/ Dr. Hahn
Attachments: Untitled Attachment
Location: Joe will call Dr. Hahn
Start: 3/24/2020 7:45:00 AM
End: 3/24/2020 8:00:00 AM
Show Time As: Busy
Recurrence: (none)
Subject: ALS Check-In
Location: Dial-in 202-395-6392
Start: 4/9/2020 5:30:00 PM
End: 4/9/2020 6:00:00 PM
Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS.GOV]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f42381ffbd983419fcd-HHS-o1x1-cd];[cms.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]

Subject: Operational Check-in

Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment;

Canceled: Operational Check-in

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [0] [0].
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@[b] [6]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbbd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[b] [6]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]

Subject: Operational Check-in

Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Canceled: Operational Check-in

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [b] [6]
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Brix, Deborah L. EOP/NSC [Deborah.L.Brix@(6)]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcdf-HHS-olx1-cd]; cms.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2b83b77989d40cc3-HHS-]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (6)
Subject: Operational Check-in

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [b.(6)w.who.eop.gov]; Merkel, Theo W. EOP/WHO [b.(6)w.who.eop.gov]; D’Angelo, Gregory B. EOP/OMB [b.(6)w.who.eop.gov]; Bonner, Maria K. EOP/WHO [b.(6)w.who.eop.gov]; Giuliani, Andrew H. EOP/WHO [b.(5)w.who.eop.gov]; Sugarman, AJ J. EOP/WHO [b.(6)w.who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [b.(6)w.who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4040ca9e98a5434f9b0cca-HHS-jackie.]

Subject: ALS Phone Call
Attachments: (b) (5)

Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel’s Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

**For those on the WH campus, we will meet in the Roosevelt Room to get on the call.**
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Brix, Deborah L. EOP/NSC [Deborah.L.Brix@]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b)
White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel’s Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392
Participant Code: [b (5)]

**For those on the WH campus, we will meet in the Roosevelt Room to get on the call.**
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOH23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@(b)(6)]; Redfield, Robert R (CDC) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOH23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOH23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-; Hahn, Stephen [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOH23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOH23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment
Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-in: (202) 395-6392
Participant Code: (b)(6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [/b] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Merkel, Theo W. EOP/WHO [/b] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; D’Angelo, Gregory B. EOP/OMB [/b] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Bruno, Grace A. EOP/OMB [/b] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Bonner, Maria K. EOP/WHO [/b] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Giuliani, Andrew H. EOP/WHO [/b] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Sugarman, AJ J. EOP/WHO [/b] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Davis, May M. EOP/WHO [/b] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy];

Subject: ALS Phone Call
Attachments: [b] [5]

Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel’s Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392
Participant Code: [b] [5]

**For those on the WH campus, we will meet in the Roosevelt Room to get on the call.**
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@(b)(6)]; Redfield, Robert R (CDC) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd9983419fcd-HHS-olix1-cd; cms.hhs.gov; Fauci, Anthony S (NIH) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b)(5); Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn; Good-Cohn, Meredith (CMS) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment
Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-in: (202) 395-6392
Participant Code: (b)(6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:54:30 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f596362221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: Phone Call: Joe/ Dr. Hahn
Attachments: Untitled Attachment
Location: Joe will call Dr. Hahn
Start: 3/24/2020 7:45:00 AM
End: 3/24/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)
White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel’s Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

**For those on the WH campus, we will meet in the Roosevelt Room to get on the call.**
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS].(6); Redfield, Robert R (CDC) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd); Fauci, Anthony S (NIH) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-.(6); Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah); Good-Cohn, Meredith (CMS) /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment
Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-in: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/31/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS.DHHS.GOV]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; cms.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-HHS]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0ca3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Untitled Attachment; Canceled: Operational Check-in

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Show Time As: Busy

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: 606
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHFI23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [/o=exchangeLabs/ou=Exchange Administrative Group (FYDIOHFI23SPDLT)/cn=Recipients/cn=795a71a92ac1b47a2bf83b77988d40cc3-HHS-Deborah.B]; Redfield, Robert R (CDC) [/o=exchangeLabs/ou=Exchange Administrative Group (FYDIOHFI23SPDLT)/cn=Recipients/cn=795a71a92ac1b47a2bf83b77988d40cc3-HHS-Deborah.B]; Fauci, Anthony S (NIH) [/o=exchangeLabs/ou=Exchange Administrative Group (FYDIOHFI23SPDLT)/cn=Recipients/cn=795a71a92ac1b47a2bf83b77988d40cc3-HHS-Deborah.B]; Hahn, Stephen [/o=exchangeLabs/ou=Exchange Administrative Group (FYDIOHFI23SPDLT)/cn=Recipients/cn=795a71a92ac1b47a2bf83b77988d40cc3-HHS-Deborah.B]; Good-Cohn, Meredith (CMS) [/o=exchangeLabs/ou=Exchange Administrative Group (FYDIOHFI23SPDLT)/cn=Recipients/cn=795a71a92ac1b47a2bf83b77988d40cc3-HHS-Deborah.B];

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment
Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (6)
Subject: Operational Check-in

Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM

Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [6] [6]
White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel’s Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

**For those on the WH campus, we will meet in the Roosevelt Room to get on the call.**
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-in: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:54:30 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: Phone Call: Joe/ Dr. Hahn
Location: Joe will call Dr. Hahn

Start: 3/24/2020 7:45:00 AM
End: 3/24/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS.GOV]; Redfield, Robert R (CDC) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381fbbdd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-.]; Hahn, Stephen [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in
Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-in: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Brix, Deborah L. EOP/NSC [Deborah.L.Brix@]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77985d40cc3-HHS-olx1-cd]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (6)
-----Original Appointment-----

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Monday, April 13, 2020 8:21 AM
To: Grogan, Joseph J. EOP/WHO; Sheehy, Janice; Williams, James H. EOP/WHO; Merkel, Theo W. EOP/WHO; D'Angelo, Gregory B. EOP/OMB; Bruno, Grace A. EOP/OMB; Bonner, Maria K. EOP/WHO; Giuliani, Andrew H. EOP/WHO; Sugarman, AJ J. EOP/WHO
Subject: HOLD: ALS Meeting
When: Friday, April 17, 2020 9:30 AM-10:00 AM (UTC-05:00) Eastern Time (US & Canada).
Where:
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@(b) (6) cms.hhs.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; cms.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b)-(6)-Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah); Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment
Location: Roosevelt Room

Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-in: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c42d3a3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [b] (6) [b]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1a0650905f424381ffbad983419fcc-HHS-olx1-cd]; [b] (6) [b]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-olx1-cd]; [b] (6) [b]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Bixr, Deborah L. EOP/NSC [bixr@nsa.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=of1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[b]5[/b][6][5]]; Hahn, Stephen H[/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[b]5[/b][6][5]]; Good-Cohn, Meredith [CMS] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah];

Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in ; Untitled Attachment
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy

Recurrence: (none)

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [b]5[b]6[b]5


From: Grogan, Joseph J. EOP/WHO [Joseph J. Grogan@who.eop.gov]
Sent: 3/23/2020 8:54:30 AM
To: Grogan, Joseph J. EOP/WHO [Joseph J. Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255f-colin.Rom]

Subject: Phone Call: Joe/ Dr. Hahn
Attachments: Untitled Attachment
Location: Joe will call Dr. Hahn

Start: 3/24/2020 7:45:00 AM
End: 3/24/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)
Subject: Call

Start: 3/31/2020 7:30:00 AM
End: 3/31/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (5)

Follow up from 2 pm meeting re: (b) (5)

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan
Subject: Copy: Operational Check-in
Location: Roosevelt Room
Start: 3/30/2020 2:30:00 PM
End: 3/30/2020 3:00:00 PM
Show Time As: Tentative
Recurrence: (none)
FDA/WAVES link: https://events.whitehouse.gov

You will enter the complex at 17th and State Place NW - you will make your way through two security checkpoints to room 176 of the EEOB.

Please call Ian DeValliere with any questions: 202-881-8007
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/9/2020 9:51:54 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Bruno, Grace A. EOP/OMB

Subject: ALS Check-In
Location: Dial-in 202-395-6392; (b) (6)
Start: 4/9/2020 5:30:00 PM
End: 4/9/2020 6:00:00 PM
Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
Subject: FDA/EOP Call on
Location: Dial-in 202-395-6392;
Start: 4/9/2020 2:00:00 PM
End: 4/9/2020 2:30:00 PM
Show Time As: Busy

Roosevelt Room for internal participants
Participant Dial-in: (202) 395-6392
Participant Code: (6)
White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel’s Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392
Participant Code: [b] (5)

**For those on the WH campus, we will meet in the Roosevelt Room to get on the call.**
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [b](6)______________who.eop.gov]; Merkel, Theo W. EOP/WHO [b](6)______________who.eop.gov]; D’Angelo, Gregory B. EOP/OMB [b](6)______________who.eop.gov]; Grace A. EOP/OMB [b](6)______________who.eop.gov]; Bonner, Maria K. EOP/WHO [b](6)______________who.eop.gov]; Giuliani, Andrew H. EOP/WHO [b](6)______________who.eop.gov]; Sugarman, AJ J. EOP/WHO [b](6)______________who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01.894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [b](6)______________who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b989138333e38a036e9f-Stephen.Hahn]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4cd040ca9e98a5434f9b0cca-HHS-jackie.]

Subject: ALS Phone Call
Attachments: [b](6)---------------------------

Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel’s Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392
Participant Code: [b](6)---------------------------

**For those on the WH campus, we will meet in the Roosevelt Room to get on the call.**
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:51:36 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Telecon: Joe/Dr. Hahn Check-in
Location: Dr. Hahn to call Joe
Start: 3/23/2020 3:40:00 PM
End: 3/23/2020 4:00:00 PM
Show Time As: Busy

Recurrence: (none)
Subject: FDA/EOP Call on [b][5]
Location: Dial-in 202-395-6392; [b][6]
Start: 4/9/2020 2:00:00 PM
End: 4/9/2020 2:30:00 PM
Show Time As: Tentative

Roosevelt Room for internal participants
Participant Dial-in: (202) 395-6392
Participant Code: [b][6]
Subject: ALS Check-In

Location: Dial-in 202-395-6392

Start: 4/9/2020 5:45:00 PM
End: 4/9/2020 6:15:00 PM

Show Time As: Tentative

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (b)
Subject: ALS Check-In
Location: Dial-in 202-395-6392; [b] (6) 

Start: 4/9/2020 5:30:00 PM
End: 4/9/2020 6:00:00 PM
Show Time As: Tentative

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: [b] (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [b] (6) [b] (6) b@who.eop.gov; Merkel, Theo W. EOP/WHO [b] (6) [b] (6) b@who.eop.gov; D'Angelo, Gregory B. EOP/OMB [b] (6) [b] (6) b@who.eop.gov; Bruno, Grace A. EOP/OMB [b] (6) [b] (6) b@who.eop.gov; Bonner, Maria K. EOP/WHO [b] (6) [b] (6) b@who.eop.gov; Giuliani, Andrew H. EOP/WHO [b] (6) [b] (6) b@who.eop.gov; Sugarman, AJ J. EOP/WHO [b] (6) [b] (6) b@who.eop.gov; Rom, Colin [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [b] (6) [b] (6) b@who.eop.gov; Hahn, Stephen [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441e85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments:
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Tentative

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel’s Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392
Participant Code: [b] (6) [b] (6) b

**For those on the WH campus, we will meet in the Roosevelt Room to get on the call.**
-----Original Appointment-----
From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Monday, April 13, 2020 8:21 AM
To: Grogan, Joseph J. EOP/WHO; Sheehy, Janice; Williams, James H. EOP/WHO; Merkel, Theo W. EOP/WHO; D'Angelo, Gregory B. EOP/OMB; Bruno, Grace A. EOP/OMB; Bonner, Maria K. EOP/WHO; Giuliani, Andrew H. EOP/WHO; Sugarman, AJ J. EOP/WHO
Subject: HOLD: ALS Meeting
When: Friday, April 17, 2020 9:30 AM-10:00 AM (UTC-05:00) Eastern Time (US & Canada).
Where:
Subject: Call

Start: 3/31/2020 7:30:00 AM
End: 3/31/2020 8:00:00 AM

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: [b] (5) 

Follow up from 2 pm meeting re: [b] (5) 

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan
Subject: Call

Start: 3/30/2020 8:00:00 PM
End: 3/30/2020 8:30:00 PM

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

Follow up from 2 pm meeting re: (b) (5)

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/9/2020 9:51:54 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB; Williams, James H. EOP/WHO; Campana, Alexandra D. EOP/WHO; Devalliere, Ian C. EOP/WHO; Merkel, Theo W. EOP/WHO; McMillin, Virginia D. EOP/WHO; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, Michael B. EOP/WHO; Giuliani, Andrew H. EOP/WHO; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a06ac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Sugarman, AJ J. EOP/WHO; Planning, David M. EOP/WHO; Riley, Sean M. EOP/WHO; Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bdf521b0105d17d2-Keagan.Leni]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bdf521b0105d17d2-Keagan.Leni]
Subject: ALS Check-In
Location: Dial-in 202-395-6392;  
Start: 4/9/2020 5:45:00 PM
End: 4/9/2020 6:15:00 PM
Show Time As: Tentative

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code:  

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 7:59:49 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]

Subject: Operational Check-in
Location: Dr. Birx Office
Start: 3/30/2020 2:00:00 PM
End: 3/30/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)
From: "Hurst, Natalie R. EOP/OVP" <b@ovp.eop.gov> on behalf of "Short, Marc T. EOP/OVP"

Date: Saturday, March 28, 2020 at 2:21 PM

To: "randal@mail.house.gov" <randal@mail.house.gov>, "Grogan, Joseph J. EOP/WHO"

Bcc: "HHS.GOV" <b@hhs.gov>, "stm77@treasury.gov"

"Kudlow, Larry A. EOP/WHO" <b@who.eop.gov>, "cdc.gov"

"AFAUCl@niaid.nih.gov" <AFAUCl@niaid.nih.gov>, "Jerome.Adams@hhs.gov"

"BiegurnSE@state.gov" <BiegurnSE@state.gov>, "sh1@fda.hhs.gov"

"as1cfw@hq.dhs.gov" <as1cfw@hq.dhs.gov>, "Birx, Deborah L. EOP/NSC"

"Pottinger, Matthew F. EOP/WHO" <b@who.eop.gov>, "Vought, Russell T. EOP/OMB"

"Troye, Nsc" <b@who.eop.gov>, "Harris, Shane M. EOP/WHO"

"Ferrer Piran Basualdo, Austin G. EOP/WHO"

"David.Lyons@sd.mil" <David.Lyons@sd.mil>, "Croghan, Mary E. EOP/WHO"

"Kate@mail.house.gov" <Kate@mail.house.gov>, "DeValliere, Ian C."
EOP/WHO" <b>(6)</b> who.eop.gov, "Campana, Alexandra D. EOP/WHO"
<b>(6)</b> who.eop.gov, "Zachary.McEntee@treasury.gov"
"Zachary.McEntee@treasury.gov", "shirley.gathers@treasury.gov" <shirley.gathers@treasury.gov>,
"Andrew.Hughes@hud.gov" <Andrew.Hughes@hud.gov>, "Jennifer.L.Naaden@hud.gov"
"Jennifer.L.Naaden@hud.gov", "Lin, Merry S. EOP/WHO" <b>(6)</b> who.eop.gov, "Baker, Brittany G. EOP/WHO"
<b>(6)</b> who.eop.gov, "Olmem, Andrew J. EOP/WHO"
<b>(6)</b> who.eop.gov, "veu4@cdc.gov" <veu4@cdc.gov>, "conradpa@naiad.nih.gov"
"conradpa@naiad.nih.gov", "hilary.marston@nih.gov" <hilary.marston@nih.gov>, "Joel.Dulaigh@hs.gov"
"Joel.Dulaigh@hs.gov", "Hurst, Natalie R. EOP/OPV" <b>(6) ovp.eop.gov, OVPSchedule
OVPSchedule@OPV.eop.gov", "BurnettJD@state.gov" <BurnettJD@state.gov>, "HattinghEF@state.gov"
"HattinghEF@state.gov", "Janice.Sheehy@fda.hhs.gov" <Janice.Sheehy@fda.hhs.gov>,
"Colin.Rom@fda.hhs.gov" <Colin.Rom@fda.hhs.gov>, "julia.bristol@hq.dhs.gov" <julia.bristol@hq.dhs.gov>,
"natalia.best@hq.dhs.gov" <natalia.best@hq.dhs.gov>, "Nkosi.thomas@hq.dhs.gov"
"Nkosi.thomas@hq.dhs.gov", "Brady.Brookes@CMS.HHS.GOV" <Brady.Brookes@CMS.HHS.GOV>,
"meredith.good-cohn@cms.hhs.gov" <meredith.good-cohn@cms.hhs.gov>, "Diana.Perez-
Rivera@cms.hhs.gov" <Diana.Perez-Rivera@cms.hhs.gov>, "pamela.powers@va.gov"
"pamela.powers@va.va.gov", "belinda.carrington@va.va.gov" <belinda.carrington@va.va.gov>,
"jacqueline.colli@va.ca.gov" <jacqueline.colli@va.ca.gov>, "Hennessy, Millicent S. EOP/NSC"
<b>(6) omb.eop.gov, beth.tignor@hs.gov" <beth.tignor@hs.gov>, "Zachary.Dareshori@hs.gov" <Zachary.Dareshori@hs.gov>,
"Lair, Kate E. EOP/WHO" <b>(6) who.eop.gov, "Goyer, Jim L. IV EOP/WHO"
<b>(6) who.eop.gov, "Riggs, Charlotte R. EOP/WHO" <b>(6) who.eop.gov, "Murrell,
Baxter R. EOP/WHO" <b>(6) who.eop.gov, "Pottebaum, Nic D. EOP/WHO"
<b>(6) who.eop.gov, "Jennifer.Stewart@sd.mil" <Jennifer.Stewart@sd.mil>, "Rader, John
N. EOP/NSC" <b>(6) who.eop.gov, "Haley, Vincent M. EOP/WHO" <b>(6) who.eop.gov, "Gabriel,
Robert Jr. EOP/WHO" <b>(6) who.eop.gov, "Worthington, Ross P. EOP/WHO"
<b>(6) who.eop.gov, "Baldwin, Brittany L. EOP/WHO" <b>(6) who.eop.gov, "Royer,
Theodore M. EOP/WHO" <b>(6) who.eop.gov, "Boudic, Brian J. EOP/OPV"
Gonzalez@sd.mil" <Hannah.Gonzalez@sd.mil>, "michael.harrison@sd.mil"
<michael.harrison@sd.mil>, "anne.powers@sd.mil" <anne.powers@sd.mil>, "Cygryn, Jen B. EOP/WHO"
<b>(6) who.eop.gov, "McGuffee, Tyler Ann A. EOP/OPV" <b>(6) ovp.eop.gov, "Hahn,
Julia A. EOP/WHO" <b>(6) who.eop.gov, "Taylor, Elizabeth A. EOP/WHO"
<b>(6) who.eop.gov, DL WHO COMM Writers
DL.COMMS.Speechwriters@whmo.mil, "Arwenthia.FordBarnes@hhs.gov"
"Arwenthia.FordBarnes@hhs.gov", "Brandy.Brunson@hhs.gov" <Brandy.Brunson@hhs.gov>,
"donna.o'berry@dot.gov" <donna.o'berry@dot.gov>, "amie.kalsbeek@dot.gov" <amie.kalsbeek@dot.gov>,
"Neshiawat, Julia EOP/NSC" <b>(6) who.eop.gov, "lauran.fischer@fema.dhs.gov"
"lauran.fischer@fema.dhs.gov", "Deere, Judd P. EOP/WHO" <b>(6) who.eop.gov, "Boyd,
Charlton J. EOP/WHO" <b>(6) who.eop.gov, "Moore, Caroline E. EOP/WHO"
<b>(6) who.eop.gov, "Tubb, Emily A. EOP/CEA" <b>(6) cea.eop.gov, "Willey, Paige F.
EOP/WHO" <b>(6) who.eop.gov, "Carla.Hammad@hhs.gov" <Carla.Hammad@hhs.gov>,
"Victoria.Callahan@hhs.gov" <Victoria.Callahan@hhs.gov>, "katie.bante@hhs.gov" <Katie.bante@hhs.gov>,
"Woolfolk, Jon J. EOP/OPV" <b>(6) ovp.eop.gov, "Myung.Kim@fema.dhs.gov"
"Myung.Kim@fema.dhs.gov", "Hicks, Hope C. EOP/WHO" <b>(6) who.eop.gov, "Fisher, Garrett C.
EOP/OPV" <b>(6) ovp.eop.gov, "Nevins, Kristan K. EOP/WHO" <b>(6) who.eop.gov,
"Hudson, Renee R. EOP/WHO" <b>(6) who.eop.gov, "O'Malley, Devin M. EOP/OPV"
<b>(6) ovp.eop.gov, "Sheehan, Matthew J. EOP/OPV" <b>(6) ovp.eop.gov, "Bonner, Maria K. EOP/WHO"
All –

There will be a White House Coronavirus Task Force Call tomorrow afternoon at 4:00pm. If you do not have access to a secure phone/SCIF, the White House Situation Room will be available.

Agenda attached.

Thank you,

Natalie Hurst
Operations Coordinator, White House Coronavirus Task Force
Executive Assistant to the Chief of Staff
The Office of the Vice President
(202) 881-9981
Thank you so much and thank you for talking with the laboratories and seems things are picking up. If in your conversations you sense there is an issue with human capacity we can follow up with the sites. Den

From: "Wainer, Andrea F" <andrea.wainer@abbott.com>
Date: Tuesday, March 31, 2020 at 6:42 PM
To: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>, "Haddad, Carla (HHS/OASH)" <Carla.Haddad@hhs.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@(...(6)> "Shuren, Jeff (FDA/CDRH)" <Jeff.Shuren@fda.hhs.gov>, "Stenzel, Timothy (FDA/CDRH)" <Timothy.Stenzel@fda.hhs.gov>
Cc: "Ford, Robert B" <Robert.Ford@abbott.com>
Subject: [EXTERNAL] Abbott’s daily COVID Data

Good evening,

Attached are: (1) ID NOW’s first report; and (2) m2000 US sites. Given this is our first inclusion of ID NOW data, I have revised the explanations below to include both sets of data and explained what we are and are not reporting on ID NOW. Given this is our first m2000 report with cumulative tests performed, positives and positive %, I have also added 2(d) below to note that we have added cumulative tests performed, etc (see last three columns in the report).

Please find attached Abbott’s data as of March 30 for (1) ID NOW tests; and (2) m2000 tests.

For m2000 test data, there are two types of data we have:

1. Information in our control such as the names and addresses of our customers and the number of tests we shipped to them cumulatively and this week.
2. Raw data we receive from a remote data link that is sent from the instruments at the customers to Abbott.

a. First, we only receive the remote data link from certain customers (on the spreadsheet, the customers we don’t receive data from are in gray).
b. Second, for those customers with the remote data link, we are providing raw data that has the number of tests run and the number of positives. Customers run their own required protocols to validate the accuracy of a test when a new test first becomes available. Those
validation processes include negative and positive samples. The raw data we get from data link of the instrument cannot distinguish between validation samples and patient samples.

c. Third, as requested, the raw data for the Prior Day Tests Performed and positive numbers and rates (columns J, K and L) are for the previous day only.

d. Fourth, we have added columns for Cumulative Tests Performed, Cumulative Positives, and Cumulative % Positive.

3. We do not have data regarding inventory at the labs.

For ID NOW test data:

1. We are reporting names, addresses, total cumulative tests shipped, and total tests shipped this week.
2. Unlike the m2000 instrument, we do not have any data on tests performed from the ID NOW instruments.

Best regards
Andrea

Abbott
Executive Vice President
Rapid & Molecular Diagnostics
Abbott
100 Abbott Park Road
Building AP6C-2
Abbott Park, IL 60064
O: +1 224-668-9155
andrea.wainer@abbott.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@ (b) (6) ]
Sent: 3/22/2020 8:18:38 AM
To: Short, Marc T. EOP/OVP [Marc.T.Short@ (b) (6) ]

Harrison, Brian (OS) Ihr=exchange.labs.gov=exchange.administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=ac2bfe7febef45ed98c87b83e5bcf8d0-HHS-Brian.H]; Pataki, Tim A. EOP/WHO [Tim.A.Pataki@ (b) (6) ]
Goyer, Jim L. IV EOP/WHO [Jim.L.Goyer@ (b) (6) ]
Pottebaum, Nic D. EOP/WHO [Nic.D.Pottebaum@ (b) (6) ]; buddad, Carla (OS) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=8627b6eb986b6442838ee69551c54187-HHS-Carla.H]; Hodgson, Christopher M. EOP/OVP [Christopher.M.Hodgson@ (b) (6) ]
Hoelscher, Douglas L. EOP/WHO [Douglas.L.Hoelscher@ (b) (6) ]; obenshain, Tucker T. EOP/OVP [Tucker.T.Obenshain@ (b) (6) ]
Nevins, Kristan K. EOP/WHO [Kristan.K.Nevins@ (b) (6) ]; Stuitt, Julie M. EOP/NSC [Julie.M.Stuitt@ (b) (6) ]; Davis, May M. EOP/WHO [May.M.Davis@ (b) (6) ]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@ (b) (6) ]; Hudson, Renee R. EOP/WHO [Renee.R.Hudson@ (b) (6) ]; Devlin, M. O'Malley@treasury.gov; Sheehan, Mathew J. EOP/OVP [Mathew.J.Sheehan@ (b) (6) ]; Moore, Caroline E. EOP/WHO [Caroline.E.Moore@ (b) (6) ]; Kushner, Jared C. EOP/WHO [Jared.C.Kushner@ (b) (6) ]; Hicks, Hope C. EOP/WHO [Hope.C.Hicks@ (b) (6) ]; Fisher, Garrett C. EOP/OVP [Garrett.C.Fisher@ (b) (6) ]; Kadlec, Robert P. (OS) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=70539a2f8bb924cb813781ea742798b12-HHS-Robert.K]; Joel.Szabat@dot.gov; randal@mail.house.gov; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@ (b) (6) ]; HHS.Gov; stm77@treasury.gov; Kudlow, Larry A. EOP/WHO [Larry.A.Kudlow@ (b) (6) ]; Redfield, Robert R (CDC) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=011ab6090f542183fbdd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=759a71a9291b47a2f83b77989d40c3-HHS (b) (5) ]; Adams, Jerome (OS) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=302991451fc341bf9a7fa53ebaf81c-HHS-Jerome.R]; BiegunSE@state.gov; Hahn, Stephen Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=a0afac0ef3ac4b98913383e38a036e9f-Stephen.Hah; as1cfw@hq.dhs.gov; rms.hhs.gov; rlw@va.gov; Pottinger, Matthew F. EOP/WHO [Matthew.F.Pottinger@ (b) (6) ]; Vought, Russell T. EOP/OVP [Russell.T.Vought@ (b) (6) ]; Miller, Katie R. EOP/OVP [Katie.R.Miller@ (b) (6) ]; Liddell, Christopher P. EOP/WHO [Christopher.P.Liddell@ (b) (6) ]; Grisham, Stephanie A. EOP/WHO [Stephanie.A.Grisham@ (b) (6) ]; Philbin, Patrick F. EOP/WHO [Patrick.F.Phillbin@ (b) (6) ]; Miller, Stephen EOP/WHO [Stephen.Miller@ (b) (6) ]; Pete.Gaynor@fema.dhs.gov; Giroir, Brett (OS) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Kate@mail.house.gov; DeValliere, Ian C. EOP/WHO [Ian.C.DeValliere@ (b) (6) ]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana@ (b) (6) ]; Zachary.McEntee@treasury.gov; shirley.gathers@treasury.gov; Andrew.Hughes@hud.gov; Jennifer.L.Naaden@hud.gov; Lin, Merys S. EOP/WHO [Merys.S.Lin@ (b) (6) ]; Baker, Brittany G. EOP/WHO [Brittany.G.Baker@ (b) (6) ]; Olm, Andrew J. EOP/WHO [Andrew.J.Olm@ (b) (6) ]; Gershom, Lynn E (CDC) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=4696e715fb22432e9dc605736ded877-HHS-veu4-cd]; Conrad, Patricia L (NIH) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Marston, Hilary D (NIH) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=87732347b8129459b55d2b7e2bacc5eb-HHS-hilya.j]; Dulaigh, Joel (OS) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=014f5f895214dd4f8112c62d40ac50e-HHS-Joel.Du]; Hurst, Natalie R. EOP/OVP [Natalie.R.Hurst@ (b) (6) ]; OVPSchedule [OVPSchedule@OVP.eop.gov]; BurnettJD@state.gov; HattinghEF@state.gov; Sheehy, Janice Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=f45a6c96f5274724a1be5970eb48f7-JSheehy]; Rom, Colin Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=59f636221f4340d69dbd43ee27255fbcollin.Rom]; julia.bristol@hq.dhs.gov; natalia.bet@hq.dhs.gov; nkosi.thomas@hq.dhs.gov; Brookes, Brady (CMS) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=be9bafde245a4e91ba1e01e7e03ad9e4-HHS-Brady.B]; Good-Cohn, Meredith (CMS) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=5e06154b83bb4c8a7b8b01816905e1300-HHS-Meredit]; Perez-Rivera, Diana (CMS) Ihr=exchange.labs.gov=exchange administrative group [FYDIOHF23SPDLT] /cn=Recipients/cn=4c8224ebeafa1e4624b0c2223b343fe6c7-HHS-Diana.P];
Subject: White House Coronavirus Task Force Meeting

Attachments: TaskForce22March.pptx
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@{(b) (6)}]
Sent: 3/21/2020 12:02:10 PM
To: Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group [FYDIOHFF23SPDLT]/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: McGuffee, Tyler A. EOP/OVP [{(b) (6)}]
Subject: A couple of edits
Attachments: 

(b) (5)

Thank you
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/21/2020 9:02:11 AM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Fwd: [EXTERNAL] Milken Institute Launches COVID-19 Treatment and Vaccine Tracker

Sent from my iPhone

Begin forwarded message:

(b) (5)
Begin forwarded message:

From: "Matthew Aleshire (maleshire@milkeninstitute.org)" <maleshire@milkeninstitute.org>
Date: March 18, 2020 at 8:16:52 PM EDT
To: "Liddell, Christopher P. EOP/WHO" <{redacted}who.eop.gov>
Cc: "Dianna Dunne (ddunne@milkeninstitute.org)" <ddunne@milkeninstitute.org>
Subject: [EXTERNAL] Milken Institute Launches COVID-19 Treatment and Vaccine Tracker

policymakers
Begin forwarded message:

**From:** "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@who.eop.gov>
**Date:** March 16, 2020 at 7:58:47 AM EDT
**To:** "Moorhead, Quellie U. EOP/WHO" <who.eop.gov>
**Subject:** Fwd: Covid-19 modeling

For printing. The word document.

Sent from my iPhone

Begin forwarded message:

**From:** "Zaidi, Irum F" <ZaidiIF@state.gov>
**Date:** March 16, 2020 at 7:55:37 AM EDT
**To:** "Birx, Deborah L" <BirxDL@state.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@who.eop.gov>, "Vitek, Charles (CDC/DDPHSIS/CGH/DGHT)" <cxv3@cdc.gov>
**Subject:** Fw: Covid-19 modeling

___

**From:** Ferguson, Neil M <neil.ferguson@imperial.ac.uk>
**Sent:** Sunday, March 15, 2020 10:48 PM
**To:** Zaidi, Irum F
**Subject:** RE: Covid-19 modeling

See attached for a slightly incomplete report on NPIs. It contains mostly UK modelling, but the results are very similar for the US. I will be including more US model runs in the next day or two, including locally triggered policies.
This report will (when tidied up) be released publicly tomorrow. Please keep this incomplete draft confidential for 24h, though it is fine to use the contents internally.

Also happy to share our estimates of CFR/IFR, healthcare demand needs (all in 5 year age bands):

<table>
<thead>
<tr>
<th></th>
<th>0 to 4</th>
<th>5 to 9</th>
<th>10 to 14</th>
<th>15 to 19</th>
<th>20 to 24</th>
<th>25 to 29</th>
<th>30 to 34</th>
<th>35 to 39</th>
<th>40 to 44</th>
<th>45 to 49</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of infections hospitalised</td>
<td>0.000744</td>
<td>0.000634</td>
<td>0.001171</td>
<td>0.002395</td>
<td>0.005346</td>
<td>0.01029</td>
<td>0.016235</td>
<td>0.023349</td>
<td>0.028945</td>
<td>0.038601</td>
</tr>
<tr>
<td>Proportion of infections needing critical care</td>
<td>3.74E-05</td>
<td>3.18E-05</td>
<td>5.88E-05</td>
<td>0.00012</td>
<td>0.000269</td>
<td>0.000517</td>
<td>0.000815</td>
<td>0.001243</td>
<td>0.001729</td>
<td>0.002885</td>
</tr>
<tr>
<td>Proportion of hospitalised cases needing critical care</td>
<td>0.050223</td>
<td>0.050223</td>
<td>0.050223</td>
<td>0.050223</td>
<td>0.050223</td>
<td>0.050223</td>
<td>0.053215</td>
<td>0.059744</td>
<td>0.074601</td>
<td></td>
</tr>
<tr>
<td>Proportion of critical cases dying</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Proportion of non-critical care cases dying</td>
<td>0.013448</td>
<td>0.013448</td>
<td>0.013448</td>
<td>0.013448</td>
<td>0.013448</td>
<td>0.013448</td>
<td>0.013448</td>
<td>0.013448</td>
<td>0.014294</td>
<td>0.016159</td>
</tr>
</tbody>
</table>

This gives 4.4% of infections hospitalised, 30% of hospitalised cases needing ICUs.

IFR is 1% overall (we rounded up from the actual estimate of 0.97%) in the UK population. Maybe different in France.

Most of these numbers will be in the final version of this (>https://www.medrxiv.org/content/10.1101/2020.03.09.20033357v1<) which hopefully will come out in Lancet ID this week.

The 30% ICU figure comes from an observation in the UK and Italy that non-invasive ventilation is largely ineffective in COVID-19 cases.

Delays we have estimated:
- Mean time from hospital admission to discharge, non-ICU and non-lethal cases = 8 days
- Mean time from hospital admission to death for lethal cases not admitted to ICU = 8 days
- Mean time from hospital admission to ICU admission = 5 days
- Mean time in ICU, non-lethal and lethal cases = 10 days
- Mean time remaining in hospital after discharge from ICU = 5 days
- Mean time in ICU for lethal cases=10 days

Best,
Neil
Thank you. Deb

From: "Wainer, Andrea F" <andrea.wainer@abbott.com>
Date: Sunday, April 12, 2020 at 6:37 PM
To: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>, "Haddad, Carla (HHS/OASH)" <Carla.Haddad@hhs.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@(D)6>, "Shuren, Jeff (FDA/CDRH)" <Jeff.Shuren@fda.hhs.gov>, "Stenzel, Timothy (FDA/CDRH)" <Timothy.Stenzel@fda.hhs.gov>
Cc: "Ford, Robert B" <Robert.Ford@abbott.com>
Subject: [EXTERNAL] Abbott's Covid Data

Good evening, Commissioner Hahn and Adm Giroir, I will be sending the pooling data as per our previous email tonight. Confirming it is in process and coming.

Please find attached Abbott's data as of April 11 for (1) ID NOW; and (2) m2000.

For m2000 test data, there are two types of data we have:

1. Information in our control such as the names and addresses of our customers and the number of tests we shipped to them cumulatively and this week (Sunday to Saturday shipments).
2. Raw data we receive from a remote data link that is sent from the instruments at the customers to Abbott.
   a. We only receive the remote data link from certain customers (on the spreadsheet, the customers we don’t receive data from are in gray).
   b. For those customers with the remote data link, we are providing raw data that has the number of tests run and the number of positives. Customers run their own required protocols to validate the accuracy of a test when a new test first becomes available. Those validation processes include negative and positive samples. The raw data we get from data link of the instrument cannot distinguish between validation samples and patient samples.
3. We do not have data regarding inventory at the labs.
For ID NOW test data:

1. We are reporting names, addresses, total cumulative tests shipped, and total tests shipped this week (Monday to Sunday shipments).
2. Unlike the m2000 instrument, we do not have any data on tests performed from the ID NOW instruments.

Best Regards,

Andrea

Andrea Wainer
Executive Vice President
Rapid & Molecular Diagnostics
Abbott
100 Abbott Park Road
Building AP6C-2
Abbott Park, IL 60064

C: +1 224-668-0155
andrea.wainer@abbott.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@] ovp.eop.gov
Sent: 4/9/2020 9:03:00 PM
To: McGuffee, Tyler Ann A. EOP/OVP [b] (b) (6) ovp.eop.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Re: FLAGGING — RE: Oracle call with Dr. Birx?

I didn’t ask them to do this – I only listened to her and did NOT commit to anything nor did I say this was a good idea. I am copying Dr Hahn and maybe he knows who activated them as we advised against it. Deb

From: "McGuffee, Tyler Ann A. EOP/OVP" <(b) (6) ovp.eop.gov>
Date: Thursday, April 9, 2020 at 8:48 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@>()
Subject: FLAGGING — RE: Oracle call with Dr. Birx?

Follow up from Oracle CEO’s staff
Flagging the note about HHS and TLS testing data

Begin forwarded message:

From: Josh Pitcock <josh.pitcock@oracle.com>
Date: April 9, 2020 at 8:37:17 PM EDT
To: "McGuffee, Tyler Ann A. EOP/OVP" <(b) (6) ovp.eop.gov>, "Pinkos, Stephen M. EOP/OVP" <(b) (6) ovp.eop.gov>
Cc: Ken Glueck <kenneth.glueck@oracle.com>
Subject: RE: [EXTERNAL] RE: Oracle call with Dr. Birx?

Tyler Ann,
Since Safra and Dr. Birx spoke we have updated the TLS and it is now capable of taking in the testing results. Through conversations with testing companies we already have some of the testing data coming in. We also have been able to integrate EHR’s from some of the hospital systems we are working with (Wake Forest for example). So, great progress for what Dr. Birx was hoping TLS could do.

But to be honest I’m not sure HHS completely understands Dr. Birx’s desire for TLS to get the testing data. We’ve heard back from them that there are a couple workstreams for testing data and they’re trying to sort that out. I raise this so you are aware (we of course have limited visibility into all of this so you may already be working through this), and if that is the case we obviously would advocate that TLS serve as at least a, if not the, testing data repository. The interfaces to pull in the data and run the analytics are built and working and the testing companies we’ve spoken to are supportive.

We’re also still working with HHS to get a TLS announcement release out so we can continue to build provider and patient enrollment. Hopefully they’ll do that soon, but as you know it is a slow process.

Let us know if you have questions. We want to help however we can.
Thanks for all your work on this. ~Josh

From: McGuffee, Tyler Ann A. EOP/OVP <(b) (6) ovp.eop.gov>
Sent: Tuesday, April 7, 2020 1:31 PM
To: Paula Chalata <paula.chalata@oracle.com>; Pinkos, Stephen M. EOP/OVP <(b) (6) ovp.eop.gov>
Cc: Josh Pitcock <josh.pitcock@oracle.com>; Ken Glueck <kenneth.glueck@oracle.com>; Dave Jentsch <david.jentsch@oracle.com>; Barry Brown <barry.x.brown@oracle.com>
Subject: RE: [EXTERNAL] RE: Oracle call with Dr. Birx?
Safra and Dr. Birx are connected. Thanks all.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: [redacted] [no text]
Email: Tyler.A.McGuffee2@oyp.eop.gov

From: Paula Chaltas <paula.chaltas@oracle.com>
Sent: Monday, April 6, 2020 6:48 PM
To: McGuffee, Tyler Ann A. EOP/OVP <mailto:(b) (6) oyp.eop.gov>; Pinkos, Stephen M. EOP/OVP <mailto:(b) (6) oyp.eop.gov>
Cc: Josh Pitcock <josh.pitcock@oracle.com>; Ken Glueck <kenneth.glueck@oracle.com>; Dave Jentsch <david.jentsch@oracle.com>; Barry Brown <barry.x.brown@oracle.com>
Subject: RE: [EXTERNAL] RE: Oracle call with Dr. Birx?

Thanks Tyler Ann,

Yes 1:30pm – 1:40pm EDT / 10:30am – 10:40am PDT tomorrow, Tuesday April 7 will work for Safra.

Please ask Dr. Birx to call Safra on her direct line: [redacted]

Thanks so much,
Paula

From: McGuffee, Tyler Ann A. EOP/OVP <mailto:(b) (6) oyp.eop.gov>
Sent: Monday, April 6, 2020 3:42 PM
To: Paula Chaltas <paula.chaltas@oracle.com>; Pinkos, Stephen M. EOP/OVP <mailto:(b) (6) oyp.eop.gov>
Cc: Josh Pitcock <josh.pitcock@oracle.com>; Ken Glueck <kenneth.glueck@oracle.com>; Dave Jentsch <david.jentsch@oracle.com>; Barry Brown <barry.x.brown@oracle.com>
Subject: RE: [EXTERNAL] RE: Oracle call with Dr. Birx?

Hi Paula,

I appreciate your patience! Can we confirm this call tomorrow (4/7) from 1:30-1:40pm, please?
If so, please provide the direct number for Dr. Birx to dial Safra.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: [redacted] [no text]
Email: Tyler.A.McGuffee2@oyp.eop.gov
Hi Tyler Ann,

Please let us know what works best for Dr. Birx and we will clear Safra’s calendar, as needed.

Thanks so much,
Paula

---

From: Josh Pitcock <josh.pitcock@oracle.com>
Sent: Monday, April 6, 2020 6:45 AM
To: McGuffee, Tyler Ann A. EOP/OVP <b>612-506-1170@ovp.eop.gov>; Pinkos, Stephen M. EOP/OVP <b>612-506-1170@ovp.eop.gov>
Cc: Ken Glueck <kenneth.glueck@oracle.com>; Dave Jentsch <david.jentsch@oracle.com>; Barry Brown <barry.x.brown@oracle.com>; Paula Chaltas <paula.chaltas@oracle.com>
Subject: RE: Oracle call with Dr. Birx?

Super, thanks Tyler Ann.
I know Safra will want to be flexible for what works for Dr. Birx, and she is very grateful for her time.
I’m copying Dave, Barry and Paula who will be able to assist on scheduling.
Thanks again and we are all thinking of you and the team this week.

---

From: McGuffee, Tyler Ann A. EOP/OVP <b>612-506-1170@ovp.eop.gov>
Sent: Monday, April 6, 2020 9:27 AM
To: Josh Pitcock <josh.pitcock@oracle.com>; Pinkos, Stephen M. EOP/OVP <b>612-506-1170@ovp.eop.gov>
Cc: Ken Glueck <kenneth.glueck@oracle.com>
Subject: RE: Oracle call with Dr. Birx?

Hi Josh,
Dr. Birx would like to schedule a call with your CEO this week.
Please let me know who I should work with on your end.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: [b] (6) [no text]
From: Josh Pitcock <josh.pitcock@oracle.com>
Sent: Wednesday, April 1, 2020 11:57 AM
To: McGuffee, Tyler Ann A. EOP/OVP @ovp.eop.gov; Pinkos, Stephen M. EOP/OVP @ovp.eop.gov
Cc: Ken Glueck <kenneth.glueck@oracle.com>
Subject: [EXTERNAL] Oracle call with Dr. Birx?

Tyler Ann and Steve,

We would like to ask if Dr. Birx is available for a short call with Oracle CEO Safra Catz to walk through the application we have built to assist with COVID-19? It has changed a little since Dr. Birx last spoke with Larry Ellison about it, and Safra would like to update her and explain how we think it can help augment clinical trials and other efforts currently underway. (By the way, Oracle software is one of the leading systems used in clinical trials, so this is familiar ground for us.)

The legal hurdles have been cleared and HHS is supportive.
The website is live at covid19.oracle.com.
I’ve attached some slides, the first 2 give a short explanation, and the rest are screen shots of what the site looks like and what kind of dashboard analytics it will produce.

Appreciate your consideration and know how busy you are.
Thanks. –Josh
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/3/2020 1:31:08 PM
To: Giroir, Brett (OS) /o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R
(CDC) /o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Hahn, Stephen
/o=ExchangeLabs/ou=Exchange Administrative Group
(b) (5)
CC: Brix, Deborah L. EOP/NSC [Deborah.L.Brix@](b) (6)
Subject: FW: DOJ's Abbott Device/BOP Request

(b) (5)

From: Mandolfo, James D. EOP/WHO <James.D.Mandolfo@who.eop.gov>
Sent: Friday, April 3, 2020 10:55 AM
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Cc: Campana, Alexandra D. EOP/WHO <(b) (6)who.eop.gov>
Subject: DOJ's Abbott Device/BOP Request

Joe,

Here is the issue regarding BOP getting access to Abbott devices:

(b) (5)

The contact at DOJ for this issue is Associate Deputy Attorney General Christopher Grieco. His cell phone is (b) (6) and email is Christopher.Grieco@usdoj.gov.

Thank you,

James Mandolfo
Special Assistant to the President
Domestic Policy Council
(202) 881-6421
Sent from my iPhone

Begin forwarded message:

From: "Foltz, Nicole" <nicole.foltz@abbott.com>
Date: April 6, 2020 at 11:57:16 AM EDT
To: "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Subject: [EXTERNAL] Abbott POC for Agency Orders

Morning Joe,
Thanks for bearing with me on the calls yesterday. We are going to hold on the requests for orders from BOP, CIA, Secret Service Army, DOE, until we hear from you on how to proceed with one point of contact from WH.

Really appreciate it.
Nicole

Abbott

Nicole Foltz
Senior Director
Federal Government Affairs
1309 New York Ave. NW
Suite 200
Washington, DC 20005
O: 202-578-2020
F: 202-783-6631
M: 202-717-7370
nicole.foltz@abbott.com
Sent from my iPhone

On Apr 5, 2020, at 9:14 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

S

Thanks. There have been document leaks out of that shop too. Confidential commercial information which is bs, especially with all these non government types over there.

Sent from my iPhone

On Apr 5, 2020, at 9:00 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

I definitely know who this is. I’ll check with Brett.
Steve

Ok. Steve can you do a friendly check in buddy buddy with Giroir and find out what these guys are doing? And let’s not waste Abbott’s time.
Thought that name sounded familiar - works with Girior - was on the Southern HIV end the epidemic

Sent from my iPhone
Thx Joe

---

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 31, 2020 at 1:07:00 PM EDT
To: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Fwd: CORONAVIRUS FLAG: First cell treatment to fight coronavirus awaits FDA approval for clinical trial

(b) (5)

Sent from my iPhone

Begin forwarded message:

From: News Alerts <NewsAlerts@WHO.eop.gov>
Date: March 31, 2020 at 9:09:44 AM EDT
Subject: CORONAVIRUS FLAG: First cell treatment to fight coronavirus awaits FDA approval for clinical trial

First cell treatment to fight the coronavirus awaits FDA approval for clinical trial
CNBC
Charlie Wood
March 31, 2020

- New Jersey-based therapeutics company Celularity is waiting permission from the FDA to test whether a cancer treatment could be effective against COVID-19.
- The cell therapy works by boosting the body’s early immune response in a way that could target the coronavirus.
- The company transforms placental stem cells into one-size-fits-all “Natural Killer” cells that act as sentinels and keep the virus from replicating out of control.
- Some researchers caution that the strategy is highly uncertain and potentially risky, but if the treatment proves safe and effective, Celularity will ramp up production quickly.

The Food and Drug Administration is expected to approve the first of a whole new type of weapon to be tested in the international struggle against COVID-19 as the disease continues to sweep across the globe.

New Jersey-based therapeutics company Celularity announced that its cancer treatment, CYNK-001, is awaiting “Investigational New Drug” status for COVID-19 from the FDA, which could come any day. The treatment will immediately enter a preliminary clinical trial to see if it can help people suffering from the illness. Independent immunologists say that the
rationale for the treatment is solid but warn that it could exacerbate the most severe cases of the disease. If the new strategy proves effective, Celularity stands ready to rapidly increase production.

“It’s important the world knows that there are companies out there developing therapies,” says Dr. Robert Hariri, Celularity’s founder, chairman and CEO. “I bet we will have a therapy.”

Celularity — which has raised $311 million in venture capital funding and attracted the support of big-name entrepreneurs like John Sculley, former CEO of Pepsi and Apple — is a growing biotech company with dreams of taking stem cell therapies mainstream. While sourcing these flexible cells has traditionally been ethically controversial, Hariri, a biomedical researcher, has developed a way to grow the regenerative cells from human placentas which would otherwise be thrown away.

Sculley, the vice chair of the company’s board of directors, envisions a wide range of applications, including someday growing synthetic lungs, but one of the company’s initial goals has been to make a cutting-edge cancer treatment more accessible. Infusions of a certain type of immune cell known as Natural Killer (NK) cells have proven effective in some cases. “All of a sudden their cancer starts melting way,” says Corey Casper, a medical researcher and president of the Infectious Disease Research Institute in Seattle. “It’s like science fiction.”

But creating personalized NK cells from a patient’s blood is a laborious and lengthy process, which is why Celularity developed CYNK-001. The company transforms placental stem cells into one-size-fits-all NK cells, which they keep on ice, ready for transfusion into any patient, at any time. “What’s really a game changer here is these end cells can be stored on the shelf and are ready, not specific to any one individual,” says Casper. “It’s a leap in the technology we haven’t had before.”

Now Celularity is hoping that its NK cells might help patients suffering from COVID-19 too. Where many of the drugs currently under investigation try to neutralize the SARS-CoV-2 virus directly, CYNK-001 — which is the first cell therapy awaiting FDA approval for trials for this illness — has a different goal: to deliver reinforcements to a beleaguered immune system.

When a virus invades the body, the immune system produces a horde of specialized cells that hunt down and kill the intruders. But learning to recognize the virus and raising an army takes days to a week. During that time, NK cells act as sentinels and keep the virus from replicating out of control. How exactly they pull off this task isn’t completely understood, but one of their abilities is to target and destroy stressed cells — a potential sign of infection.

This general capacity to target any and all diseased cells is what makes NK cells effective against certain cancers, and it also makes them the body’s first line of defense against viruses of all varieties. Celularity hopes that additional NK cells will curb SARS-CoV-2’s ability to spread through the body, buying enough time for the immune system to start producing its own antibodies and permanently quell the infection.

**Natural Killer cells foe of viruses**

But will it work? Some research suggests that transplanting mature NK cells into baby mice makes them less susceptible to one particular virus, but no researcher has yet succeeded in using the all-purpose fighters to defeat a virus in humans. One challenge is that viruses and NK cells are ancient foes, and many viruses have become skilled in deception over the eons. “We kind of get hoodwinked by the virus’ ability to evade the NK cells,” says Wayne Yokoyama, an immunologist at the Washington University School of Medicine in St. Louis and longtime researcher of NK cells.

Yokoyama calls the CYNK-001 treatment “an intriguing idea,” but says that the only way to discover whether SARS-CoV-2 will prove a stealth master or a sitting duck is to try and see.

He warns, however, that testing should proceed with extreme caution. COVID-19 turns lethal when the immune system goes on a rampage in what’s known as a “cytokine storm,” recklessly attacking otherwise healthy lung cells. For these people, pushing the immune system even further into overdrive with additional NK cells is the last thing doctors want to do.
Celularity has proved CYNK-001 safe in small numbers of cancer patients, but in those cases the immune system generally remains calm, at little risk of being pushed over the edge. It has been used as a treatment for acute myeloid leukemia, multiple myeloma, and glioblastoma multiforme. “Findings in cancer patients cannot be transposed to COVID-19 patients,” says Puck van Kasteren, a virologist at the National Institute for Public Health in the Netherlands.

But Dr. Hariri notes that the immune system does sometimes respond strongly while fighting cancer, and that Celularity has not observed any signs of cytokine storms while treating cancer patients with CYNK-001. He does not expect that CYNK-001 will cause any adverse effects in COVID-19 patients either. “Although this viral disease is different, we have taken steps to design our clinical trial to ‘tune’ the anti-viral effect by escalating dose slowly while monitoring for evidence of toxicity,” says Dr. Hariri.

He notes that there is early evidence this treatment holds promise. The National Research Project for SARS, Beijing Group has studied NK cell number and function in patients of severe acute respiratory syndrome and the findings point to the fact that they play a direct role in fighting coronavirus.

With the FDA’s blessing, Casper will immediately begin recruiting 86 patients for a combined Phase I/Phase II clinical trial to test whether CYNK-001 is safe and effective for patients with COVID-19. The full trial will last for 11 months from recruitment to analysis, but he hopes the treatment’s effects will become visible within weeks to months. Celularity is funding the trial, which will cost millions of dollars.

To minimize the risk of patients succumbing to what Casper calls “friendly fire” from a rampaging immune system, the trial will focus on moderately ill people — patients who are hospitalized but not those who already need intensive care. Doctors will monitor the first 14 patients especially closely for any signs that CYNK-001 is triggering cytokine storms. “This is a new therapy, and safety comes first,” Casper says. “If we see any signal, we will stop immediately. My hope is that we won't see this.”

Rush to fast-track experimental treatments
The therapy will join hundreds of other treatments currently undergoing FDA-approved testing for Covid-19. Statistically speaking, about one-third of such experimental drugs advance to Phase III for large-scale, rigorous testing.

If CYNK-001 is among the effective treatments, Celularity will be ready to ramp up production quickly. It can derive about 1,000 stem cells from a single placenta. The company recently built a $75 million factory in New Jersey and anticipates being able to produce tens to hundreds of thousands of treatments by summer, according to Sculley. “This is not a dream of the future,” he says.

Early price projections put CYNK-001 at between $2,000 and $7,000 per dose, and in the clinical trial, each patient will receive three doses over the course of one week. But a Celularity spokesperson said that it’s too early to know what the treatment might cost if it reaches the market.

And if NK cells aren’t able to bring the SARS-CoV-2 virus to heel, that lesson could be useful to researchers, too. In the global war against COVID-19, every battle helps turn the tide. “You've got to start somewhere,” Yokoyama says. “Maybe this in itself gives us some valuable clues as to what the next step might be.”
From: News Alerts <NewsAlerts@WHO.eop.gov>
Sent: Wednesday, March 25, 2020 2:28 PM
Subject: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

Coronavirus test: UK to make 15-minute at-home kits available within days
The Independent
Kate Ng
March 25, 2020

‘Once they have been tested this week and the bulk of tests arrive, they will be distributed into the community,’ says Public Health England director

New 15-minute home test kits for coronavirus will be made available to the British public within days, said a Public Health England (PHE) director.

Thousands of tests will be sold in chemists such as Boots or delivered by Amazon to people with symptoms who are self-isolating as soon as next week.

Professor Sharon Peacock, director of the national infection service at PHE, told MPs on the science and technology committee once the tests are cleared, they will be “distributed to the community”.

Matt Hancock, the health secretary, said the government bought millions of the tests on Tuesday and is ordering millions more.

The antibody test involves pricking a finger and analysing a drop of blood in a device that looks like a pregnancy test. It will only tell the person if they have had Covid-19, not if they currently have it.
The test will detect the presence of the antibodies IGM, which emerges in the early stages of infection, and IGG, which increases during the body’s response to the virus.

Ms Peacock said the tests would “absolutely” be available within days, rather than weeks or months, when asked by MPs. She said: “Several million tests have been purchased for use. These are brand new products. We have to be clear they work as they are claimed to do.

“Once they have been tested this week and the bulk of tests arrive, they will be distributed into the community.”

Currently, only patients admitted to hospital are being routinely tested for Covid-19. Between 5,000 to 6,000 people are being tested a day, but the government plans to increase this to 25,000 tests a day within four weeks.

The new antibody tests could help the UK achieve what the World Health Organisation (WHO) has urged governments to do, which is to “test, test, test”.

Tedros Adhanom Ghebreyesus, director-general of the WHO, said: “We cannot stop this pandemic if we do not know who is infected.”

The antibody tests are also being ordered across Europe and Southeast Asia, said Ms Peacock.

“We are not alone in doing this,” she added.
Thanks, Joe. We’ll work on this.

Steve
Coronavirus test: UK to make 15-minute at-home kits available within days

The Independent
Kate Ng
March 25, 2020
'Once they have been tested this week and the bulk of tests arrive, they will be distributed into the community,' says Public Health England director.

New 15-minute home test kits for coronavirus will be made available to the British public within days, said a Public Health England (PHE) director.

Thousands of tests will be sold in chemists such as Boots or delivered by Amazon to people with symptoms who are self-isolating as soon as next week.

Professor Sharon Peacock, director of the national infection service at PHE, told MPs on the science and technology committee once the tests are cleared, they will be “distributed to the community”.

Matt Hancock, the health secretary, said the government bought millions of the tests on Tuesday and is ordering millions more.

The antibody test involves pricking a finger and analysing a drop of blood in a device that looks like a pregnancy test. It will only tell the person if they have had Covid-19, not if they currently have it.

The test will detect the presence of the antibodies IGM, which emerges in the early stages of infection, and IGG, which increases during the body’s response to the virus.

Ms Peacock said the tests would “absolutely” be available within days, rather than weeks or months, when asked by MPs.

She said: “Several million tests have ben purchased for use. These are brand new products. We have to be clear they work as they are claimed to do.

“Once they have been tested this week and the bulk of tests arrive, they will be distributed into the community.”

Currently, only patients admitted to hospital are being routinely tested for Covid-19. Between 5,000 to 6,000 people are being tested a day, but the government plans to increase this to 25,000 tests a day within four weeks.

The new antibody tests could help the UK achieve what the World Health Organisation (WHO) has urged governments to do, which is to “test, test, test”.

Tedros Adhanom Ghebreyesus, director-general of the WHO, said: “We cannot stop this pandemic if we do not know who is infected.”

The antibody tests are also being ordered across Europe and Southeast Asia, said Ms Peacock.

“We are not alone in doing this,” she added.
From: Hahn, Stephen [O=EXCHANGELABS/O=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CF3A3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/27/2020 9:39:38 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@ovp.eop.gov]
Hodgson, Christopher M. EOP/OVP @ovp.eop.gov
Cc: Troye, Olivia EOP/NSC @ovp.eop.gov
Subject: Re: Best person to conact

The company stopped compassionate use but they started an expanded access protocol which we approved on Tuesday. It is worth reaching out to the company

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@ovp.eop.gov>
Date: March 27, 2020 at 9:04:31 PM EDT
To: Hodgson, Christopher M. EOP/OVP <ovp.eop.gov>
Cc: Troye, Olivia EOP/NSC <Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Best person to conact

Steve is compassion use an option?

Sent from my iPhone

On Mar 27, 2020, at 8:54 PM, Hodgson, Christopher M. EOP/OVP <ovp.eop.gov>
wrote:

Per the email below from Rep. Liz Cheney’s CoS, is there a good contact for them to reach out to about the Ramdesivir trial?

Chris Hodgson
Director of Legislative Affairs
Office of the Vice President

Begin forwarded message:

From: "Ahern, Kara" <Kara.Ahern@mail.house.gov>
Date: March 27, 2020 at 8:45:36 PM EDT
To: "Hodgson, Christopher M. EOP/OVP" <ovp.eop.gov>
Subject: Best person to conact

Chris - sorry to bother you as I know you are swamped. Liz asked me to reach out and see if you could point me in the right direction. The mother of the the former is in a hospital in NYC on a ventilator with COVID-19. Her Doctor asked him to see if there is anyway to get Ramdesivir to their hospital as they believe it will help his mother. The reason he is told that they can not get it is that it is not an approved test site. I am wondering who I can speak with to figure out timing on the drug and if it may be possible to get into the trial. Any advice?
Yes, I do think we (FDA) should engage. We are working with manufacturers so we have to be careful about CCI. Do you have a POC and number?
Steve

---

From: McGuffee, Tyler A. EOP/OVP <bobbie6@ovp.eop.gov>
Date: March 30, 2020 at 6:57:17 PM EDT
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@bobbie6@ovp.eop.gov> Hahn, Stephen <SH1@fda.hhs.gov>
Subject: FW: potential call

Any interest in taking this call or delegate to staff?

---

From: Pinkos, Stephen M. EOP/OVP <bobbie6@ovp.eop.gov>
Sent: Monday, March 30, 2020 5:26 PM
To: McGuffee, Tyler A. EOP/OVP <bobbie6@ovp.eop.gov>
Subject: potential call

Tyler Ann,

Please see below and attached when you get a chance. This is a group of medical and investor heavy hitters who have been expending a great deal of time convening folks and developing ideas. Marty Obst and Michael Milken have been the principal conveners of this group.

Do you think this would be worth of Dr. Birx and/or Dr Hahn time? If not, we can take care of it at a staff level and report back.

Thanks,
Steve

---

From: Thomas Cahill <tom@newpath.partners>
Sent: Monday, March 30, 2020 3:52 PM
To: Marty Obst <martyobst@mostrat.com>
Cc: Pinkos, Stephen M. EOP/OVP <bobbie6@ovp.eop.gov>; Cydney Couch <cydney@mostrat.com>; Lauren Denman <ldenman@newpath.partners>
Subject: [EXTERNAL] Re: Follow Up Call

Dear Marty and Steve,

Thank you for reaching out. It would be great to find a time to chat with you all -- some from our team will join as well (Drs. Michael Rosbash, Stuart Schreiber, Ed Scolnick, David Liu, and Ramnik Xavier). Our team of citizen-scientists has been iterating on the proposal (attached) for the last month. We anticipate that implementing the proposal will provide an effective and safe therapy for COVID-19 within as little as 3 months
(June). This approach could provide a broadly available therapeutic to the general public by late summer, prior to the widely anticipated second wave of coronavirus outbreaks.

Lauren, cc’d, can help coordinate a time to speak.

Best,
Tom

On Mon, Mar 30, 2020 at 3:22 PM Marty Obst <martyobst@mostrat.com> wrote:

Steve,

I thought it would be helpful for us to have a follow up call at some point over the next couple of days. I think Tom’s group can be tremendous impactful and I’d like to compare notes and agree on some action items. I’m willing to help on whatever I can do to assist.

Let me know if there would be a time tomorrow or Wednesday that would work.

Thanks,
Marty Obst

Sent from my iPad

--

Thomas J. Cahill III, M.D., Ph.D.
Founder and Managing Partner
Newpath Partners, L.P.
800 Boylston Street, Suite 2222
Boston, MA 02199
978-771-9999 | tom@newpath.partners

This electronic mail message, including any attachments hereto, is from Newpath Management and may contain information which is confidential, subject to legal privilege, or should otherwise be safeguarded from disclosure. The information in this message is intended solely for the use of the intended recipient(s) and Newpath Management does not waive confidentiality by inadvertent transmission. This e-mail is not a solicitation or an offer to buy or sell securities or related financial instruments. If you are not the addressee indicated in this message (or responsible for delivery of the message to such person), you are hereby notified that you must not use, disseminate, copy it in any form, or take any action based upon it. If you have received this message by error, please immediately delete it and any electronic and/or hard copies of it, including any attachments thereto, and notify the sender at Newpath Management by reply electronic mail message, fax or phone. Please note that Newpath Management accepts no liability for the content of this e-mail, or for the consequences of any actions taken on the basis of the information provided herein. Newpath Management may intercept, monitor and retain e-mails sent to and from its electronic communications systems as permitted by applicable law. WARNING: Computer viruses can be transmitted via e-mail. It is your responsibility to keep your system free from viruses and any other harmful codes or devices. The recipient should check this e-mail and any attachments hereto for the presence of viruses. Newpath Management accepts no liability for any damage caused by any virus transmitted by this e-mail. E-mail transmissions cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. Therefore, Newpath Management accepts no liability for any errors or omissions in the contents of this e-mail which arise as a result of e-mail transmission.
Yes, we need to revisit. Have additional updates on therapeutics for you Joe

That’s what CDER is comfortable with, yes.

It’s a tough situation.

Sent from my iPhone

FDA has been working with Gilead to provide investigational antiviral drug remdesivir to hospitalized COVID-19 patients in the U.S. through both clinical trials to evaluate safety and efficacy to fight the virus, as well as emergency use to individual patients of clinicians without access to a clinical trial. To date, the company has provided emergency access to remdesivir patients who are severely ill in the United States, Europe and Japan. Working with FDA, Gilead is moving to a broad expanded access program that is less burdensome to providers and patients. This is expected to accelerate the delivery of the drugs to hospitals, physicians and patients.
Sent from my iPhone

On Mar 24, 2020, at 8:18 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

Sent from my iPhone
That is very interesting. This is definitely a patient-doctor issue within a local (state) context.

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 25, 2020 at 9:34:51 AM EDT
To: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>
Subject: Re: STATE FLAG: Nevada governor bans malaria drugs for coronavirus patients

(b) (5)

Sent from my iPhone

On Mar 25, 2020, at 9:24 AM, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov> wrote:


The FDA issued a Consumer Update advising consumers to be beware of fraudulent coronavirus tests, vaccines and treatments. The FDA is particularly concerned that deceptive and misleading products might cause Americans to delay or stop appropriate medical treatment, leading to serious and life-threatening harm. It’s likely that the products do not do what they claim, and the ingredients in them could cause adverse effects and could interact with, and potentially interfere with, essential medications. There are no FDA-approved products to prevent COVID-19. For example, the FDA is aware of people trying to prevent COVID-19 by taking a product called chloroquine phosphate, which is sold to treat parasites in aquarium fish. Products for veterinary use or for “research use only” may have adverse effects, including serious illness and death, when taken by people. The agency warns not to take any form of chloroquine unless it has been prescribed by a health care provider and obtained from legitimate sources.

(b) (5)

Sent from my iPhone
Sent from my iPhone

Begin forwarded message:

From: "Lyons, Derek S. EOP/WHO" <Derek.S.Lyons@who.eop.gov>
Date: March 25, 2020 at 9:04:39 AM EDT
To: "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>, "Cipollone, Pat A. EOP/WHO" <(b)(6)who.eop.gov>, "Philbin, Patrick F. EOP/WHO" <(b)(6)who.eop.gov>
Subject: FW: STATE FLAG: Nevada governor bans malaria drugs for coronavirus patients

From: News Alerts <NewsAlerts@WHO.eop.gov>
Sent: Wednesday, March 25, 2020 7:23 AM
Subject: STATE FLAG: Nevada governor bans malaria drugs for coronavirus patients

Nevada governor bans malaria drugs for coronavirus patients
Associated Press
Michelle Price
March 24, 2020

Nevada’s governor has signed an emergency order barring the use of anti-malaria drugs for someone who has the coronavirus.

Democratic Gov. Steve Sisolak’s order Tuesday restricting chloroquine and hydroxychloroquine comes after President Donald Trump touted the medication as a treatment for the virus.

Trump last week falsely stated that the Food and Drug Administration had just approved the use of chloroquine to treat patients infected with coronavirus. After the FDA’s chief said the drug still needs to be tested for that use, Trump overstated the drug’s potential benefits in containing the virus.

Sisolak said in a statement that there’s no consensus among experts or Nevada doctors that the drugs can treat people with COVID-19. His order also limits a prescription to a 30-day supply to ensure it’s available for “legitimate medical purposes” and so that people cannot find a way to stockpile the drug.

The governor’s rule comes a day after a Phoenix-area man died and his wife was in critical condition from taking an additive used to clean fish tanks known as chloroquine phosphate, similar to the drug used to treat malaria.
Deb,
Thank you very much for the information, your caution, and please take care.
Steve
Yes, for sure

Let me know –

They tell us today
From: Hahn, Stephen [O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23PDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C498913B33E38A036E9F-STEPHEN.HAH]

Sent: 3/2/2020 3:33:48 PM

To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@](b)(6) Redfield, Robert R (CDC) [O=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23PDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]

Subject: Re: [EXTERNAL] Urgent Oz: Clinical Trial Drug Shortage

(b)(6)

Thanks

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@>(b)(6)

Date: March 22, 2020 at 3:33:19 PM EDT

To: Hahn, Stephen <SH1@fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>

Subject: Re: [EXTERNAL] Urgent Oz: Clinical Trial Drug Shortage

Will call you after task force – what is your cell number?

From: "Hahn, Stephen" <SH1@fda.hhs.gov>

Date: Sunday, March 22, 2020 at 3:31 PM

To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@>(b)(6) Redfield, Robert R (CDC) <(b)(6) cdc.gov>

Subject: Re: [EXTERNAL] Urgent Oz: Clinical Trial Drug Shortage

Not doing press. I have lots of data on this.

S

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@>(b)(6)

Date: March 22, 2020 at 3:28:13 PM EDT

To: Hahn, Stephen <SH1@fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>

Subject: Re: [EXTERNAL] Urgent Oz: Clinical Trial Drug Shortage

Yes – after call – are you doing press?

From: "Hahn, Stephen" <SH1@fda.hhs.gov>

Date: Sunday, March 22, 2020 at 3:26 PM

To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@>(b)(6) Redfield, Robert R (CDC) <(b)(6) cdc.gov>

Subject: Re: [EXTERNAL] Urgent Oz: Clinical Trial Drug Shortage

(b)(6) Do you have any time to talk about this?

S

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@>(b)(6)

Date: March 22, 2020 at 10:28:38 AM EDT
Thanks for sharing but this does not address the shortage issue. We already have an IRB for prophylaxis and applying for treatment trial today but don’t have drugs to complete so please share expectations that can inform our work. Can we at least get batches of drugs for a hundred trial patients? If you don’t wish to put in writing, please call but I need guidance for my show and dozens of media interviews that I am doing tomorrow.

Also, the below summary correctly shares that no outcomes data is available from Marseille, but you should know that the French researcher confirmed clinical benefits but needs more data so will not release report for another 10 days. These findings offer hope to our people.

On Mar 22, 2020, at 10:17 AM, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@eop.eop.gov> wrote:

Dr Oz
This was posted yesterday on the CDC website and serves to address the issues you raised. Deb

Information for Clinicians on Therapeutic Options for COVID-19 Patients

There are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19. At present clinical management includes infection prevention and control measures and supportive care, including supplementary oxygen and mechanical ventilatory support when indicated. An array of drugs approved for other indications as well as several investigational drugs are being studied in several hundred clinical trials that are underway across the globe. The purpose of this document is to provide information on two of the approved drugs (chloroquine and hydroxychloroquine) and one of the investigational agents (remdesivir) currently in use in the United States.

Remdesivir
Remdesivir is an investigational intravenous drug with broad antiviral activity that inhibits viral replication through premature termination of RNA transcription and has in-vitro activity against SARS-CoV-2 and in-vitro and in-vivo activity against related betacoronaviruses [1,3]. There are currently four options for obtaining remdesivir for treatment of hospitalized patients with COVID-19 and pneumonia in the United States:

- A National Institutes of Health (NIH)-sponsored adaptive double-blinded, placebo-controlled trial of remdesivir versus placebo in COVID-19 patients with pneumonia and hypoxia is enrolling
non-pregnant persons aged 18 years and older with oxygen saturation of \( \leq 94\% \) on room air or requiring supplemental oxygen or mechanical ventilation (https://clinicaltrials.gov/ct2/show/NCT04280705). Exclusion criteria include alanine aminotransaminase or aspartate aminotransaminase levels >5 times the upper limit of normal, stage 4 severe chronic kidney disease or a requirement for dialysis (i.e., estimated glomerular filtration rate (eGFR) <30);

- Two phase 3 randomized open-label trials of remdesivir (5-days versus 10-days versus standard of care) are open to enrollment in persons aged 18 years and older with COVID-19, radiographic evidence of pneumonia and oxygen saturation of \( \leq 94\% \) on room air (severe disease https://clinicaltrials.gov/ct2/show/NCT04292899 or >94\% on room air (moderate disease https://clinicaltrials.gov/ct2/show/NCT04292730).

Exclusion criteria include alanine aminotransaminase or aspartate aminotransaminase levels >5 times the upper limit of normal, participation in another clinical trial of an experimental treatment for COVID-19, requirement for mechanical ventilation, or creatinine clearance <50 mL/min; and finally, in areas without clinical trials, COVID-19 patients in the United States and other countries have been treated with remdesivir on an uncontrolled compassionate use basis. While clinical trials are critical to establish the safety and efficacy of this drug, clinicians without access to a clinical trial may request remdesivir for compassionate use through the manufacturer for patients with clinical pneumonia: compassionateaccess@gilead.com

Hydroxychloroquine and Chloroquine
Hydroxychloroquine and chloroquine are oral prescription drugs that have been used for treatment of malaria and certain inflammatory conditions. Chloroquine has been used for malaria treatment and chemoprophylaxis, and hydroxychloroquine is used for treatment of rheumatoid arthritis, systemic lupus erythematosus and porphyria cutanea tarda. Both drugs have in-vitro activity against SARS-CoV, SARS-CoV-2, and other coronaviruses, with hydroxychloroquine having relatively higher potency against SARS-CoV-2 (0.6-9). A study in China reported that chloroquine treatment of COVID-19 patients had clinical and virologic benefit versus a comparison group, and chloroquine was added as a recommended antiviral for treatment of COVID-19 in China (13). Based upon limited in-vitro and anecdotal data, chloroquine or hydroxychloroquine are currently recommended for treatment of hospitalized COVID-19 patients in several countries. Both chloroquine and hydroxychloroquine have known safety profiles with the main concerns being cardiotoxicity (prolonged QT syndrome) with prolonged use in patients with hepatic or renal dysfunction and immunosuppression but have been reportedly well-tolerated in COVID-19 patients.

Due to higher in-vitro activity against SARS-CoV-2 and its wider availability in the United States compared with chloroquine, hydroxychloroquine has been administered to hospitalized COVID-19 patients on an uncontrolled basis in multiple countries, including in the United States. One small study reported that hydroxychloroquine alone or in combination with azithromycin reduced detection of SARS-CoV-2 RNA in upper respiratory tract specimens compared with a non-randomized control group but did not assess clinical benefit (14). Hydroxychloroquine and azithromycin are associated with QT prolongation and caution is advised when considering these drugs in patients with chronic medical conditions (e.g. renal failure, hepatic disease) or who are receiving medications that might interact to cause arrhythmias.

Hydroxychloroquine is currently under investigation in clinical trials for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection, and treatment of patients with mild, moderate, and severe COVID-19. In the United States, several clinical trials of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection are planned or will be enrolling soon. More information on trials can be found at: https://clinicaltrials.gov. 
There are no currently available data from Randomized Clinical Trials (RCTs) to inform clinical guidance on the use, dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection. Although optimal dosing and duration of hydroxychloroquine for treatment of COVID-19 are unknown, some U.S. clinicians have reported anecdotally different hydroxychloroquine dosing such as: 400mg BID on day one, then daily for 5 days; 400 mg BID on day one, then 200mg BID for 4 days; 600 mg BID on day one, then 400mg daily on days 2-5.

Other Drugs
Lopinavir-ritonavir did not show promise for treatment of hospitalized COVID-19 patients with pneumonia in a recent clinical trial in China [11]. This trial was underpowered, and lopinavir-ritonavir is under investigation in a World Health Organization study.
Several other drugs are under investigation in clinical trials or are being considered for clinical trials of prophylaxis or treatment of COVID-19 in the United States and worldwide. Information on registered clinical trials for COVID-19 in the United States is available at: >>>https://clinicaltrials.gov/ <<<; external icon.

References
Coronavirus Disease 2019 (COVID-19)

- How to Prepare
- Symptoms & Testing
- Are You at Higher Risk for Severe Illness?
- If You Are Sick or Caring for Someone
- Frequently Asked Questions
- Travel
- Cases & Latest Updates
- Schools, Workplaces & Community Locations

Healthcare Professionals

- Evaluating and Testing PUI
- Postmortem Guidance
- Interim Guidance for EMS
- Infection Control

Clinical Care

- Therapeutic Options for Patients with COVID-19
- Pediatric Healthcare Providers
- Disposition of Hospitalized Patients with COVID-19
- Inpatient Obstetric Healthcare Guidance

What Healthcare Personnel Should Know

- Strategies to Optimize PPE & Equipment
- Healthcare Personnel with Potential Exposure to COVID-19

Preparedness Resources

- Implementing Home Care
- Healthcare Supply of Personal Protective Equipment
- FAQ for Healthcare Professionals

- Healthcare Facilities
- Health Departments
- Laboratories
- Communication Resources

Get Email Updates

To receive email updates about COVID-19, enter your email address:

Email Address

What's this?

Submit
Can we get Taskforce commitment for academic centers to procure at least enough drugs for 100 patient trials like the project below. Does the Taskforce have an idea of the magnitude of shortage and estimates of length of time required to remedy situation?

If we cannot do trials, can we free US clinicians to start using this combo drug protocol. We cannot hide behind study protocols if we are not allowed to proceed. We should have started enrollment on Friday and I want to push brave Americans to join trials on my show tomorrow, but cannot without a game plan for accessing drugs.

P.S. The French physician Raoul argued that withholding access is unethical.

On Mar 22, 2020, at 9:59 AM, Bix, Deborah L. EOP/NSC <Deborah.L.Birx@HHS.gov> wrote:
Guidelines to clinicians is coming out today or tomorrow around this essential issue. Deb

From: Dr Mehmet Oz <drmaz@zoco.com>
Date: Sunday, March 22, 2020 at 9:52 AM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@HHS.gov>
Cc: "McGuffee, Tyler A. EOP/OVP" <tyler.mcguffee@ovp.eop.gov>, Michael Crupain <MCrupain@zoco.com>
Subject: [EXTERNAL] Urgent Oz: Clinical Trial Drug Shortage

I interviewed the respected Marseille Prof Dr Didier Raoul at 6am today. He authored the French hydroxychloroquine + azithromycin study and has very provocative un-published findings that are worth sharing. I shared his beliefs with my New York Presbyterian – Columbia team and we are writing IRBs for approval early this week but we need medications. However, in our massive hospital, we currently have enough hydroxychloroquine for 75 patients and azithromycin for 20 patients. I will personally fund the trial and committed $250,00 but nothing can progress without medications. The President should sequester these medications for clinical trials like ours. Can you help us? I am taping material for tomorrow and would appreciate any advice on how to phrase the Task Force’s efforts.
Mehmet Oz (917 648 8553)
From: Andrew Whitney <andrew.whitney@vespasian.com>
Date: March 21, 2020 at 11:50:29 PM EDT
Cc: Robert Newman PHD <newmanscientificconsulting@gmail.com>, Debra Birnkrant <Debra.Birnkrant@fda.hhs.gov>
Subject: [EXTERNAL] Post-Call Report/Summary on FDA/Phoenix Biotechnology INC Call

Dear Taylor Ann,

It is certainly our conclusion that we had a very positive and productive call with Debbie (naturally I hope she agrees) and we are very grateful for the opportunity to meet the Director of Antivirals for FDA.

We sought to provide a very succinct and compelling account of the achievements to date, the envelope hypothesis that we believe explains our results against multiple viruses (our solution damages the ability of viral progeny to properly form their protective envelope and thus they fall victim to the body's immune system) and we also covered the Phase 1&2 clinical trials success to date that underscores safety.

We informed Debbie about the prearranged test against COVID19 at ALG labs in Minnesota this coming week.

We briefly touched on the situation in Mexico (with a suitable number of caveats and disclaimers so as not to overplay the point) but as of 9pm this evening it has been confirmed that the 8mo baby boy appears to be recovering well, no more fever or diarrhea and only some coughing, quite a reversal on the terminal status recorded by the doctor at the time the decision was taken to deploy Anvirzel as a last ditch move.

We felt the call was very positive and the follow up actions are:

1) Provide papers/data to Debbie/FDA team to support claims on tests to date

2) Provide corroborating evidence against COVID19 once received from ALG labs this week coming

3) Submit 'Pre-IND' application; essentially all the above plus the material originally submitted for the Phase 1&2 (but repeated because last time it went in the system for oncology and this time it will go in as antiviral/COVID19).

A REQUEST: Tyler Ann we did ask if FDA personnel could perhaps put in a call to a couple of labs to get us some further testing opportunities (the labs all say they are too busy to fit us in, which is to some degree understandable given the current pressure on the system and also the fact that we are nobodies in the grand scheme) but while we understand that the FDA cannot insert itself/step forward to wield influence here I'd like to ask you if someone from Ambassador Birx's office might be willing to make that call on our behalf. We are very certain that if such a call were to come from her office and/or the White House these labs would likely find a test opportunity for us. I would be pleased to provide the contact details if you believe that could be made to happen.

We are very grateful for Debbie's advice, clarity and positive drive and engagement on this, particularly on a Saturday evening and indeed to you too Tyler Ann; it is an inspiring demonstration of what happens when great people assert themselves on a situation to bring about results.
We fully believe we have something unique here and we stand ready to respond at any hour.

Very best

Andrew

Andrew Whitney
Executive Chairman
Phoenix Biotechnology Inc

Cell: [phone number]
Yes, pre-brief Thursday. Colin can you make sure that happens?

S

------------------

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 25, 2020 at 11:52:38 AM EDT
To: Rom, Colin <Colin.Rom@fda.hhs.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: [b] [5]

Ok. So pre brief Thursday?

Sent from my iPhone

> On Mar 25, 2020, at 11:51 AM, Rom, Colin <Colin.Rom@fda.hhs.gov> wrote:
> 
> > Will be ready to announce to task force on Friday
> > 
> > -----Original Message-----
> > From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
> > Sent: Wednesday, March 25, 2020 11:22 AM
> > To: Hahn, Stephen <SH1@fda.hhs.gov>
> > Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>
> > Subject: [b] [5]
> > 
> > I'm getting pressed to schedule it.
> > 
> > Sent from my iPhone
Joe,

It’s coronavirus treatment acceleration plan

FDA will be ready to present their Coronavirus Therapy Action Plan to the Task Force Friday. Please put it on the agenda.
Mitch

I believe we know each other from time at UCSF.
I’ve attached the guidance.
Please let me know how we can help.
Steve

https://www.fda.gov/media/136318/download

---

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@ah>  
Date: March 22, 2020 at 8:45:38 PM EDT  
To: mitchell.katz@nychhc.org <mitchell.katz@nychhc.org>  
Cc: Hahn, Stephen <S1@fda.hhs.gov>, Mary Dale Peterson <M.Peterson@asahq.org>  
Subject: Fwd: [EXTERNAL] re ramping up personnel and ventilators

Trying again.

Sent from my iPhone

Begin forwarded message:

From: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@ah>  
Date: March 22, 2020 at 8:38:14 PM EDT  
To: "mitchellkatz@NYCHHC.org" <mitchellkatz@NYCHHC.org>  
Cc: Stephen Hahn <S1@fda.hhs.gov>, Mary Dale Peterson <M.Peterson@asahq.org>  
Subject: Fwd: [EXTERNAL] re ramping up personnel and ventilators

Mitchell

I have copied Stephen Hahn and Mary Peterson. FDA has approved the use of OR vents and Dr. Peterson has been amazing on the below. She also has all the filter change information. Let us know how we can help. Deb

Sent from my iPhone

Begin forwarded message:

From: Mary Dale Peterson <M.Peterson@asahq.org>  
Date: March 22, 2020 at 6:26:26 PM EDT  
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@ah> "Adams, Jerome (HHS/OASH)" <Jerome.Adams@hhs.gov>  
Cc: Manuel Bonilla <M.Bonilla@asahq.org>, Paul Pomerantz <p.pomerantz@asahq.org>  
Subject: [EXTERNAL] re ramping up personnel and ventilators

Drs. Birx and Adams- I wanted to let you know that ASA and APSF will be coming out with a statement recommending that anesthesia professionals wear N95 masks or have equivalent protection (CAPR/PAPR) for all intubations. We are
beginning to see more community spread and instances where one day a person is not a PUI and the next day they are ill with COVID 19. We can’t afford to lose our workforce at this critical time and those performing intubations are at the highest risk for aerosolized particles and the close proximity required for intubation. We understand that many hospitals are running low on N95s. Do you all have any idea how much could be released from stockpiles while manufacturing ramps up production or what the status is for n95s?

On another work stream, I want to share what we are doing to repurpose anesthesia ventilators and create an additional workforce:

1) By Tuesday evening we will have more specific, practical guidance to anesthesiologists on how to convert anesthesia gas machines to ventilate COVID19 patients that would include the common ventilatory modes needed and how to accomplish that. We will have short videos that demo this with the most common anesthesia gas machines as well as an FAQ section.

2) By the end of the week we will have a educational approach for critical care patient management
   - Commons dos and don’ts
   - Infectious Disease 101- the right antibiotics to consider with co-infections
   - Nutrition 101
   - The role of ECMO (very limited)

3) We are looking at developing an ongoing resource where we would set up a hotline with our experts to assist anesthesiologists with repurposing their anesthesia machines for ICU ventilation. We are not sure exactly how to do this, but will be investigating the logistics. We have the volunteer experts.

We are organizing a tele town hall this Thursday that will concentrate on these 3 topics with our members.

We are working nonstop to help our members with resources to take care of the surge of patients. Please let me know if you have other thoughts or suggestions.

Sincerely,

Mary Dale Peterson, MD, MSHCA, FASA
President-Elect, ASA
(cell) 361-774-5530

---

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@HHS.GOV>
Sent: Sunday, March 22, 2020 5:07 PM
To: Mary Dale Peterson <M.Peterson@asahq.org>; Adams, Jerome (HHS/OASH) <Jerome.Adams@hhs.gov>
Cc: Manuel Bonilla <M.Bonilla@asahq.org>
Subject: Re: [EXTERNAL] FW: [External] From the President of the Illinois Society of Anesthesiologists

Thank you – I have sent to the right people. Deb

---

From: Mary Dale Peterson <M.Peterson@asahq.org>
Date: Sunday, March 22, 2020 at 6:05 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@HHS.GOV>, "Adams, Jerome (HHS/OASH)"
<Jerome.Adams@hhs.gov>
Cc: Manuel Bonilla <M.Bonilla@asahq.org>
Subject: [EXTERNAL] FW: [External] From the President of the Illinois Society of Anesthesiologists
Drs. Birx and Adams- Not sure who I should send this contact re manufacturing N95s.

Mary Dale

Mary Dale Peterson, MD, MSHCA, FASA
President-Elect, ASA
(cell) 361-774-5530

From: Feldman, Jeffrey <FELDMANJ@email.chop.edu>
Sent: Sunday, March 22, 2020 4:58 PM
To: Mary Dale Peterson <M.Peterson@asahq.org>; Manuel Bonilla <M.Bonilla@asahq.org>
Subject: FW: [External] From the President of the Illinois Society of Anesthesiologists

FYI

From: Sean Adams <ssadamss@me.com>
Date: Sunday, March 22, 2020 at 5:49 PM
To: “feldman@apsf.org” <feldman@apsf.org>
Cc: Doug Bennett <Douglas@aura-tech.us>
Subject: [External] From the President of the Illinois Society of Anesthesiologists

Good afternoon Jeff:

Thanks for all you are doing in these times.

I appreciated your comments during the Town Hall.

The CEO of a defense contractor (card below Doug Bennett, copied this email, >>http://aura.company<<) specialized in 3D print technology solutions was referred to me as potential to make N95 supplies and other needs that may be in short supply at the local level.

Who might I refer him towards for specific conversation?

You brought up N95 technical issues during the Town Hall that sound like you could have a productive discussion with him.

Please let me know anything I might do.

Thanks,

Sean
Sean S. Adams, M.D. FASA
Sean S. Adams, M.D.
mobile 312 961 0348
2019-2020 President to the Illinois Society of Anesthesiologists
(312) 580-2455
>>www.isahq.org<<
Confidentiality notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. All personal messages express views solely of the sender, which are not to be attributed to the Illinois Society of Anesthesiologists. Unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

** This email originated from an EXTERNAL sender to CHOP. Proceed with caution when replying, opening attachments, or clicking links. Do not disclose your CHOP credentials, employee information, or protected health information to a potential hacker**.
Ambassador Birx,

I know you are extremely busy but I am forwarding this as it is high profile and tied to Keith Schiller and his recent conversations with the President on this subject. Both he and Vinh are cc’d so they can connect with the appropriate member of your team.

Thanks,

Drew

Begin forwarded message:

From: Vinh Vuong <vinh@vuonginc.com>
Date: March 22, 2020 at 7:21:41 PM EDT
To: "Horn, Drew L. EOP/OVP" <b@ovp.eop.gov>
Subject: [EXTERNAL] URGENT: Significantly More Viable Coronavirus Test Kits - Made in USA

Drew,
We have a more a far more viable solution for coronavirus (and other viruses) testing which will get around sample prep and DNA extraction bottlenecks -- and more importantly has a specificity and sensitivity at 100% respectively.

The test is from DiaCarta, based in Richmond, CA, please find their product flyer for the COVID-19 test attached:

- DiaCarta-Flyer-QuantiVirus-SARS-CoV-2-Test-Kit-03212020 [100% specificity / 100% sensitivity]. This test already has already received an acknowledgement letter from the FDA on an EUA submission (attached).

Currently, [b] (4)

Diacarta can scale up to [b] (4)

These tests have been validated on multiple PCR platforms, which solves the current bottleneck created by existing tests from Roche.

All tests MADE IN USA. See attached for the Manufacturer submission.

Please let me know of interest and will connect you or others to them.

Many thanks,
Vinh

--
Vinh Vuong

Chairman, Vuong Enterprises
Partner, Bork Communication Group
Partner, Lucas | Compton

P: +1 646-946-2176
LinkedIn: https://www.linkedin.com/in/vinhvuong/<
Twitter: https://www.twitter.com/thevinhvuong/<
Website: https://www.vinhvuong.com/<

DISCLAIMER: This email and any attachments may be confidential, privileged or otherwise exempt from disclosure under applicable law. No confidentiality or privilege is waived or lost by any transmission errors. This communication is intended solely for the intended recipient, and if you are not the intended recipient, please notify the sender immediately, delete it from your system and do not copy, redistribute, disclose or otherwise act upon any part of this email communication or its attachments.
Used to be called ATF

From: Grogan, Joseph J. EOP/WHO &lt;Joseph.J.Grogan@who.eop.gov&gt;  
Date: March 21, 2020 at 6:28:29 PM EDT  
To: Hahn, Stephen &lt;SH1@fda.hhs.gov&gt;  
Subject: Re: Hand Sanitizer

What is TTB?

Sent from my iPhone

On Mar 21, 2020, at 6:25 PM, Hahn, Stephen &lt;SH1@fda.hhs.gov&gt; wrote:

FYI if you could help with pro-active situational awareness.
S

From: Lenihan, Keagan &lt;Keagan.Lenihan@fda.hhs.gov&gt;  
Date: March 21, 2020 at 6:22:55 PM EDT  
To: Hahn, Stephen &lt;SH1@fda.hhs.gov&gt;  
Subject: Hand Sanitizer

We should chat again on this. You are going to hear about this at WH and from Hill. Below what was agreed to between FDA/TTB.

TTB Action items:
- Update guidance to remove production with undenatured alcohol, send to FDA
- Provide information on labeling and permit requirements for shipping both denatured and undenatured alcohol
- Provide Q&A on website with cross reference to FDA Q&A/Guidance
- If questions come in from manufacturers citing difficulty denaturing alcohol, ask whether the denaturants themselves are in short supply and who they purchase the denaturing chemicals from. Provide info to TTB

FDA Action items:
- Provide Q&A on website with cross reference to TTB Q&A/Guidance, include information on safety issue with undenatured alcohol
- Review TTB Denaturant list and provide input on which formulas would be appropriate for hand sanitizers
- Draft further guidance on production of ethanol as API, and describe safety issue with undenatured alcohol
- Discuss policy with Chief of Staff
Got it

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 22, 2020 at 10:55:43 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>, Shah, Anand <Anand.Shah@fda.hhs.gov>
Subject: Margolis COVID-19 tx working paper.pdf
Would be happy to do so. Colin or Keagan, would you check in with the VP’s leg affairs person who was on the line to find out exactly what the senators want from us? One thing I wrote down is to create a document that speaks to the different technologies that we are looking out for diagnostic and serology testing. 

Thanks
Steve

---

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@(b) (6)>
Date: April 15, 2020 at 4:37:11 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Senator Blunt and Senator Alexander call

Can you start and I will fill in whatever you need from me

---

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Wednesday, April 15, 2020 at 4:29 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@(b) (6)>
Subject: Senator Blunt and Senator Alexander call

Debi,
We have a couple of deliverables for the Senators. What do you want me to work on?
thanks
Steve
From:  Hahn, Stephen /O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP
        (FYDIHO8F23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913B33E38A036E9F-STEPHEN.HAH]
Sent:  3/15/2020 7:44:27 PM
To:    Birx, Deborah L. EOP/NSC [Deborah.L.Birx@] (6)
Subject:  Re: [EXTERNAL] Rapid Immunoassay Kits

Beautifully done.
Very very nice
S

---

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@(b) (6)
Date: March 15, 2020 at 7:36:23 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Fwd: [EXTERNAL] Rapid Immunoassay Kits

Are you all looking at this.

Sent from my iPhone

Begin forwarded message:

From: Jonathan Cohen <jonathan@biocheckinfo.com>
Date: March 15, 2020 at 7:11:10 PM EDT
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@(b) (6)
Subject: [EXTERNAL] Rapid Immunoassay Kits

Dr. Birx:

Thank you for the call today.

As discussed, our company has acquired exclusive U.S. distribution rights from two large Chinese manufacturers of rapid IgM / IgG antibody detection kits. Notwithstanding the extraordinary progress which the White House Coronavirus Task Force seems to be making to advance testing, there are several reasons why rapid antibody tests should be immediately deployed to augment America’s COVID-19 armamentarium. In short, they include the following:

- Rapid results (under 10 minutes)
- High sensitivity (~98%) and specificity (~92%)
- Well validated on numerous cohorts in China
- Whole blood testing likely remedies some false negatives inherent in respiratory swab samples
- Low cost (under $10 per test)
- Ease of use; no need for laboratory personnel, equipment or sample transport
- Can be easily mass produced to over 200,000 per day

The attached manuscript from a large group of Chinese practitioners makes the case for IgM / IgG antibody tests for COVID-19. (The two manufacturers that we have under contract report better sensitivity of 98%.)

Last week we submitted an FDA Emergency Use Authorization request notwithstanding the fact that the current EUA template is geared to RT-PCR based laboratory tests.
We would welcome further discussions with you and the Task Force on ways in which rapid antibody testing might augment current lab based RT-PCR testing. Your confirmation of receipt of this message would be most appreciated.
I’ll ask my Deputy, Anand Shah to look into it.
Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@HHS.GOV>
Date: March 15, 2020 at 7:36:23 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Fwd: [EXTERNAL] Rapid Immunoassay Kits

Sent from my iPhone

Begin forwarded message:

From: Jonathan Cohen <jonathan@biocheckinfo.com>
Date: March 15, 2020 at 7:11:10 PM EDT
To: “Birx, Deborah L. EOP/NSC” <Deborah.L.Birx@HHS.GOV>
Subject: [EXTERNAL] Rapid Immunoassay Kits

Dr. Birx:

Thank you for the call today.

As discussed, our company has acquired exclusive U.S. distribution rights from two large Chinese manufacturers of rapid IgM / IgG antibody detection kits. Notwithstanding the extraordinary progress which the White House Coronavirus Task Force seems to be making to advance testing, there are several reasons why rapid antibody tests should be immediately deployed to augment America’s COVID-19 armamentarium. In short, they include the following:

- Rapid results (under 10 minutes)
- High sensitivity (~98%) and specificity (~92%)
- Well validated on numerous cohorts in China
- Whole blood testing likely remedies some false negatives inherent in respiratory swab samples
- Low cost (under $10 per test)
- Ease of use; no need for laboratory personnel, equipment or sample transport
- Can be easily mass produced to over 200,000 per day

The attached manuscript from a large group of Chinese practitioners makes the case for IgM / IgG antibody tests for COVID-19. (The two manufacturers that we have under contract report better sensitivity of 98%.)

Last week we submitted an FDA Emergency Use Authorization request notwithstanding the fact that the current EUA template is geared to RT-PCR based laboratory tests.
We would welcome further discussions with you and the Task Force on ways in which rapid antibody testing might augment current lab based RT-PCR testing. Your confirmation of receipt of this message would be most appreciated.
I can confirm what Deb and I said was accurate. The legal question can be directed to CDC. That being said, if a laboratory is having any difficulty getting tests, we can connect them to the 2 manufacturers very quickly.

Olivia Troye
Special Advisor for Homeland Security and Counterterrorism
Office of the Vice President
Office: (202) 456-2641
Mobile: (b) (6) (Does not receive texts)

On Mar 10, 2020, at 9:13 PM, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@(b) (6)> wrote:

Sent from my iPhone

On Mar 10, 2020, at 9:05 PM, Troye, Olivia EOP/NSC <(b) (6) (b) (6)> wrote:

This got routed to me internally to OVP.

Thank you.

Wellstar Health in GA

“From what I am hearing, WellStar doesn’t have the legal ability to give the test to whoever they want to. What I have heard is that, since the only test kits effectively in the market today are the CDC’s kits, WellStar has to request and obtain approval from the CDC (sometimes in conjunction with the Georgia department of health). Sadly, I know several other people who have very similar symptoms to those the Fleeman’s have (including some elderly people) and everyone is having the same issue. I will let you all know as soon as the
situation appears to change...I heard the VP today say that 1M kits have been distributed...I don’t where they have gone as they don’t appear to have come here”

On Mar 10, 2020, at 2:57 PM, Josh Youssef <josh@htp.org> wrote:

I am on the phone with a board member of one of the largest healthcare systems in the south. Can we talk?

Josh
404 451 9051
Olivia

What Deb has written is correct in terms of not knowing to whom the tests were sold. We could ask the company and they could voluntarily tell us although that doesn’t sound like the issue here. I don’t know Wellstar and I also don’t know to whom they would like to give the tests. In any event, if possible.

Steve

Re: Wellstar in GA

I see. Okay. This puts it in the ongoing context.

Olivia Troye
Special Advisor for Homeland Security and Counterterrorism
Office of the Vice President
Office: (202) 456-2641
Mobile: (202) 881-9378 (Does not receive texts)

On Mar 10, 2020, at 9:13 PM, Bīrx, Deborah L. EOP/NSC <Deborah.L.Birx@b (6) wrote:

It could be the case as we don’t know where any of the commercial IDT test kits have gone. At least I don’t know and no one can answer me. If hospitals or others didn’t buy them they don’t have anything outside of the CDC state health labs provided tests. All we know is there are kits to ship we don’t know where they have gone as they don’t have to show us. This is the same with usage. It’s why we are focused on use and force reporting of use and positive and negatives.

Sent from my iPhone

On Mar 10, 2020, at 9:05 PM, Bīrx, Deborah L. EOP/NSC <Deborah.L.Birx@b (6) wrote:

Can either of you shed some light on how this could be the case? This got routed to me internally to OVP. Thank you.
Wellstar Health in GA

“From what I am hearing, WellStar doesn’t have the legal ability to give the test to whoever they want to. What I have heard is that, since the only test kits effectively in the market today are the CDC’s kits, WellStar has to request and obtain approval from the CDC (sometimes in conjunction with the Georgia department of health). Sadly, I know several other people who have very similar symptoms to those the Fleeman’s have (including some elderly people) and everyone is having the same issue. I will let you all know as soon as the situation appears to change...I heard the VP today say that 1M kits have been distributed...I don’t where they have gone as they don’t appear to have come here”

On Mar 10, 2020, at 2:57 PM, Josh Youssef <josh@htp.org> wrote:

I am on the phone with a board member of one of the largest healthcare systems in the south. Can we talk?

Josh
404 451 9051
From: Hahn, Stephen /O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP
[FYDIBOHF23SPDLT]/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]

Sent: 3/12/2020 6:29:00 AM

To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Redfield, Robert R [CDC] /o=ExchangeLabs/ou=Exchange Administrative Group
[FYDIBOHF23SPDLT]/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; McGowan, Robert K
[CDC] /o=ExchangeLabs/ou=Exchange Administrative Group
[FYDIBOHF23SPDLT]/cn=Recipients/cn=e6175b088b1d49a4bfa2de3862800d4a-HHS-omc2-cd]; Shah, Anand
/o=ExchangeLabs/ou=Exchange Administrative Group
[FYDIBOHF23SPDLT]/cn=Recipients/cn=e2172ebbd96946e08e189fd612855f51-Anand.Shah]; Rom, Colin
/o=ExchangeLabs/ou=Exchange Administrative Group
[FYDIBOHF23SPDLT]/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: Re: The Reagents come from Germany

We are in constant contact in the manufacturers of reagents and while we have not had anyone reach out to
us about this issue, we are looking into it. I've spoken to Jeff Shuren's team and they will
specifically reach out about this.
Steve

Sent from my iPad

> On Mar 11, 2020, at 9:10 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:
> Guys, I'm being told that the reagents for the tests come from Germany and they have put export
controls on everything covid-19. [R](G)
> Sent from my iPhone
We’re on it.
Steve

Sent from my iPad

On Mar 3, 2020, at 7:57 AM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

Thanks. James give them whatever they need. This company comes highly recommended — I.e., they aren’t kooks.

Sent from my iPhone

On Mar 3, 2020, at 6:50 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

James,
We will look at it.
Thanks.
Steve
Sent from my iPad

On Mar 2, 2020, at 7:22 PM, Williams, James H. EOP/WHO <James.H.Williams@who.eop.gov> wrote:

Good evening Commissioner,

Well done at the press conference this evening.

Please see the attached document from Beyond Air, a company that produces a portable Nitric Oxide (NO) system. The company has already demonstrated safety for high levels of NO in a number of clinical settings. Given prior safety assessments, can this product be prioritized for consideration of approved testing and an open label trial with COVID-19 infected patients? Let us know if FDA would prefer an alternative approval process for this candidate product.

Thank you,

James H. Williams
Special Assistant to the President
Domestic Policy Council
The White House
<200226 Beyond Air COV-19 Background.pdf>
Michael,

I am happy to facilitate.

Steve

---

From: Liddell, Christopher P. EOP/WHO (b) (6) who.eop.gov
Date: April 14, 2020 at 5:11:38 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Fauci, Anthony S (NIH) (b) (6) niaid.nih.gov, Kratsios, Michael J. EOP/OSTP (b) (6) ostp.eop.gov
Cc: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@b (6) Kushner, Jared C. EOP/WHO <jck@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Seema Verma (b) (6) cms.hhs.gov>, Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Tromberg, Bruce J (NIH) <bruce.tromberg@nih.gov>, Collins, Francis S (NIH) (b) (6) butterfield, Nicholas W. EOP/WHO <b (6) who.eop.gov>, Droegemeier, Kelvin K. EOP/OSTP (b) (6) ostp.eop.gov
Subject: RE: Quick description of our app

+ Michael Kratsios (CTO)

---

(b) (5)

please just email him directly

---

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Monday, April 13, 2020 10:12 PM
To: Fauci, Anthony (NIH/NIAD) [E] (b) (6) niaid.nih.gov
Cc: Hahn, Stephen <SH1@fda.hhs.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@b (5) Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Seema Verma <(b) (6) cms.hhs.gov>; Sharpless, Norman (NIH/NCI) [E] <norman.sharpless@nih.gov>; Tromberg, Bruce (NIH/NIBIB) [E] <bruce.tromberg@nih.gov>; Collins, Francis (NIH/OD) [E] (b) (6) Liddell, Christopher P. EOP/WHO
Let’s do it. Chris Liddell is working with a number tech companies on response

Sent from my iPhone

On Apr 13, 2020, at 10:08 PM, Fauci, Anthony (NIH/NIAID) [E] <n ia.d.nih.gov> wrote:

Steve:

NIH (Sharpless and Tromberg) have an app that we should have presented to a subset of the Task Force.
Best,
Tony

From: Hahn, Stephen <SH1@fda.hhs.gov>
Sent: Monday, April 13, 2020 2:17 PM
To: Debi Birx MD <Deborah.L.Birx@who.eop.gov>; Jared Kushner <Jck@who.eop.gov>; Fauci, Anthony (NIH/NIAID) [E] <niaid.nih.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Joe Grogan <Joseph.J.Grogan@who.eop.gov>; Seema Verma <cms.hhs.gov>
Subject: Fwd: Quick description of our app

Is this something we have an interest in?
Steve

Sent from my iPhone

Begin forwarded message:

From: (4)
Date: April 13, 2020 at 12:51:47 PM EDT
To: "Hahn, Stephen" <SH1@fda.hhs.gov>
Cc: Bob Jackson (4)
Subject: Quick description of our app

Thanks Dr. Hahn – below are very quick thoughts and I am working to get your more visual material for your discussion-slides in a couple minutes

The wellness app (developed by Elemental Cognition) provides a mechanism to answer important questions about the epidemic that will inform risk to any given participant as well as to society or employer.

The app functions as daily verification that the participant is symptom free and also captures de-identified information that can be used for monitoring the epidemic in real time and at the same time capturing very important longitudinal data about various categories of participants.

This app can be a very important public health tool and also be used to provide meaningful information back to participants, employers, state and local and federal officials.

1. Provides daily confirmation that someone feels well is afebrile and symptom free
2. Contains information about viral and antibody testing (note antibody testing and viral are only one of many features and are not mandatory)
   a. Collects meaningful data that is informative to public health decision making
   b. Avoids controversy around antibody testing certificates or other certification
   c. Collects meaningful information regarding serology and risk and clinical course over time
3. Displays information about number and rate of those in various categories – these categories are used for multidimensional tracking of outcome and risk assessment
   a. Well vs not well
   b. Viral history and recovery history
   c. Antibody history
   d. Working vs Isolation
   e. Vaccine yes or no (one of many future uses)
4. **App is one mechanism to enable employee check in** (vs clip board or home grown apps) and collect meaningful informative data
5. Detailed “state” logic that recommends testing strategy- very much optional element related to incorporating serology testing
6. QR code to store testing data linked to demographic and daily data in de-identified way
7. Allows optional participation in clinical trial with reach back capability
   a. Will be enable many meaningful clinical trials, real-time learnings, and publications
   b. Ability to combine our data with many other app and web based data collection
8. Design to systematically collect information to inform society about the epidemic
   a. Proportions of patients in states
   b. Rates of re-infection
   c. Duration to re-infection
   d. Rates of return to work
   e. Geographic elements – of all categories and early identification of new outbreaks
   f. Multiple variable baseline data analysis- demographics, race, co-morbidity, living arrangement, disability
9. Functions as a very important bio surveillance app as well serving same purpose for employers and institutions
10. Has visual displays demonstrating well participants vs ill and any other dimensions
11. Can partner with academic institutions and employers and other groups (organizations, cities, etc.)

This e-mail message is intended for the use of its intended recipient and may contain proprietary, confidential and/or privileged information. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this e-mail, its contents and any attachment(s), in whole or in part, is strictly prohibited without the prior written consent of (b) (4)  __________________________. If you have received this e-mail in error or are not the intended recipient, you are not authorized to use the information in this message in any way. Please do not read, copy, forward or store this message unless you are an intended recipient of it. Please notify the sender immediately by return e-mail, delete this e-mail and any attachment(s) and destroy all copies. Any unauthorized use is strictly prohibited. If you reply to this message, (b) (4)  __________________________ collect personal information about you in accordance with our Privacy Policy. For additional information on our privacy practices, please click here. Thank you.
From: Hahn, Stephen [O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAOCFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/9/2020 8:02:33 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@{b}(6)]
    Giroir, Brett (OS) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G];
    Seema Verma [Seema.Verma.OA@cms.hhs.gov]
CC: Polowczyk, John P RADM USN JS J4 (USA) [john.p.polowczyk.mil@mail.mil]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: Re: Excellent call with the lab directors

Deb,
We are very happy to have a call with them. Who is their point of contact and we will arrange?
Steve

---

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@{b}(6)>
Date: April 8, 2020 at 9:40:50 PM EDT
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Seema Verma <Seema.Verma.OA@cms.hhs.gov>
Cc: Polowczyk, John P RADM USN JS J4 (USA) <john.p.polowczyk.mil@mail.mil>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: Excellent call with the lab directors

To summarize
Many issues discussed from labs around the country and this is a group we have left out of regular outreach and calls. 

(b)(5)
I did. Our approvals are dependent upon which company is able to provide the validation data. Obviously, we are prioritizing PoC tests.

S

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@(b) (6)
Date: April 12, 2020 at 3:40:58 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Finally read the packet insert
Look good to me. Thanks
Steve
Updated remarks attached. Please let Staff Sec know if you have any edits by 12:30 pm today.

Thanks,

Staff Sec

From: Staff Secretary
Sent: Monday, April 6, 2020 10:11 AM
To: DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Salvi, Mary E. EOP/WHO <Mary.E.Salvi@who.eop.gov>; Eisenberg, John A. EOP/WHO <John.A.Eisenberg@who.eop.gov>; Philbin, Patrick F. EOP/WHO <pfp2dcp@who.eop.gov>; int@who.eop.gov; Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Berkowitz, Avraham J. EOP/WHO <avi@who.eop.gov>; Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>; Vought, Russell T. EOP/OMB <b6b6b6b6 who.eop.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@b6b6b6 who.eop.gov>; Troye, Olivia EOP/NSC <Olivia.Troye@b6b6b6 who.eop.gov>; Pottinger, Matthew F. EOP/WHO <b6b6b6 who.eop.gov>; 'john.gountanis@hq.dhs.gov' <john.gountanis@hq.dhs.gov>; 'Blackwell, Juliana' <juliana.blackwell@HQ.DHS.GOV>; Ditto, Jessica E. EOP/WHO <Jessica.E.Ditto@who.eop.gov>; Grisham, Stephanie A. EOP/WHO <b6b6b6 who.eop.gov>; Gidley, Hogan H. EOP/WHO <Hogan.Gidley@who.eop.gov>; Hahn, Julia A. EOP/WHO <b6b6b6 who.eop.gov>; Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>; Short, Marc T. EOP/OVP <b6b6b6 ovp.eop.gov>; Hoelscher, Douglas L. EOP/WHO <b6b6b6 who.eop.gov>; Pataki, Tim A. EOP/WHO <b6b6b6 who.eop.gov>; 'Fauci, Anthony (NIH/NAID) [E]' <b6b6b6 niaid.nih.gov>; Ueland, Eric M. EOP/WHO <Eric.M.Ueland@who.eop.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>; Liddell, Christopher P. EOP/WHO <b6b6b6 who.eop.gov>; 'Harrison, Brian (HHS/IOS)' <Brian.Harrison@hhs.gov>; Kudlow, Larry A. EOP/WHO <b6b6b6 who.eop.gov>; Olmem, Andrew J. EOP/WHO <b6b6b6 who.eop.gov>; Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>; 'adam.boehler@dfc.gov' <adam.boehler@dfc.gov>; 'Colin.Rom@fda.hhs.gov' <Colin.Rom@fda.hhs.gov>
Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: FOR QUICK REVIEW: POTUS Remarks for Call with pharmaceutical industry CEOs

Attached for quick review are POTUS remarks for today’s call with pharmaceutical industry CEOs.

Please let Staff Sec know by 11:00 am if you have any edits or comments.

Reach out directly with questions.

Thanks,

Staff Sec
That is correct Joe

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 6, 2020 at 10:20:38 AM EDT
To: Staff Secretary <staffsecretary@who.eop.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Campana, Alexandra D. EOP/WHO <(b) (6)>(@who.eop.gov), Troutman, Joel D. EOP/WHO <Joel.D.Truetman@who.eop.gov>, Pataki, Tim A. EOP/WHO <(b) (6)>(@who.eop.gov), Williams, Michael B. EOP/WHO <(b) (6)>(@who.eop.gov)

Subject: Re: FOR QUICK REVIEW: POTUS Remarks for Call with pharmaceutical industry CEOs

These are good. (b) (5)

Thank you.

Sent from my iPhone

On Apr 6, 2020, at 10:10 AM, Staff Secretary <staffsecretary@who.eop.gov> wrote:

Attached for quick review are POTUS remarks for today’s call with pharmaceutical industry CEOs.

Please let Staff Sec know by 11:00 am if you have any edits or comments.

Reach out directly with questions.

Thanks,

Staff Sec

<Call with Pharmaceutical Company Executives - 10 am.docx>
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS.GOV]
Sent: 3/19/2020 1:38:31 PM
To: Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOHF235PDLT]/cn=Recipients/cn=a0afac0efa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Fwd: Hydroxychloroquine supply (>100 million tablets) + other COVID-19 therapeutic updates

Sent from my iPhone

Begin forwarded message:

From: "Achrekar, Angeli" <AchrekarA@state.gov>
Date: March 19, 2020 at 1:10:43 PM EDT
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@HHS.GOV>
Subject: Fw: Hydroxychloroquine supply (>100 million tablets) + other COVID-19 therapeutic updates

FYI

Sent from my BlackBerry 10 smartphone.

From: Anil Soni <Anil.Soni@mylan.com>
Sent: Thursday, March 19, 2020 12:17 PM
To: Birx, Deborah L
Cc: Giroir, Brett (HHS/OASH); Fauci, Anthony (NIH/NIAID) [E]; Harder, Kristina (HHS/IOS); Valentine, Steven (HHS/OASH); Beckham, Tammy (HHS/OASH); Bembo, Dinah (HHS/OASH); Haigwood, Patricia (OS/ASPR/BARDA) (CTR); Haddad, Carla (HRSA)
Subject: Hydroxychloroquine supply (>100 million tablets) + other COVID-19 therapeutic updates

Debbi,

See below for updates from Mylan on therapeutics under evaluation for uses related to COVID-19. Please connect me to the relevant person(s) to quickly supply hydroxychloroquine. I'll send updates on the rest when available.

**Hydroxychloroquine:** Mylan's product is FDA approved, manufactured in bottles of 100 200mg tablets. Tablets will be available to ship by the first week of April treatments if taken as 600mg daily for 10 days – based on Raoul's trial in France. We have enough API to then produce tablets (at least treatments); we're working to secure API to produce more.

**Lopinavir/ritonavir:** Mylan has FDA tentative approval under PEPFAR for LPV/r (200/50mg in bottles of 120 tablets), manufactured. Though we are one of the largest suppliers of this product,

**Favipiravir:** We do *not* currently manufacture this product, a 200mg tablet.
Remdesivir: We do *not* currently manufacture this product, still under development by Gilead (10-day IV administration, 200mg Day 1 + 100mg (b) (4))

I hope this information is helpful. Mylan has a long history of supplying products directly to the US government, including current contracts with the CDC under the National Strategic Stockpile program. If helpful, we can leverage existing contractual relationships with Mylan to ensure we move as quickly as possible. Please let me know how to follow up on hydroxychloroquine supply ASAP (b)(4). I can be a first point of contact (b)(6) mobile) to mobilize the relevant colleagues at Mylan. We will, in parallel, continue to pursue the steps noted for the other therapeutics being investigated.

Best wishes,
Anil

Head of Global Infectious Diseases
Mylan

This email message and any attachments are for the exclusive use of the intended addressee(s). This message may contain confidential, privileged and/or proprietary information, and unauthorized review, use or distribution by persons other than the intended addressee(s) is strictly prohibited and may be unlawful. Unintended transmission does not waive any privilege including attorney-client, attorney work product or claims to confidentiality. If you received this email in error or it was forwarded from recipients who received it in error, please contact me by return message and immediately destroy all electronic, paper and other versions of this message. Thank you.
From: Ashok KUMAR MIRPURI (MFA)  
Sent: Wednesday, 18 March 2020 17:30  
To: 'deborah.l.brix@b) (6)  
Cc: (b) (6)  
Subject: From Singapore Ambassador Ashok Mirpuri

Message Classification: Restricted

Dr Deborah Birx  
White House Coronavirus Task Force Coordinator

Dear Dr Birx,

Thank you for taking the time to speak to the ASEAN Ambassadors in Washington D.C. yesterday afternoon. We appreciate that you reached out, and offered a clear perspective of the current situation in the United States regarding Covid-19.

As promised, I write to follow up on our discussion on the Covid-19 test kits from Singapore. Eight Singaporean companies have developed diagnostic test kits for the Covid-19 virus. They allow for fast and highly accurate detection of the Covid-19 virus and utilise a range of technologies, viz. six based on Polymerase Chain Reaction (PCR) to detect the viral genome, one on Point of Care Testing (POCT) to detect viral antigens or antibodies, and one on Artificial Intelligence analysis of chest CT scans.
Veredus have already received Provisional Authorisation from Singapore’s Health Sciences Authority (HSA); MiRXES has also been granted CE-IVD certification from the European Union. The remaining five – AIT Biotech, (b) (4) – are expected to submit their applications shortly. I attach a document containing information about the various test kits from Singapore.

My Embassy is happy to follow up on this matter, and I welcome your support for expedited approval of these Singapore-made test kits. Please feel free to reach out if you or your team have questions or require more information.

Thank you again for your valuable time, and please know that Singapore stands ready to work with the United States and our regional partners to combat the spread of Covid-19.

Yours sincerely,
Ashok Mirpuri

cc
The Honorable David Stilwell
Assistant Secretary of State for East Asian and Pacific Affairs
United States of America

The Honorable Matthew Pottinger
Deputy National Security Advisor
National Security Council
Executive Office of the President
Q: What happens if I do not have the extraction platform referenced in the authorization of CDC’s EUA-authorized test?

A: FDA believes that the CDC’s EUA-authorized test could be used with the following extraction platforms which FDA cleared with the CDC’s RNA-based influenza panel:

- **Roche MagNA Pure LC**
  Kit: Roche MagNA Pure Total Nucleic Acid Kit
  Protocol: Total NA External_lysis
  Recommendation(s): Add 100 μL of sample to 300 μL of pre- aliquoted TNA isolation kit lysis buffer (total input sample volume is 400 μL). Elution volume is 100 μL.

- **Roche MagNA Pure Compact**
  Kit: Roche MagNA Pure Nucleic Acid Isolation Kit I
  Protocol: Total NA_Plasma100_400
  Recommendation(s): Add 100 μL of sample to 300 μL of pre- aliquoted TNA isolation kit lysis buffer (total input sample volume is 400 μL). Elution volume is 100 μL.

- **Roche MagNA Pure 96**
  Kit: Roche MagNA Pure 96 DNA and Viral NA Small Volume Kit
  Protocol: Viral NA Plasma Ext Lys SV Protocol
  Recommendation(s): Add 100 μL of sample to 350 μL of pre- aliquoted External Lysis Buffer (supplied separately) (total input sample volume is 450 μL). Proceed with the extraction on the MagNA Pure 96. (Note: Internal Control = None). Elution volume is 100 μL.

- **QIAGEN QIAcube with the QIAamp DSP Viral RNA Mini Kit**
  Kit: QIAGEN QIAamp® DSP Viral RNA Mini Kit
  Recommendations: Utilize 140 μL of sample and elute with 100 μL of buffer.
Thank you so much for your amazing work! What’s there is fabulous. Deb

Sent from my iPhone

On Mar 9, 2020, at 12:33 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

You mean online at coronavirus.gov?
If so, the answer is yes, it is online and was by the deadline.
I have more updated information, as well.
Thanks
S

Sent from my iPhone
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@(6)

Sent: 3/31/2020 9:19:18 AM

To: Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah

Subject: Re: Testing prioritization

\(\text{(b) (6)}\)

Sent from my iPhone

On Mar 31, 2020, at 8:18 AM, Hahn, Stephen <SHI@fda.hhs.gov> wrote:

Debi,
\(\text{(b) (5)}\)

Steve
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDSOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDSOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: When can you present CTAP to the TF?

I'm getting pressed to schedule it.

Sent from my iPhone
Awesome.

---

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Wednesday, March 25, 2020 2:41 PM
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>; Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana@who.eop.gov>
Subject: Re: Ban on gay men's blood donations

Sent from my iPhone

On Mar 25, 2020, at 2:16 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

KEagan,
When will this new guidance be done? I think it is going through clearance.
S

---

From: Rom, Colin <Colin.Rom@fda.hhs.gov>
Date: March 25, 2020 at 2:10:19 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Cc: Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana@who.eop.gov>
Subject: RE: Ban on gay men's blood donations

+ Anand who has been running this issue

---

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Wednesday, March 25, 2020 2:09 PM
To: Hahn, Stephen <SH1@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Rom, Colin <Colin.Rom@fda.hhs.gov>
Cc: Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana@who.eop.gov>
Subject: Ban on gay men’s blood donations
Thanks
Laura to the info you are sharing, can you please add a daily update [B] (S)
These are great. Since Steve is at the press conference today, if these don’t get inserted into Potus comments, he should

For talkers today:

(b)(5)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/20/2020 8:46:53 AM
To: Shah, Anand [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIOH23SPDLT)/cn=Recipients/cn=e2172ebbd96946c08e189fd612855f51-Anand.Shah]; Rom, Colin
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIOH23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIOH23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Campana, Alexandra D. EOP/WHO [b] (8)**********who.eop.gov]
Subject: Political all hands this afternoon

Guys I'd like to come up today and do a political all hands and get our arms around this. Colin can you help Alex set this up

Sent from my iPhone
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@(b) (6)]
Sent: 3/10/2020 11:08:47 AM
To: Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOHF23SPDLT]/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: if you get a chance can you call me

(b) (6)
Sent from my iPhone
Looking forward to this. Deb

Sent from my iPhone

On Apr 9, 2020, at 5:14 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Robert,
Thanks for the call. We think your suggestion of an in-person meeting with your Chairman and you is a good idea. The purpose of the meeting, as I understand it, is to 1) discuss serology test development in all facets including manufacturing ramp up and 2) discuss how serology testing would be incorporated into ‘back to work’ plans including your own company’s plan. I’ve copied the individuals who we’ve discussed would be invited. If you have any other comments/suggestions, please let me know. Once I have the go ahead form you, I’ll ask Janice Sheehy to work with the White House on the meeting details.
Thanks again.
Steve
No

On 4/4/20, 8:15 PM, "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov> wrote:

Sent from my iPhone
Of course

Sent from my iPhone

On Apr 6, 2020, at 1:35 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

FYI

From: Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>
Date: April 6, 2020 at 1:33:04 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: Fw: Journal publisher raises red flags about French malaria drug study

FYI. I think that the issue of patient selection is one that is going to come up over and over again, as per our conversation this morning.

Journal publisher raises red flags about French malaria drug study

By Sarah Owermohle

04/06/2020 01:30 PM EDT

The society that recently published a French study that suggested malaria drug hydroxychloroquine could help coronavirus patients has raised formal concerns about the research.

In a statement, the International Society of Antimicrobial Chemotherapy says it "shares the concerns" raised by critics of the study, which was published on March 20 in a society-run journal. Such statements of concern are often the first step towards retracting a scientific paper.

The small study, led by controversial French researcher Didier Raoult, helped fuel growing interest in the drugs in the United States. President Donald Trump has cited Raoult's work while championing hydroxychloroquine as having "very, very encouraging" early results against the coronavirus.

But the society, which runs the International Journal of Antimicrobial Agents, has now said that the French study does not meet their standards — citing its "lack of better explanations" for how study participants were
chosen. Experts have pointed out that Raoult's team chose who would get the drug versus who would not, even though the gold standard for clinical trials is to assign patients to treatment groups randomly.

Raoult has not yet responded to a request for comment on the society's statement.

The results from other studies of hydroxychloroquine have been mixed, and the studies themselves have been small.

The president's focus on hydroxychloroquine has sparked divides within his administration, where several health officials feel there has been outsized attention on the drug even as other medicines are in trials.

The Food and Drug Administration last week authorized emergency use of the drug for severely ill patients but acknowledged there was still limited data about whether the treatment is effective.

To view online:

You received this POLITICO Pro content because your customized settings include: Medical Data Management, Drugs and Pharmaceuticals, Clinical Trials and Research. To change your alert settings, please go to >https://subscriber.politicopro.com/settings<.
sheesh

From: Hahn, Stephen <SH1@fda.hhs.gov>
Sent: Wednesday, April 8, 2020 8:25 AM
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: Fwd: [EXTERNAL] ...

Wanted you to be aware of this. I spoke to the health officials at NY State and there is no randomized trial and there is no placebo.
Steve

__________________________________________________________

From: Bauer, Zachary C. EOP/OVP <b6b076f8@who.eop.gov>
Date: April 7, 2020 at 5:55:17 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Fwd: [EXTERNAL] ...

Sent from my iPhone

Begin forwarded message:

From: "Michael, Molly A. EOP/WHO" <Molly.A.Michael@who.eop.gov>
Date: April 7, 2020 at 5:30:48 PM EDT
To: "Bauer, Zachary C. EOP/OVP" <b6b076b8@who.eop.gov>
Subject: FW: [EXTERNAL] ...

Thank you!

__________________________________________________________

From: Laura Ingraham <tvingraham@gmail.com>
Sent: Tuesday, April 7, 2020 5:29 PM
To: Michael, Molly A. EOP/WHO <Molly.A.Michael@who.eop.gov>
Subject: [EXTERNAL] ...

Please tell POTUS this is worth a call from someone on his staff to New York’s Health Commissioner Mr. Zucker. What is the placebo being used in the Hydroxy study? Are our trusted doctors getting the complete methodology being utilized? This is extremely important that full transparency be demanded.

BTW, Perricone is a world-famous dermatologist, best-selling author.
Begin forwarded message:

From: Nicholas Perricone <nypmd2@icloud.com>

We need to get word out on the so-called double blind study being carried out in New York. They are using vitamin C as the placebo and of course it is an active antiviral agent. This can’t be an oversight so I have to assume they are trying to make the hydroxychloroquine look in effective when compared to a placebo. It was \supposed to be an inert agent Laura needs to know about this so she can tell her viewers what the opposition is up to.

Nicholas Perricone M.D.
Chairman and Founder
Perricone MD
639 Research Parkway
Meriden, Ct 06450
2039350315

(b) (6)
Thank you so much. Of all your ID NOW equipment out there are these the only ones that requested tests? Deb

Good evening,

In addition to our daily shipment and testing report, I am including at the request of Tim, an outlook of our shipments in the US. In the supply outlook we only show what we will be shipping in the US for the next 5 weeks. Our ID now production is dedicated to the US. But for the m2000, our actual production is more than double what we will be sending to the US. Based on the forecast throughput of our machines, this outlook is what we expect to ship to US customers.

Here's today's data. We'll be reporting Saturdays and Sundays from here on out so look for an email tomorrow afternoon. The m2000 utilization is showing a pickup.

Please find attached Abbott's data as of April 2 for (1) ID NOW; and (2) m2000.

For m2000 test data, there are two types of data we have:

1. Information in our control such as the names and addresses of our customers and the number of tests we shipped to them cumulatively and this week.
2. Raw data we receive from a remote data link that is sent from the instruments at the customers to Abbott.
   a. First, we only receive the remote data link from certain customers (on the spreadsheet, the customers we don’t receive data from are in gray).
b. Second, for those customers with the remote data link, we are providing raw data that has the number of tests run and the number of positives. Customers run their own required protocols to validate the accuracy of a test when a new test first becomes available. Those validation processes include negative and positive samples. The raw data we get from data link of the instrument cannot distinguish between validation samples and patient samples.

3. We do not have data regarding inventory at the labs.

For ID NOW test data:

1. We are reporting names, addresses, total cumulative tests shipped, and total tests shipped this week.
2. Unlike the m2000 instrument, we do not have any data on tests performed from the ID NOW instruments.
Thank you so much for looking into this and working through this and understanding the issues. We stand ready to support. Deb

From: "Wainer, Andrea F" <andrea.wainer@abbott.com>
Date: Thursday, April 2, 2020 at 9:32 PM
To: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>, "Haddad, Carla (HHS/OASH)" <Carla.Haddad@hhs.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@(b) (6)>, "Shuren, Jeff (FDA/CDRH)" <Jeff.Shuren@fda.hhs.gov>, "Stenzel, Timothy (FDA/CDRH)" <Timothy.Stenzel@fda.hhs.gov>
Cc: "Ford, Robert B" <Robert.Ford@abbott.com>
Subject: [EXTERNAL] Abbott COVID Data

Good evening,
Along with our daily report, we have done some research with our customers to understand where they are at with their COVID testing. Below is a snapshot of the customers who report to be running less than 300 tests per day. I have asked for the list of customers reporting short staffing so stay tuned.
Please find attached Abbott’s data as of April 1 for (1) ID NOW tests; and (2) m2000 tests.

For m2000 test data, there are two types of data we have:

1. Information in our control such as the names and addresses of our customers and the number of tests we shipped to them cumulatively and this week.
2. Raw data we receive from a remote data link that is sent from the instruments at the customers to Abbott.

   a. First, we only receive the remote data link from certain customers (on the spreadsheet, the customers we don’t receive data from are in gray).
   b. Second, for those customers with the remote data link, we are providing raw data that has the number of tests run and the number of positives. Customers run their own required protocols to validate the accuracy of a test when a new test first becomes available. Those validation processes include negative and positive samples. The raw data we get from data link of the instrument cannot distinguish between validation samples and patient samples.
   c. Third, as requested, the raw data for the Prior Day Tests Performed and positive numbers and rates (columns J, K and L) are for the previous day only.
3. We do not have data regarding inventory at the labs.

For ID NOW test data:

1. We are reporting names, addresses, total cumulative tests shipped, and total tests shipped this week.
2. Unlike the m2000 instrument, we do not have any data on tests performed from the ID NOW instruments.

Best regards, Andrea
224-430-0870

---

Andrea Wainer  
Executive Vice President  
Rapid & Molecular Diagnostics  
Abbott  
100 Abbott Park Road  
Building AF6C-2  
Abbott Park, IL 60064  
O: +1 224-668-9155  
andrea.wainer@abbott.com
Thank you.

Sent from my iPhone
Whole Foods workers planning strike on Tuesday
The Hill
Chris Mills Rodrigo
March 30, 2020

Whole Foods workers are set to strike on Tuesday to protest what they say is a lack of employee protections amid the spread of coronavirus.

Workers at the national grocery chain will call out sick to demand guaranteed sick leave to employees who self-isolate, reinstatement of health care coverage for part-time workers, double hazard pay, a commitment to ensuring workplaces stay clean and the closure of any store where a worker tests positive.

The strike had originally been scheduled on May first.

"As this situation has progressed, our fundamental needs as workers have become more urgent," Whole Worker, a labor movement within the grocery chain, wrote in a statement.

"COVID-19 poses a very real threat to the safety of our workforce and our customers. We cannot wait for politicians, institutions, or our own management to step in to protect us."

Cases of COVID-19, the disease caused by the novel coronavirus, have been reported at Whole Foods locations in Chicago, New York City and Huntington Beach, Calif.

All of those locations have remained open.

In response to the pandemic, Whole Foods has boosted wages for U.S. and Canadian workers by $2 per hour. It also promised workers diagnosed with COVID-19 or quarantined two weeks of paid leave.

The Hill has reached out to the chain for comment on the planned strike.
Tuesday’s sickout at Whole Foods, which is owned by Amazon, would be the latest in a wave of worker activism amid the pandemic.

Amazon workers in Staten Island, N.Y. walked out Monday after their warehouse was kept open despite at least one positive case of COVID-19. The company said that the building has been cleaned.

Instacart shoppers also stopped accepting deliveries Monday in protest of the grocery delivery service’s worker protections.
Guys we need tps on the suspension of the EUA. Recognize this is wh tps and not fda tps so it needs to be in English and doesn't need to be as precise as you would require.

Sent from my iPhone
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@هيلا] (6)
Sent: 3/5/2020 8:13:21 AM
To: Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOHF23SPDLT]/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Test

Sent from my iPhone
White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel’s Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392
Participant Code: (b)(5)

**For those on the WH campus, we will meet in the Roosevelt Room to get on the call.**
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/9/2020 10:08:14 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0fa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697d43ee27255fb-Colin.Rom]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@EOP.GOV]; Ruggiero, Anthony J. EOP/NSC [ Anthony.R.Ruggiero@EOP.GOV]; Kanapathy, Ivan J. EOP/NSC [Ivan.Kanapathy@EOP.GOV]; Hooker, Allison M. EOP/NSC [Allison.Hooker@EOP.GOV]; Sinclair, Michael R. EOP/NSC [Michael.Sinclair@EOP.GOV]

Subject: FDA/EOP Call on
Location: Dial-in 202-395-6392;
Start: 4/9/2020 2:00:00 PM
End: 4/9/2020 2:30:00 PM
Show Time As: Busy

Recurrence: (none)

Roosevelt Room for internal participants
Participant Dial-in: (202) 395-6392
Participant Code: [b] [b]
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/20/2020 2:16:26 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Joe/ Dr. Hahn Connect
Location: WW217
Start: 3/21/2020 8:30:00 AM
End: 3/21/2020 9:00:00 AM
Show Time As: Busy
Recurrence: (none)
Pre-Meet for Policy Time

Location: WW217

Start: 4/3/2020 12:30:00 PM
End: 4/3/2020 1:00:00 PM

Show Time As: Free

Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/20/2020 2:12:30 PM
Subject: DPC/FDA Connect
Location: EEOB 180A
Start: 3/21/2020 9:00:00 AM
End: 3/21/2020 10:00:00 AM
Show Time As: Busy

Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:54:30 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=f596362221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Phone Call: Joe/ Dr. Hahn
Attachments: Untitled Attachment; Untitled Attachment
Location: Joe will call Dr. Hahn
Start: 3/24/2020 7:45:00 AM
End: 3/24/2020 8:00:00 AM
Show Time As: Busy
Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:51:36 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Joe/Dr. Hahn Check-in
Location: WW217
Start: 3/23/2020 3:40:00 PM
End: 3/23/2020 4:00:00 PM
Show Time As: Busy

Recurrence: (none)
Subject: Call

Start: 3/31/2020 7:30:00 AM
End: 3/31/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: [b] (5) [b] (5)

Follow up from 2 pm meeting re: [b] (5) [b] (5)

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan
Subject: Operational Check-in
Attachments: Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Operational Check-in; Untitled Attachment; Untitled Attachment; Untitled Attachment; Untitled Attachment; Operational Check-in
Location: Roosevelt Room
Start: 3/31/2020 2:30:00 PM
End: 3/31/2020 3:00:00 PM
Show Time As: Busy
Recurrence: Weekly
Occurs every weekday from 2:30 PM to 3:00 PM effective 3/31/2020.

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [redacted]
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/9/2020 9:51:54 AM
Cc: Lenihan, Keagan [mailto:Keagan.Lenihan@who.eop.gov]

Subject: ALS Check-In
Location: Dial-in 202-395-6392; (b) (6)
Start: 4/9/2020 5:45:00 PM
End: 4/9/2020 6:15:00 PM
Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)
FDA Briefing

FDA WAVES link: https://events.whitehouse.gov

You will enter the complex at 17th and State Place NW- you will make your way through two security checkpoints into the West Wing lobby. Please provide me with a list of all attending who will require a name tent.

Please call Ian DeValliere with any questions: 202-881-8007
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 2/18/2020 1:52:45 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Amin, Stacy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOF23SPDLT)/cn=Recipients/cn=cb3764b7438648838c22881a06fc6af8-Stacy.Amin]; Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOF23SPDLT)/cn=Recipients/cn=ee7320e8e8c184d66bfdf521b0105d17d2-Keagan.Lenil]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOF23SPDLT)/cn=Recipients/cn=a0fac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; DeValliere, Ian C. EOP/WHO [b](6)@who.eop.gov]; Campana, Alexandra D. EOP/WHO [b](6)@who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: FDA/DPC Meeting
Location: EEOB 176
Start: 2/21/2020 8:30:00 AM
End: 2/21/2020 9:00:00 AM
Show Time As: Busy

Recurrence: (none)

FDA WAVES link: https://events.whitehouse.gov

You will enter the complex at 17th and State Place NW- you will make your way through two security checkpoints to room 176 of the EEOB.

Please call Ian DeValliere with any questions: 202-881-8007
We’re on it.  
Steve

Sent from my iPad

On Mar 3, 2020, at 7:57 AM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

Thanks. James give them whatever they need. This company comes highly recommended — I.e., they aren’t kooks.

Sent from my iPhone

On Mar 3, 2020, at 6:50 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

James,
We will look at it.

Thanks.
Steve
Sent from my iPad

On Mar 2, 2020, at 7:22 PM, Williams, James H. EOP/WHO <who.eop.gov> wrote:

Good evening Commissioner,

Well done at the press conference this evening.

Please see the attached document from Beyond Air, a company that produces a portable Nitric Oxide (NO) system. The company has already demonstrated safety for high levels of NO in a number of clinical settings. Given prior safety assessments, can this product be prioritized for consideration of approved testing and an open label trial with COVID-19 infected patients? Let us know if FDA would prefer an alternative approval process for this candidate product.

Thank you,

James H. Williams
Special Assistant to the President
Domestic Policy Council
The White House
Office: (202) 395-5812
Cell: (202) 881-7443

<200226 Beyond Air COV-19 Background.pdf>
From: Grogen, Joseph J. EOP/WHO [Joseph.J.Grogen@who.eop.gov]
Sent: 2/18/2020 1:52:45 PM
To: Grogen, Joseph J. EOP/WHO [Joseph.J.Grogen@who.eop.gov]; Amin, Stacy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cb376ab77438648838c22881a06f6af8-Stacy.Amin]; Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bdf521b0105d17d2-Keagan.Lenil]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b989138333e38a036e9f-Stephen.Hahn]; DeValliere, Ian C. EOP/WHO [DeValliere.Ian@who.eop.gov]; Campana, Alexandra D. EOP/WHO [Campana.Alexandra@who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: FDA/DPC Meeting
Location: EEOB 176
Start: 2/21/2020 8:30:00 AM
End: 2/21/2020 9:00:00 AM
Show Time As: Tentative
Recurrence: (none)

FDA WAVES link: https://events.whitehouse.gov/(b)(6)

You will enter the complex at 17th and State Place NW- you will make your way through two security checkpoints to room 176 of the EEOB.

Please call Ian DeValliere with any questions: 202-881-8007
FDA Briefing

Roosevelt Room

2/19/2020 11:30:00 AM

2/19/2020 12:00:00 PM

Tentative

FDA WAVES link: https://events.whitehouse.gov

You will enter the complex at 17th and State Place NW- you will make your way through two security checkpoints into the West Wing lobby. Please provide me with a list of all attending who will require a name tent.

Please call Ian DeValliere with any questions: 202-881-8007
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/23/2020 8:54:30 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHFF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHFF23SPDLT)/cn=Recipients/cn=f596362221f4340d697dbd43ee27255fb-Colin.Rom

Subject: Phone Call: Joe/ Dr. Hahn
Location: Joe will call Dr. Hahn
Start: 3/24/2020 7:45:00 AM
End: 3/24/2020 8:00:00 AM
Show Time As: Tentative

Recurrence: (none)
Subject: Joe/Dr. Hahn Check-in
Location: WW217
Start: 3/23/2020 3:40:00 PM
End: 3/23/2020 4:00:00 PM
Show Time As: Tentative
Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/20/2020 2:16:26 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913333e38a036e9f-Stephen.Hah]

Subject: Joe/ Dr. Hahn Connect

Location: WW217

Start: 3/21/2020 8:30:00 AM
End: 3/21/2020 9:00:00 AM

Show Time As: Tentative

Recurrence: (none)
We are in constant contact in the manufacturers of reagents and while we have not had anyone reach out to us about this issue, we are looking into it. I’ve spoken to Jeff Shuren’s team and they will specifically reach out about this.

Steve

Sent from my iPad

> On Mar 11, 2020, at 9:10 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:
> Guys, I’m being told that the reagents for the tests come from Germany and they have put export controls on everything covid-19. [b](5)
> Sent from my iPhone
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 2/18/2020 1:52:45 PM

Subject: FDA/DPC Meeting
Location: EEOB 176
Start: 2/21/2020 8:30:00 AM
End: 2/21/2020 9:00:00 AM
Show Time As: Busy

Recurrence: (none)

FDA WAVES link: https://events.whitehouse.gov

You will enter the complex at 17th and State Place NW- you will make your way through two security checkpoints to room 176 of the EEOB.

Please call Ian DeValliere with any questions: 202-881-8007
FDA Briefing

Location: Roosevelt Room

Start: 2/19/2020 11:30:00 AM
End: 2/19/2020 12:00:00 PM

Show Time As: Busy

Recurrence: (none)

FDA WAVES link: https://events.whitehouse.gov/

You will enter the complex at 17th and State Place NW - you will make your way through two security checkpoints into the West Wing lobby. Please provide me with a list of all attending who will require a name tent.

Please call Ian DeValliere with any questions: 202-881-8007
FDA Briefing

Location: Roosevelt Room

Start: 2/19/2020 11:30:00 AM
End: 2/19/2020 12:30:00 PM

Show Time As: Busy

Recurrence: (none)

FDA WAVES link: https://events.whitehouse.gov/ (b) (6)

You will enter the complex at 17th and State Place NW - you will make your way through two security checkpoints into the West Wing lobby. Please provide me with a list of all attending who will require a name tent.

Please call Ian DeValliere with any questions: 202-881-8007
Subject: (b)(6) Meeting

Location: WHSR Exec

Start: 5/4/2020 1:15:00 PM
End: 5/4/2020 2:15:00 PM
Show Time As: Busy

Recurrence: (none)

**There will be no dial-in option**
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@b (6)]
Sent: 5/14/2020 9:16:43 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@b (6)]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989ed40cc3-HHS-b (6)] Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381fbbd98341fcd-HHS-olx1-cd]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; McGuffee, Tyler Ann A. EOP/OVP [b (6)] ovp.eop.gov

Subject: Confirmed: Follow up discussion
Location: 1-877-465-7975,// Dr. Birx office

Start: 5/14/2020 3:00:00 PM
End: 5/14/2020 4:00:00 PM
Show Time As: Tentative

Recurrence: (none)

Quick Dial: 1-877-465-7975,

Agenda items for 5/14

Attendees
Dr. Birx     [in person]
Dr. Hahn
Dr. Fauci    [in person]
Dr. Redfield [by phone]
Follow up discussion

Dial in forthcoming

5/14/2020 3:00:00 PM
5/14/2020 4:00:00 PM

(none)

Attendees
Dr. Birx [in person]
Dr. Hahn
Dr. Fauci
Dr. Redfield [by phone]
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@EOP.OVPO] (b) (6)
Sent: 5/13/2020 9:32:13 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@EOP.OVPO] (b) (6) Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0fca3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-R (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; McGuffee, Tyler Ann A. EOP/OVP (b) (6) ********ovp.eop.gov]

Subject: Confirmed - Follow up discussion
Location: 1-877-465-7975,, (b) (6) #
Start: 5/13/2020 1:30:00 PM
End: 5/13/2020 2:15:00 PM
Show Time As: Busy

Recurrence: (none)

Dial In: 1-877-465-7975,, (b) (6) #
Dr. Birx will convene a follow up discussion today with the doctors at 1:30 pm.

Attendees:
Dr. Birx [in-person]
Dr. Hahn [in-person]
Dr. Fauci
Dr. Redfield [by phone]

Agenda:
TBD
From: [redacted]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@ovp.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [redacted]; Hahn, Stephen [redacted]; Redfield, Robert R (CDC) [redacted]; Fauci, Anthony S (NIH) [redacted]; Rom, Colin [redacted]; [redacted]

Subject: HOLD - Follow up discussion with Dr. Birx
Attachments: FW: [redacted]
Location: Dial-in forthcoming
Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Busy

Recurrence: (none)

Attendees:
Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

[(b)(5)]
Follow up Discussion

Ward Room

5/8/2020 3:00:00 PM
5/8/2020 4:00:00 PM

Dr. Birx
Dr. Hahn
Dr. Fauci
Dr. Redfield
Dr. Adams
Administrator Verma (by phone)
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@oep.eop.gov]
Sent: 5/10/2020 7:24:55 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@oep.eop.gov]; McGuffee, Tyler Ann. EOP/OVP
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahj; Redfield, Robert R
(CDC) /[o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cdl]; Fauci, Anthony S (NIH)
/[o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[b][6]; Rom, Colin
/[o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: HOLD - Follow up discussion with Dr. Birx
Attachments: FW: 
Location: Dial-in forthcoming
Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:
Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:
(b)[5]
Subject: HOLD - Follow up discussion with Dr. Birx

Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS.GOV]
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS.GOV], Hahn, Stephen [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-Redfield, Robert R (CDC) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cdl]; Adams, Jerome (OS) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=302991451fc341bf9a7ffa53ba3f81c-HHS-Jerome.]; cms.hhs.gov
CC: Anderson-Villaluz, Dennis (OS) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=fba1863bf2d44fada3b3c8ee83cc63dc-HHS-Dennis.]

Subject: Follow up Discussion
Location: Dial In Only: [b](6)

Start: 5/8/2020 3:00:00 PM
End: 5/8/2020 4:00:00 PM
Show Time As: Busy

Importance: High
Recurrence: (none)

Attendees:
Dr. Birx
Dr. Hahn
Dr. Fauci
Dr. Redfield
Dr. Adams
Administrator Verma (by phone)
Follow up Discussion
Ward Room
5/8/2020 3:00:00 PM
5/8/2020 4:00:00 PM
High
(no)

Attendees:
Dr. Birx
Dr. Hahn
Dr. Fauci
Dr. Redfield
Dr. Adams
Administrator Verma
Follow up Discussion

Start: 5/8/2020 3:00:00 PM
End: 5/8/2020 4:00:00 PM

Attendees:
Dr. Birx
Dr. Hahn
Dr. Fauci
Dr. Redfield
Dr. Adams
Administrator Verma (by phone)
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@](b) (6)
Sent: 5/13/2020 9:32:13 AM

Subject: HOLD - Follow up discussion
Location: Dr. Birx office or Dial In: (forthcoming)
Start: 5/13/2020 1:30:00 PM
End: 5/13/2020 2:15:00 PM
Show Time As: Busy

Recurrence: (none)

Dr. Birx will convene a follow up discussion today with the doctors at 1:30pm.

Attendees:
Dr. Birx
Dr. Hahn
Dr. Fauci
Dr. Redfield

Agenda:
TBD
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@OVP.EOP.GOV]
Sent: 5/13/2020 9:32:13 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@OVP.EOP.GOV] Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a0360e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83e77989d40cc3-HHS-Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbddd98341fcd-HHS-olx1-cd]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697bd43ee27255fb-Colin.Rom]; McGuffee, Tyler Ann A. EOP/OVP [b] [OVP.EOP.GOV]

Subject: TIME CHANGE 2PM - Follow up discussion
Location: 1-877-465-7975,,,[b] #
Start: 5/13/2020 2:00:00 PM
End: 5/13/2020 2:20:00 PM
Show Time As: Tentative

Recurrence: (none)

FLAGGING -- Dr. Birx is with the VP until 2pm

Dial In: 1-877-465-7975,,,[b] #
Dr. Birx will convene a follow up discussion today with the doctors at 2:00pm-3:30pm.

Attendees:
Dr. Birx [in-person]
Dr. Hahn [in-person]
Dr. Fauci
Dr. Redfield [by phone]

Agenda:
TBD
Confirmed - Follow up discussion

Start: 5/13/2020 1:45:00 PM
End: 5/13/2020 2:20:00 PM
Show Time As: Busy
Recurrence: (none)

Dial In: 1-877-465-7975

Dr. Birx will convene a follow up discussion today with the doctors at 1:30pm.

Attendees:
Dr. Birx [in-person]
Dr. Hahn [in-person]
Dr. Fauci
Dr. Redfield [by phone]

Agenda:
TBD
Confirmed - Follow up discussion with Dr. Birx

Attendance:
Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

[Content of the agenda is not visible in the image]
Confirmed - Discussion

Location: Ward Room

Start: 5/7/2020 4:00:00 PM
End: 5/7/2020 5:00:00 PM

5/7 Agenda

Attendees:
Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma
From: ovp.eop.gov
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@ovp.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee@ovp.eop.gov]; Hahn, Stephen [stephen.hahn@exchange leveons/ou=Exchange Administrative Group (FYDIOHOF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R [Robert.Redfield@CDC.gov/ou=Exchange Administrative Group (FYDIOHOF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cld]; Fauci, Anthony S [fauci@nih.gov/ou=Exchange Administrative Group (FYDIOHOF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-olx1-cld]; Rom, Colin [colin.rom@exchange leveons/ou=Exchange Administrative Group (FYDIOHOF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: UPDATED DIAL IN Confirmed - Follow up discussion with Dr. Birx

Attachments: FW: 

Location: 1-866-617-3597;; Participant Passcode:

Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Busy

Recurrence: (none)

Dial-In Information
Toll-Free #1-866-617-3597
Participant Passcode:
Leader Passcode:

Attendees:
Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:
(b) (6)
Confirmed - Follow up discussion with Dr. Birx

FW:

Location: 202-395-6392

Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

Attendees:
Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:
(b) (5)
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@OVP] (6)
Sent: 5/19/2020 4:31:22 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@OVP] (6); Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0fac9cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f4243811fbddd983419fcd-HHS-olx1-cd]; McGuffee, Tyler Ann A. EOP/OVP [b6]ovp.eop.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ff45a6c96f5274724a1be5970eb648ff7-JSheehy]; Olivarria, Frank [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c180721db774423f9990dd86e67057c-Frank.Oliva]; Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224ae6f49c795844f43f78a049-HHS-conradp]; Gershman, Lynn E (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=466fe715fb22432e9dcef605736ded877-HHS-veu4-cd]

Subject: Confirmed -- Dr. Birx follow up discussion

Location: Dr. Birx office // Dial In: 1-877-465-7975,,,(b)(6)

Start: 5/20/2020 10:15:00 AM
End: 5/20/2020 11:00:00 AM

Show Time As: Tentative

Recurrence: (none)

Quick dial: 1-877-465-7975,,,(b)(6)
Confirmed - Video Conference Call w/ Emilio Emini
EEOB 176 / Video Meeting link: https://fda1.webex.com/fda1/j.php?MTID=m2037415d800f23d93894e9ea3268001
Video Conference with Drs. Birx & Hahn

Wednesday, May 20, 2020 | 11:00 am Eastern Daylight Time (GMT-04:00) | 1 hour 0 minutes | Not started

Meeting link: https://fda1.webex.com/fda1/j.php?MTID=m2037415d800f23d93894e9ea3268001

Meeting number:
(b) (6)

Meeting password:
(b) (6)

Audio connection:
+1-877-465-7975 US Toll Free
Global call-in numbers
Show toll-free dialing restrictions
Access code: (b) (6)
Confirmed - Dr. Birx call w/ ACOG/AAP Leadership

ACOG participants:
Maureen Phipps, MD, MPH, FACOG – CEO
Skye Perryman, JD – Chief Legal Officer and General Counsel
Rachel Tetlow, Federal Affairs Director

AAP participants:
Mark DelMonte, CEO
Tamar Haro, Senior Director, Federal and State Advocacy

ACOG/AAP Agenda:
- Opening and thanks (Mark and Maureen)
- HHS funding for physicians and hospitals – concerns with distribution (Mark and Maureen)
- Immunization rates (Mark)
- Continued concerns regarding home birth/birth settings (Maureen and Mark)
- Opportunity to partner in the lead up to Mother’s Day (Maureen)
- PPE & Testing shortages (Maureen and Mark)
- Prioritization of L&D for rapid response testing
Subject: HOLD - Follow up discussion with Dr. Birx
Attachments: FW: (b)(5)
Location: Dial-in forthcoming
Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:
Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:
Dr. Birx will convene a follow up discussion today with the doctors at 1:30pm.

Attendees:
Dr. Birx
Dr. Hahn
Dr. Fauci
Dr. Redfield

Agenda:
TBD
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS.GOV]
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@HHS.GOV]; Hahn, Stephen [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a92b91a4b7a2bf83b77989d40cc3-HHS-Jerome.R]; Redfield, Robert R (CDC) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Adams, Jerome (OS) [o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=302991451fc341bf9a7ffa53eba3f81c-HHS-Jerome.]; cms.hhs.gov (b)
(b)

Subject: Follow up Discussion
Location: Ward Room
Start: 5/8/2020 3:00:00 PM
End: 5/8/2020 4:00:00 PM
Show Time As: Tentative
Importance: High
Recurrence: (none)

Attendees:
Dr. Birx
Dr. Hahn
Dr. Fauci
Dr. Redfield
Dr. Adams
Administrator Verma
Subject: TIME CHANGE: - Discussion: [redacted]

Location: Ward Room

Start: 5/7/2020 3:30:00 PM
End: 5/7/2020 4:30:00 PM

Show Time As: Tentative

Recurrence: (none)

5/7 Agenda

Attendees:
Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma
Subject: HOLD - Discussion
Location: Ward Room
Start: 5/7/2020 4:00:00 PM
End: 5/7/2020 5:00:00 PM
Show Time As: Tentative

5/7 Agenda
TBD

Attendees:
Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D’Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; L. EOP/NSC; Fauci, Anthony S (NIH); Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Buirk, Deborah; Conrad, Patricia L (NIH); Conard, Patricia L (NIH); Good-Cohn, Meredith (CMS); Sheehy, Janice [o=ExchangeLabs/ou=Exchange Administrative Group]; Hahn, Stephen [o=ExchangeLabs/ou=Exchange Administrative Group]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@who.eop.gov]; Pottinger, Matthew F. EOP/WHO [Matthew.F.Pottinger@who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@who.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [Joseph.Keith.K.Jr.Kellogg@ovp.eop.gov]; Williams, Teresa (CDC) [o=ExchangeLabs/ou=Exchange Administrative Group]; Redfield, Robert R (CDC) [o=ExchangeLabs/ou=Exchange Administrative Group]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana@who.eop.gov]; DeValliere, Ian C. EOP/WHO [Ian.C.DeValliere@who.eop.gov]; Williams, Michael B. EOP/WHO [Michael.B.Williams@who.eop.gov];
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]
Subject: Canceled: HOLD
Location: WHSR
Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Free
Importance: High

*Will be combined with the Wednesday Briefing*
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@EOP] (6)
Sent: 5/26/2020 4:54:34 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@EOP] (6) Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF235PDLT)/cn=Recipients/cn=a0fafac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF235PDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF235PDLT)/cn=Recipients/cn=0f1ab650905f4243811fbbdd983419fcd-HHS-o1x1-cd]; McGuffee, Tyler Ann A. EOP/OVP [o=ovp.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF235PDLT)/cn=Recipients/cn=f596e6221f4340d697dbd43ee27255fb-Colin.Rom]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF235PDLT)/cn=Recipients/cn=f45a6c96f5274774a1be5970eb648f17-JSheehy]; Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF235PDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43f78a049-HHS-conrads]; Gershman, Lynn E (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF235PDLT)/cn=Recipients/cn=466fe715fb22432e9dcf605736ded877-HHS-veu4-cd]

Subject: Confirmed - Follow up discussion
Location: Dr. Birx office
Start: 5/27/2020 3:30:00 PM
End: 5/27/2020 5:00:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:
Dr. Birx [confirmed in-person]
Dr. Redfield [confirmed in-person]
Dr. Hahn [confirmed in-person]
Dr. Fauci [confirmed in-person]
Absolutely correct

Sent from my iPhone

On May 16, 2020, at 6:48 AM, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@dheaway.gov> wrote:

(b) (5)
Confirmed - Video Conference Call w/ Emilio Emini

Subject: Confirmed - Video Conference Call w/ Emilio Emini
Location: EEOB 176 / Video Meeting link: https://fda1.webex.com/fda1/j.php?MTID=m2037415d800f23d93894e9ea3268001a

Start: 5/20/2020 11:00:00 AM
End: 5/20/2020 11:45:00 AM
Show Time As: Busy
Recurrence: (none)

Attendees:
• Dr. Deborah Birx [White House]
• Dr. Stephen Hahn [FDA]
• Dr. Peter Marks [FDA]
• Dr. Emilio Emini [Director, TB and HIV Program, Bill & Melinda Gates Foundation]

Video Meeting link: https://fda1.webex.com/fda1/j.php?MTID=m2037415d800f23d93894e9ea3268001a

Video Conference with Drs. Birx & Hahn

Wednesday, May 20, 2020 | 11:00 am Eastern Daylight Time (GMT-04:00) | 1 hour 0 minutes | Not started

Meeting link: https://fda1.webex.com/fda1/j.php?MTID=m2037415d800f23d93894e9ea3268001a

Meeting number: (b) (6)

Meeting password: (b) (6)

Audio connection:
+1-877-465-7975 US Toll Free
Global call-in numbers
Show toll-free dialing restrictions
Access (b) (6)
From: ovp.eop.gov
Sent: 5/11/2020 2:07:34 PM
To: Birx, Deborah L. EOP/NSC; McGuffee, Tyler Ann A. EOP/OVP; Hahn, Stephen; Redfield, Robert R (CDC); Fauci, Anthony S (NIH); Rom, Colin

Subject: UPDATED DIAL IN Confirmed - Follow up discussion with Dr. Birx
Attachments: FW: testing, testing, testing
Location: 1-866-617-3597;; Participant Passcode: (b) (5)
Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Busy

Recurrence: (none)

Dial-In Information
Toll-Free #1-866-617-3597
Participant Passcode: (b) (6)
Leader Passcode: (b) (6)

Attendees:
Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)
Thanks

From: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Date: April 27, 2020 at 10:39:39 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Testing Strategy

CDC ayes.

Sent from my iPhone

On Apr 27, 2020, at 10:22 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Hi Katie,
Our logo can be used. [b] (5)
Steve

From: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Date: April 27, 2020 at 8:25:21 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Fwd: Testing Strategy

[b] (5)

Thanks!
Absolutely
Deb, let me know how you want to proceed

Do you both want to take over hosting this daily operations meeting? See below.

Would you guys mind hosting the meeting? We will largely defer to you moving forward

Any chance to reschedule? I know Dr. Birx and Dr. Hahn want to have the check in tomorrow

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: [no text]
Email: [no text]
Joe – quickly flagging that Dr. Birx is with POTUS tomorrow from 2-3pm.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: [no text]
Email: Tyler.A.McGuffee2@ovp.eop.gov

-----Original Appointment-----
From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Sunday, March 29, 2020 3:10 PM
To: Grogan, Joseph J. EOP/WHO; Giroir, Brett (HHS/OASH); Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); [no text] cms.hhs.gov; Fauci, Anthony (NIH/NIAID) [E]; SH1@fda.hhs.gov; Good-Cohn, Meredith (CMS/OA)
Subject: Operational Check-in
When: Wednesday, May 6, 2020 2:30 PM-3:00 PM (UTC-05:00) Eastern Time (US & Canada).
Where: Roosevelt Room

If you are unable to join in the Roosevelt room, please use the below dial-in:

Participant Dial-In: (202) 395-6392
Participant Code: [no text]
Joe
That's a good plan. Will your office coordinate?
Steve
From: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Date: April 29, 2020 at 5:57:30 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Question

Sent from my iPhone

On Apr 29, 2020, at 5:27 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Legit. This could work. It’ll be interesting to see the results of their study

From: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Date: April 29, 2020 at 5:11:54 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Question

Is this legit?


Sent from my iPhone
No worries, Joe.
From: Hahn, Stephen [O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]  
Sent: 5/6/2020 7:16:42 PM  
To: McGuffee, Tyler Ann A. EOP/OVP [b][6][ovp.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@b][6][ovp.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]  
Subject: Re: Task Force mtg is now at 5pm tomorrow

4pm is best and more convenient for everyone, I think.
Steve

---

From: McGuffee, Tyler Ann A. EOP/OVP <Tyler.A.McGuffee2@ovp.eop.gov>  
Date: May 6, 2020 at 5:59:40 PM EDT  
To: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@b>(6)ovp.eop.gov>  
Subject: FW: Task Force mtg is now at 5pm tomorrow  
Importance: High

FYSA – Task Force mtg is now at 5pm tomorrow

do you want to move operations to 4pm?  
Or leave at 12pm?

Also, who are the attendees for tomorrows operations meeting?

---

From: Troye, Olivia EOP/NSC <Olivia.Troye@[b](6)>  
Sent: Wednesday, May 6, 2020 5:58 PM  
To: McGuffee, Tyler Ann A. EOP/OVP <b>(6)ovp.eop.gov>  
Subject: Task Force mtg is now at 5pm tomorrow  
Importance: High

FYI- Just moved from 1pm.

Olivia Troye  
Special Advisor to the Vice President for  
Homeland Security, Counterterrorism, and North America  
Office of the Vice President, National Security Affairs  
White House Coronavirus Task Force  
O: (202) 456-2641 | M: [b][6] (Does not receive texts)
Thanks, Deb. We will appropriately rename the meeting.
Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@b(6)>
Date: May 6, 2020 at 7:58:49 PM EDT
To: Rom, Colin <Colin.Rom@fda.hhs.gov>, Fauci, Anthony S (NIH) <b(6) niaid.nih.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, CMS SV1 <svl1@cms.hhs.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>, Campana, Alexandra D. EOP/WHO <b(6) who.eop.gov>, McGuffee, Tyler Ann A. EOP/OVP <b(6) ovp.eop.gov>
Subject: Re: Operational Check-In

This is not a reoccurrence of the operational meeting but Deb

From: "Rom, Colin" <Colin.Rom@fda.hhs.gov>
Date: Wednesday, May 6, 2020 at 7:31 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@b(6)>, "Fauci, Anthony S (NIH)" <b(6) niaid.nih.gov>, "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>, "Redfield, Robert R (CDC)" <b(6) cdc.gov>, CMS <b(6) cms.hhs.gov>
Cc: "Hahn, Stephen" <SH1@fda.hhs.gov>, "Campana, Alexandra D. EOP/WHO"
Subject: Operational Check-In

All—

The Operational Check-In meeting will start back up tomorrow, one hour before the task force meeting. Tyler Ann will be sending out the invite shortly. Please send agenda items for the next three days so we can prioritize. For tomorrow, the following items will be discussed:

(b) (5)
Thank you!
Hi Ambassador,
I had a call today with the Ambassador today. Could we touch base tomorrow?
Thanks
Steve

From: O'Brien, Robert C. EOP/WHO <rco84@who.eop.gov>
Date: April 29, 2020 at 2:32:35 PM EDT
To: BONNE Emmanuel <emmanuel.bonne@elysee.fr>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Vaccines

Emmanuel,

Per our conversation on vaccines, please have your team reach out to Dr. Stephen M. Hahn, Commissioner of the Food and Drug Administration. Stephen is standing by to hear from your colleagues and is copied on this Email. Stephen’s personal Email is [redacted].

Stephen,

Ambassador Bonne is the French National Security Advisor.

Best,

RCO
From: Hahn, Stephen <SH1@fda.hhs.gov>
Date: April 21, 2020 at 2:29:14 PM EDT
To: Rom, Colin <Colin.Rom@fda.hhs.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: POTUS comment for today

Some edits. Will forward to Joe.
S

From: Rom, Colin <Colin.Rom@fda.hhs.gov>
Date: April 21, 2020 at 2:25:33 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: FW: POTUS comment for today
Importance: High

Suggested edits

(b) (5)
From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Tuesday, April 21, 2020 1:32 PM
To: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Rom, Colin <Colin.Rom@fda.hhs.gov>; Hahn, Stephen <SH1@fda.hhs.gov>
Subject: POTUS comment for today
Importance: High

Guy, in the next 45 minutes, can you get me more than what I have below? For POTUS to say.
From: Hahn, Stephen /O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF235PDLT)/CN=RECIPIENTS/CN=A04FAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH
Sent: 4/21/2020 1:51:34 PM
To: Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]
CC: Lenihan, Keagan /o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF235PDLT)/cn=Recipients/cn=ee7320ee8c184d66bfdf521b0105d17d2-Keagan.Leni
Subject: Re: Follow Up - White House Correspondence

Katie,

On the FDA website they can go to our CTAP inbox and send us a message. We’ll follow up when they do.

Steve

---

From: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Date: April 21, 2020 at 11:50:54 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Fwd: Follow Up - White House Correspondence

Can you please check into the below

Sent from my iPhone

Begin forwarded message:

From: "Hicks, Hope C. EOP/WHO" <Hope@who.eop.gov>
Date: April 21, 2020 at 11:19:55 AM EDT
To: "Miller, Katie R. EOP/OVP" <Katie.R.Miller@ovp.eop.gov>
Subject: FW: Follow Up - White House Correspondence

See attached from a doctor I know in California. Should I forward directly to Hahn or someone else?

From: David C. Socol MD <David@SocolMD.com>
Sent: Tuesday, April 21, 2020 3:17 AM
To: Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>
Cc: Chanda Zaveri <zaveri.chanda@yahoo.com>; dfinklestein@gmail.com
Subject: [EXTERNAL] Follow Up - White House Correspondence

To Whom It May Concern,

Our group forwarded correspondence to White House Physician Dr. Sean Conley on March 30, 2020 through the offices of Dr. Sharon Hausman-Cohen regarding Cell Armour, a product which is demonstrating notable efficacy against SARS-CoV-2. Cell Armour prevents people from getting sick, makes sick people better faster, confers immunity, and achieves all of the above without the risk of cardiac toxicity.

We received a notice of receipt from the White House Coronavirus Response Team on April 8, 2020 regarding our initial forward, stating a member of that team would reach out to our group within 48 hours. To our knowledge, that outreach did not occur.
On April 15, 2020, we forwarded the attached high-level correspondence to the Coronavirus Response Team to alert the team to additional findings and applications, absent any acknowledgement to date.

While we appreciate the tremendous burden that the White House team is under, Cell Armour is currently being evaluated by the Republic of India as a prophylactic and treatment alternative to COVID-19 given information that has been provided to date. Local clinicians are also scheduled to run a clinical trial to validate our real-world findings in Hong Kong, China, South Korea and Singapore, among others. We are also preparing to start additional trials with emergency department physicians in the United States momentarily.

Given these rapidly advancing discussions in India, our offices are of the mindset that we would be remiss not to alert your offices of our progress to date and Cell Armour’s strong potential to change the trajectory of the COVID-19 pandemic given our current fund of knowledge. We also believe that the White House should be appraised of our progress, learn about the science of Cell Armour, and what it can accomplish in order to explore an expedited path to widespread provision of Cell Armour to the American people.

Wishing you all the best at this challenging time.

Respectfully,
David

David C. Socol | Physician
8383 Wilshire Boulevard, Suite 610
Beverly Hills, CA  90211
Direct 310-561-4021
Office 323-951-0200
Facsimile 310-388-0762

Confidentiality Warning | This communication and its contents may contain confidential and/or legally privileged information. It is solely for the use of the intended recipient(s). Unauthorized interception, review, use or disclosure is prohibited and may violate applicable laws including the Electronic Communications Privacy Act. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of this communication.
Let’s talk

From: Hahn, Stephen [O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP {FYDIBOHF23SPDLT}/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B989138333E38A036E9F-STEPHEN.HAH]
Sent: 4/20/2020 1:54:44 PM
To: Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]
Subject: Re: clinical trials

From: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Date: April 20, 2020 at 1:16:54 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Fwd: clinical trials

(b)(5)

Sent from my iPhone

Begin forwarded message:

From: "Hicks, Hope C. EOP/WHO" <Hope@who.eop.gov>
Date: April 20, 2020 at 1:15:53 PM EDT
Subject: clinical trials

(b)(5)

Cuomo said today, over 20 hospitals conducted hydroxychloroquine trials, report of results will go to the FDA and CDC today.
Thanks
Ok thanks

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@(b) (6)>
Date: April 23, 2020 at 9:53:58 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Call with Dr. Hahn tomorrow

Some of this is in the plan.

Sent from my iPhone

On Apr 23, 2020, at 7:22 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Thoughts?

From: Gross, Karas <Karas.Gross@fda.hhs.gov>
Date: April 22, 2020 at 8:59:07 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: FW: Call with Dr. Hahn tomorrow

Hi Dr. Hahn-

Sharing the attached from Alexander’s staff in lead up to the call tomorrow. We’ve asked CDRH for any info, but haven’t head back yet.

Have a good night!
Karas

From: Coulter, Margaret (HELP Committee) <Margaret_Coulter@help.senate.gov>
Sent: Wednesday, April 22, 2020 5:38 PM
To: Gross, Karas <Karas.Gross@fda.hhs.gov>
Cc: Tantillo, Andrew <Andrew.Tantillo@fda.hhs.gov>
Subject: Call with Dr. Hahn tomorrow

Hi Karas and Andy,

I wanted to share the attached memo with you that Sen. Alexander received from Andy Slavitt so that you have this information if helpful. Senator Alexander may ask Dr. Hahn tomorrow morning about screening tests.

We are not certain exactly what is meant by a “screening test” so any thoughts from Dr. Hahn would be most welcome.
Happy to chat if I can be helpful in advance of tomorrow’s call. Hope you’re both doing well and staying healthy!

Best,
Margaret
<Testing for America - Scaling screening tests to re-open America.docx>
From:  Hahn, Stephen [O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP
[FYDIBOHF23SPDLT]/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent:  4/20/2020 12:50:00 PM
To:    Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]
CC:    O'Malley, Devin M. EOP/OVP [Devin.M.O'Malley@ovp.eop.gov]
Subject:  Re: Press today

Yes, for sure. Expected timing?

---

From:  Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Date:  April 20, 2020 at 12:36:37 PM EDT
To:    Hahn, Stephen <SH1@fda.hhs.gov>
Cc:    O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>
Subject:  Press today

Can you join to go over antibody testing please

Sent from my iPhone
I agree with Bob. I'll be following the critical infrastructure guidance.

S

From: Debi Birx <Deborah.L.Birx@HHS.GOV>
Date: Tuesday, May 12, 2020 at 8:21 AM
To: Stephen Hahn <SH1@fda.hhs.gov>, Robert Redfield <cdc.gov>, Tony Fauci <niaid.nih.gov>
Subject: Re: CDC Guidelines

Thanks, Deb. These are guidelines for docs and nurses who are involved in patient care, right? I think we have reasonable wording for our response which is shown below.
I spoke to Bob this morning and I believe that he, Tony and I will be attending any meetings by phone for the next 10-14 days.
Thanks
Steve

From: McGuffee, Tyler A. EOP/OVP <(b) (6)ovp.eop.gov>
Date: May 9, 2020 at 10:01:30 AM EDT
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@(b) (6)>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>
Subject: Re: Agenda items for Monday’s doctors meeting

Will set up the meeting for Monday and include a dial in for those not coming to campus.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: (b) (6) [no text]
Email: (b) (6)ovp.eop.gov
From: Hahn, Stephen /O=EXCHANGE LABS/OU=EXCHANGE ADMINISTRATIVE GROUP
(FYDIOHF235PDTL)/CN=RECIPIENTS/CN=A0AFA0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/8/2020 12:47:21 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@(b) (6) McGuffee, Tyler Ann A. EOP/OVP
(p) (6) lenihan.keagan@fda.hhs.gov]
CC: Lenihan, Keagan /o=Exchange Labs/ou=Exchange Administrative Group
(FYDIOHF235PDTL)/cn=Recipients/cn=ee7320ee8c184d66bf9d521b0105d17d2 Keagan.Leni
Subject: Re: Follow up discussion (5/8) 3:00pm Ward Room

Oh ok.

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@(b) (6) McGuffee, Tyler Ann A. EOP/OVP
(p) (6) lenihan.keagan@fda.hhs.gov
Date: May 8, 2020 at 12:46:27 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, McGuffee, Tyler Ann A. EOP/OVP
(<Tyler.A.McGuffee2@opv.eop.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: Re: Follow up discussion (5/8) 3:00pm Ward Room

This was just to give us cover for the (b) (5) discussion. Deb

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Friday, May 8, 2020 at 12:42 PM
To: "McGuffee, Tyler Ann A. EOP/OVP" <(b) (6) lenihan.keagan@fda.hhs.gov>
Cc: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@(b) (6) lenihan.keagan@fda.hhs.gov>
"Lenihan, Keagan" <Keagan.Lenihan@fda.hhs.gov>
Subject: Re: Follow up discussion (5/8) 3:00pm Ward Room

(b) (5)

Steve

From: McGuffee, Tyler Ann A. EOP/OVP <(b) (6) lenihan.keagan@fda.hhs.gov>
Date: May 8, 2020 at 12:38:31 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@(b) (6) lenihan.keagan@fda.hhs.gov>
Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: Re: Follow up discussion (5/8) 3:00pm Ward Room

Correct, helpful context. We will have a dial in for Dr. Woodcock.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: (b) (6) [no text]
Email: (b) (6) lenihan.keagan@fda.hhs.gov
On May 8, 2020, at 12:36 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Just saw this. Deb, should I for early next week or this weekend?  
Steve

From: McGuffee, Tyler A. EOP/OVP <b>6</b> ovp.eop.gov
Date: May 8, 2020 at 9:57:36 AM EDT
To: Sheehy, Janice <Janice.Sheehy@fda.hhs.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>, Conrad, Patricia L (NIH) <conradpa@niaid.nih.gov>, Knotts, Ashley (CDC) <vqf0@cdc.gov>, Good-Cohn, Meredith (CMS) <Meredith.Good-Cohn@cms.hhs.gov>, Sherman, Jennifer (OS) <Jennifer.Sherman@hhs.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>, Fauci, Anthony S (NIH) <b>6</b> niaid.nih.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, cms.hhs.gov’<b>6</b> cms.hhs.gov>, Adams, Jerome (OS) <Jerome.Adams@hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@b>6</b>
Subject: Follow up discussion (5/8) 3:00pm Ward Room

Dr. Birx is requesting to convene a follow up discussion with principals in the Ward Room today at 3:00pm. Please let me know if your principal is able to attend. Thank you.

Attendees:
Dr. Birx
Dr. Hahn
Dr. Fauci
Dr. Redfield
Dr. Adams
Administrator Verma

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: <b>6</b> [no text]
Email: Tyler.A.McGuffee2@ovp.eop.gov
We put out additional information/guidance. Abbott did as well. We alerted the WH.

Sent from my iPhone
Ok. I’m on a BARDA call until 6. Let me know what works for you.

S

---

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@(b) (6)>
Date: May 14, 2020 at 4:51:10 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Clarification

I will call you

---

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Thursday, May 14, 2020 at 4:43 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@(b) (6)>
Subject: Clarification

Deb, (b) (6) couldn’t hear very well so I wanted to make sure we delivered on your request. Can you clarify?
thanks
Steve
From: Hahn, Stephen [O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP
{FYDIBOHF23SPDLT}/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/13/2020 7:58:27 PM
To: Michael, Molly A. EOP/WHO [Molly.A.Michael@who.eop.gov]; Birx, Deborah L. EOP/NSC
[Deborah.L.Birx@{b}(6).Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HH5-affauci-]
Subject: Re: From POTUS

thanks, Molly

From: Michael, Molly A. EOP/WHO <Molly.A.Michael@who.eop.gov>
Date: May 13, 2020 at 6:35:37 PM EDT
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@{b}(6) Fauci, Anthony S (NIH)
<niaid.nih.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Subject: From POTUS

Hi Dr. Birx, Dr. Fauci, and Dr. Hahn,

[b] (6)

Thank you!

Molly Michael
Executive Assistant to the President
202-456-3570 (office)
[b] (6) (cell)
From: Hahn, Stephen [O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A03E69F-STEPHEN.HAH]
Sent: 5/11/2020 4:57:14 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Woodcock, Janet [O=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; Redfield, Robert R (CDC) [O=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cdl]; Marks, Peter [O=ExchangeLabs/ou=Exchange Administrative Group (FYDIOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP]
Subject: Re: [EXTERNAL] FW: BARDA Proposal - RMP v4.docx

Thanks, Joe. Copying Peter
Steve

From: Joe Grogan <Joseph.J.Grogan@who.eop.gov>
Date: Monday, May 11, 2020 at 10:39 AM
To: Stephen Hahn <SH1@fda.hhs.gov>, Janet Woodcock <Janet.Woodcock@fda.hhs.gov>, Robert Redfield <b>6</b> cdc.gov
Subject: Fwd: [EXTERNAL] FW: BARDA Proposal - RMP v4.docx

I sent this to Debi but you should have it to incorporate into your thinking. For some reason I didn’t have Peter’s email.
Thanks, Joe

Sent from my iPhone

Begin forwarded message:

From: "Perlmutter, Roger M" <b>6>
Date: May 8, 2020 at 6:02:27 PM EDT
To: "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Subject: [EXTERNAL] FW: BARDA Proposal - RMP v4.docx

CONFIDENTIAL

Joe:

Attached is the proposal for BARDA that I promised to send when we last spoke. My colleagues and I have tried to outline a comprehensive approach to address the need for enhanced biological manufacturing capabilities in the United States, both with specific reference to the COVID-19 pandemic, and as well taking into account the broader need for pandemic preparedness.

I wish also to take this opportunity to wish you well in whatever future endeavors you undertake. Please let me know if I can help in any way.

With all best wishes,

RMP

Roger M. Perlmutter, MD, PhD
President, Merck Research Laboratories
K1-4009
2000 Galloping Hill Road
Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (2000 Galloping Hill Road, Kenilworth, New Jersey, USA 07033), and/or its affiliates. Direct contact information for affiliates is available at >http://www.merck.com/contact/contacts.html< that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.
Thanks, Marc.

Steve

---

From: Short, Marc T. EOP/OVP <ovp.eop.gov>
Date: May 7, 2020 at 7:00:12 PM EDT
To: Fauci, Anthony S (NIH) <niaid.nih.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Subject: FW: Abbott ID Now Test

FYSA

---

From: Foltz, Nicole <nicole.foltz@abbott.com>
Sent: Thursday, May 7, 2020 6:23 PM
To: Grogan, Joseph J. EOP/WHO @ovp.eop.gov>; Short, Marc T. EOP/OVP <ovp.eop.gov>; Hodgson, Christopher M. EOP/OVP <ovp.eop.gov>
Subject: [EXTERNAL] Abbott ID Now Test

Hi there,

Wanted to flag something for you after the Senate HELP BARDA/NIH hearing today. This is likely going to come up in the news, and at the hearing next week.

The NIH director mentioned that IDNow has a false negative rate of around 15%. The study to which he is referring had some issues in how the samples were handled (more specifics on that below).

We have already worked with the FDA to further advise providers on how to administer the test and transport the sample properly. If it is used as intended, we are confident in its accuracy.

This is a news article about a study the Detroit Mayor did on our machine with his state public health lab where they used the proper sample collection method:

Wanted you to be aware that we have already gotten some media inquiries about this. Happy to jump on the phone and explain if easier.

Nicole

---

**Study referred to by NIH Director Collins:**
The Cleveland Clinic study used viral transport media. When we identified that viral transport media could be diluting samples several weeks ago, we immediately communicated with our customers that they should use the direct swab method. When the direct swab method is used, the test is performing as expected and we are confident in its performance.

We communicated with our customers and posted this to our website on April 15th. Our statement from Apr 15 2020: Abbott is providing additional information and direction for clinicians, laboratory professionals, and our customers on our ID NOW COVID-19 rapid test.

Some of our hospital and academic laboratory users have been validating our ID NOW COVID-19 rapid test (part of a lab's normal process) with the use of viral transport media (VTM) samples. VTM is a liquid solution used to store, preserve, and transport a virus sample. This method can reduce the sensitivity of the test through dilution, which can potentially lead to false negative results.

ID NOW is designed for – and typically used within – urgent care clinics, physicians’ office labs, emergency departments, and retail settings. This means that patient samples (swabs) are collected and tested directly on the ID NOW instrument, near the patient and without the use of VTM.

In consultation with the FDA, we have instructed our customers not to use VTM for the ID NOW COVID-19 rapid test. The sample (swab) should be placed directly in the instrument for testing and not placed in any other media. We have updated our product information and are directly communicating with our customers.

When a direct swab is used, the test is performing as expected and we have confidence in the performance of the test.

For more information about Abbott’s work on COVID-19 testing, visit: >https://www.abbott.com/IDNOW.html<.
FYI
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment

Stat
Adam Feuerstein and Matthew Herper
April 16, 2020

A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.

Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.

The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.

“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital.

Her comments were made this week during a video discussion about the trial results with other University of Chicago faculty members. The discussion was recorded and STAT obtained a copy of the video.

The outcomes offer only a snapshot of remdesivir’s effectiveness. The same trials are being run concurrently at other institutions, and it’s impossible to determine the full study results with any certainty. Still, no other clinical data from the Gilead studies have been released to date, and excitement is high. Last month, President Trump touted the potential for remdesivir — as he has for many still-unproven treatments — and said it “seems to have a very good result.”

In a statement Thursday, Gilead said: “What we can say at this stage is that we look forward to data from ongoing studies becoming available.”

Gilead had said to expect results for its trial involving severe cases in April. Mullane said during her presentation that data for the first 400 patients in the study would be “locked” by Gilead Thursday, meaning that results could come any day.
Mullane, while encouraged by the University of Chicago data, made clear her own hesitancy about drawing too many conclusions.

“It’s always hard,” she said, because the severe trial doesn’t include a placebo group for comparison. “But certainly when we start [the] drug, we see fever curves falling,” she said. “Fever is now not a requirement for people to go on trial, we do see when patients do come in with high fevers, they do [reduce] quite quickly. We have seen people come off ventilators a day after starting therapy. So, in that realm, overall our patients have done very well.”

She added: “Most of our patients are severe and most of them are leaving at six days, so that tells us duration of therapy doesn’t have to be 10 days. We have very few that went out to 10 days, maybe three,” she said.

Reached by STAT, Mullane confirmed the authenticity of the footage but declined to comment further.

Asked about the data, Eric Topol, director of the Scripps Research Translational Institute, described them as “encouraging.”

“The severely hit patients are at such high-risk of fatality. So if it’s true that many of the 113 patients were in this category and were discharged, it’s another positive signal that the drug has efficacy,” he said, adding that it will be important to see more data from randomized controlled studies.

Gilead’s severe Covid-19 study includes 2,400 participants from 152 different clinical trial sites all over the world. Its moderate Covid-19 study includes 1,600 patients in 169 different centers, also all over the world.

The trial is investigating five- and 10-day treatment courses of remdesivir. The primary goal is a statistical comparison of patient improvement between the two treatment arms. Improvement is measured using a seven-point numerical scale that encompasses death (at worst) and discharge from hospital (best outcome), with various degrees of supplemental oxygen and intubation in between.

The lack of a control arm in the study could make interpreting the results more challenging.

A lack of data has led to yo-yoing expectations for the drug. Two studies in China had enrollment suspended partway through because there were not enough patients available. A recent report of patients given the drug under a special program to make it available to those who are very ill generated both excitement and skepticism.

In scientific terms, all the data are anecdotal until the full trial reads out, meaning that they should not be used to draw final conclusions. But some of the anecdotes are dramatic.

Slawomir Michalak, a 57-year-old factory worker from a suburb west of Chicago, was among the participants in the Chicago study. One of his daughters started feeling ill in late March and was later diagnosed with mild Covid-19. Michalak, by contrast, came down with a high fever and reported shortness of breath and severe pain in his back.

“It felt like someone was punching me in the lungs,” he told STAT.

At his wife’s urging, Michalak went to the University of Chicago Medicine hospital on Friday, April 3. His fever had spiked to 104 and he was struggling to breath. At the hospital, he was given supplemental oxygen. He also agreed to participate in Gilead’s severe Covid-19 clinical trial.

His first infusion of remdesivir was on Saturday, April 4. “My fever dropped almost immediately and I started to feel better,” he said.

By his second dose on Sunday, Michalak said he was being weaned off oxygen. He received two more daily infusions of remdesivir and recovered enough to be discharged from the hospital on Tuesday, April 7.
“Remdesivir was a miracle,” he said.

The world is waiting to find out if it is really so.
In case any are doing media or the CNN townhall

Most recent data
New hospitalizations down 50% from first week of April and first week of May. Mortality down 15% from week over week.
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@](D) (6)
Sent: 5/7/2020 9:28:16 PM
To: Hahn, Stephen /o=ExchangeLabs/ou=Exchange Administrative Group [FYDIBOHF23SPDLT]/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah
Subject: Did you find it. Is it there?

Sent from my iPhone
Of course.

Sent from my iPhone

On Apr 28, 2020, at 6:34 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

I’m ok. You?
May I call you to touch base when I land?
Thank you Steve.

Sent from my iPhone

> On Apr 21, 2020, at 8:52 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

(b) (5)
Thank you

From: "Ford, Robert B" <Robert.Ford@abbott.com>
Date: Sunday, April 19, 2020 at 6:03 PM
To: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@(b)(6)>, "Shuren, Jeff (FDA/CDRH)" <Jeff.Shuren@fda.hhs.gov>, "Stenzel, Timothy (FDA/CDRH)" <Timothy.Stenzel@fda.hhs.gov>, "Haddad, Carla (HHS/OASH)" <Carla.Haddad@hhs.gov>
Subject: [EXTERNAL] Re: Abbott's Covid Data

Dear All,
I wanted to make sure I read this comment regarding utilization of the automated antibody test.

As you can see we made a commitment to ship (b)(4) tests between Thur, Fri and Saturday. (b)(4)

You will see that the column on tests performed is zero. I will expect that column to start to get populated by Monday/Tuesday. The reason for this is:
A) These are shipments; so many of these accounts have not even received them yet, although we are expediting them.
B) The lab will need to run calibrations and controls so they can validate the test per their internal protocols. Some labs are faster than others. But this system is much easier to use vs the m2000 RNA test, so I believe it will be done faster.
B) The pre-test process requires the doctor prescription and obviously the sample collection process.

Best,
Robert B. Ford

On Apr 19, 2020, at 4:37 PM, Wainer, Andrea F <andrea.wainer@abbott.com> wrote:

Good evening,
Please find attached Abbott’s data as of April 18 for (1) m2000; (2) ID NOW; and (3) ARCHITECT testing platforms.

For m2000 test data, there are two types of data we have:

1. Information in our control such as the names and addresses of our customers and the number of tests we shipped to them cumulatively and this week (Sunday to Saturday shipments).
2. Raw data we receive from a remote data link that is sent from the instruments at the customers to Abbott.
   a. We only receive the remote data link from certain customers (on the spreadsheet, the customers we don’t receive data from are in gray).
   b. For those customers with the remote data link, we are providing raw data that has the number of tests run and the number of positives. Customers run their own required protocols to validate the accuracy of a test when a new test first becomes available. Those validation processes include negative and positive samples. The raw data we get from data link of the instrument cannot distinguish between validation samples and patient samples.
3. We do not have data regarding inventory at the labs.

For ID NOW test data:

1. We are reporting names, addresses, total cumulative tests shipped, and total tests shipped this week (Monday to Sunday shipments).
2. Unlike the m2000 instrument, we do not have any data on tests performed from the ID NOW instruments.

For ARCHITECT test data, there are two types of data we have:

1. Information in our control such as the names and addresses of our customers and the number of tests we shipped to them cumulatively and this week (Sunday to Saturday shipments).
2. Raw data we receive from a remote data link that is sent from the instruments at the customers to Abbott.
   a. We only receive the remote data link from certain customers (on the spreadsheet, the customers we don’t receive data from are in gray).
   b. For those customers with the remote data link, we will be providing raw data that has the number of tests run and the number of positives.
3. We do not have data regarding inventory at the labs.

Best regards,
Andrea
This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

Probably the dummy inbox we set up

Sent from my iPhone

On Apr 21, 2020, at 12:25 PM, Hahn, Stephen [b](5)@fda.hhs.gov wrote:

Will do. Do you know who received the April 8 outreach?
Steve

Can you please check into the below

Sent from my iPhone

Begin forwarded message:

From: "Hicks, Hope C. EOP/WHO" <Hope@who.eop.gov>
Date: April 21, 2020 at 11:50:54 AM EDT
To: "Miller, Katie R. EOP/OVP" <Katie.R.Miller@ovp.eop.gov>
Subject: FW: Follow Up - White House Correspondence

See attached from a doctor I know in California. Should I forward directly to Hahn or someone else?

From: David C. Socol MD <David@SocolMD.com>
Sent: Tuesday, April 21, 2020 3:17 AM
To: Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>
Cc: Chanda Zaveri <zaveri.chanda@yahoo.com>; dfinklestein@gmail.com
Subject: [EXTERNAL] Follow Up - White House Correspondence

To Whom It May Concern,

Our group forwarded correspondence to White House Physician Dr. Sean Conley on March 30, 2020 through the offices of Dr. Sharon Hausman-Cohen regarding Cell Armour, a product which is demonstrating notable efficacy against SARS-CoV-2. Cell Armour prevents people from getting sick, makes sick people better faster, confers immunity, and achieves all of the above without the risk of cardiac toxicity.
We received a notice of receipt from the White House Coronavirus Response Team on April 8, 2020 regarding our initial forward, stating a member of that team would reach out to our group within 48 hours. To our knowledge, that outreach did not occur.

On April 15, 2020, we forwarded the attached high-level correspondence to the Coronavirus Response Team to alert the team to additional findings and applications, absent any acknowledgement to date.

While we appreciate the tremendous burden that the White House team is under, Cell Armour is currently being evaluated by the Republic of India as a prophylactic and treatment alternative to COVID-19 given information that has been provided to date. Local clinicians are also scheduled to run a clinical trial to validate our real-world findings in Hong Kong, China, South Korea and Singapore, among others. We are also preparing to start additional trials with emergency department physicians in the United States momentarily.

Given these rapidly advancing discussions in India, our offices are of the mindset that we would be remiss not to alert your offices of our progress to date and Cell Armour’s strong potential to change the trajectory of the COVID-19 pandemic given our current fund of knowledge. We also believe that the White House should be apprised of our progress, learn about the science of Cell Armour, and what it can accomplish in order to explore an expedited path to widespread provision of Cell Armour to the American people.

Wishing you all the best at this challenging time.

Respectfully,

David

David C. Socol | Physician
8383 Wilshire Boulevard, Suite 610
Beverly Hills, CA  90211
Direct 310-561-4021
Office 323-951-0200
Facsimile 310-388-0782

Confidentiality Warning | This communication and its contents may contain confidential and/or legally privileged information. It is solely for the use of the intended recipient(s). Unauthorized interception, review, use or disclosure is prohibited and may violate applicable laws including the Electronic Communications Privacy Act. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of this communication.
Yes

Sent from my iPhone

On May 27, 2020, at 1:21 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Are you all aware of this study?

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@{6}]
Sent: 5/16/2020 2:40:08 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIOHF23SPDLT)/cn=Recipients/cn=a0fac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Olivarria, Frank
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIOHF23SPDLT)/cn=Recipients/cn=c180721db774423f99990dd86e67057c-Frank.Oliva]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bdf521b0105d17d2-Keagan.Leni]; Marks, Peter
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIOHF23SPDLT)/cn=Recipients/cn=dffbb2b5bd384a5cb9c9adca3f72df53a-MarksP]
Subject: Re: Call tomorrow 11am

I am free

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Saturday, May 16, 2020 at 1:58 PM
To: "Olivarria, Frank" <Frank.Olivarria@fda.hhs.gov>
Cc: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@{6}>, "Lenihan, Keagan"
<Keagan.Lenihan@fda.hhs.gov>, "Marks, Peter" <Peter.Marks@fda.hhs.gov>
Subject: Call tomorrow 11am

Frank,
Could you arrange a call for Drs. Marks, Birx and me tomorrow at 11 am if everyone is free?
Thanks
Steve
Sent from my iPhone
Sent from my iPhone
Thank you

Hi Dr. Birx, Dr. Fauci, and Dr. Hahn,

Thank you!

Molly Michael
Executive Assistant to the President
202-456-3570 (office)
(b) (6)(cell)
Call me. I tried your phone.

Sent from my iPhone

On May 14, 2020, at 5:46 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:
Awesome.

BTW, Janet gave a great presentation on therapeutics to a small group led by Dr. Birx. It went well.

Steve

I sent this to Debi but you should have it to incorporate into your thinking. For some reason I didn’t have Peter’s email. Thanks, Joe

Sent from my iPhone

Begin forwarded message:

CONFIDENTIAL

Joe:

Attached is the proposal for BARDA that I promised to send when we last spoke. My colleagues and I have tried to outline a comprehensive approach to address the need for enhanced biological manufacturing capabilities in the United States, both with specific reference to the COVID-19 pandemic, and as well taking into account the broader need for pandemic preparedness.

I wish also to take this opportunity to wish you well in whatever future endeavors you undertake. Please let me know if I can help in any way.

With all best wishes,

RMP

Roger M. Perlmutter, MD, PhD
President, Merck Research Laboratories
Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (2000 Galloping Hill Road, Kenilworth, New Jersey, USA 07033), and/or its affiliates Direct contact information for affiliates is available at >>>http://www.merck.com/contact/contacts.html<<;) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.
More deaths, no benefit from malaria drug in VA virus study
Associated Press
Marilynn Marchione
April 21, 2020
https://apnews.com/a5077c7227b8eb8b0dc23423c0bbe2b2

A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers reported.

The nationwide study was not a rigorous experiment. But with 368 patients, it's the largest look so far of hydroxychloroquine with or without the antibiotic azithromycin for COVID-19, which has killed more than 171,000 people as of Tuesday.

The study was posted on an online site for researchers and has been submitted to the New England Journal of Medicine, but has not been reviewed by other scientists. Grants from the National Institutes of Health and the University of Virginia paid for the work.

Researchers analyzed medical records of 368 male veterans hospitalized with confirmed coronavirus infection at Veterans Health Administration medical centers who died or were discharged by April 11.

About 28% who were given hydroxychloroquine plus usual care died, versus 11% of those getting routine care alone. About 22% of those getting the drug plus azithromycin died too, but the difference between that group and usual care was not considered large enough to rule out other factors that could have affected survival.

Hydroxychloroquine made no difference in the need for a breathing machine, either.

Researchers did not track side effects, but noted hints that hydroxychloroquine might have damaged other organs. The drug has long been known to have potentially serious side effects, including altering the heartbeat in a way that could lead to sudden death.

Earlier this month, scientists in Brazil stopped part of a hydroxychloroquine study after heart rhythm problems developed in one-quarter of people given the higher of two doses being tested.
Many doctors have been leery of the drug.

At the University of Wisconsin, Madison, “I think we’re all rather underwhelmed” at what’s been seen among the few patients there who’ve tried it, said Dr. Nasia Safdar, medical director of infection control and prevention.

Patients asked about it soon after Trump started promoting its use, “but now I think that people have realized we don’t know if it works or not” and needs more study, said Safdar, who had no role in the VA analysis.

The NIH and others have more rigorous tests underway.

To Unsubscribe Email COMMSALERT-signoff-request@L.GOP.COM
Confirmed -- Dr. Birx follow up discussion

Dr. Birx office // Dial In: 1-877-465-7975
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@ (b) (6)]
Sent: 5/19/2020 4:29:15 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@ (b) (6)]; Emilio Emini [Emilio.Emini@gatesfoundation.org]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Olivarria, Frank [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c180721db774423f99990dd86e67057c-Frank.Oliva]; Marks, Peter [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; McGuffee, Tyler Ann A. EOP/OVP [(b) (6) ovp.eop.gov]

Subject: Confirmed - Video Conference Call w/ Emilio Emini
Location: EEOB 176 / Video Meeting link: https://fda1.webex.com/fda1/j.php?MTID=m2037415d800f23d93894e9ea3268001a

Start: 5/20/2020 11:00:00 AM
End: 5/20/2020 11:45:00 AM
Show Time As: Busy

Recurrence: (none)

Attendees:
- Dr. Deborah Birx [White House]
- Dr. Stephen Hahn [FDA]
- Dr. Peter Marks [FDA]
- Dr. Emilio Emini [Director, TB and HIV Program, Bill & Melinda Gates Foundation]

Video Meeting link: https://fda1.webex.com/fda1/j.php?MTID=m2037415d800f23d93894e9ea3268001a

Video Conference with Drs. Birx & Hahn

Wednesday, May 20, 2020 | 11:00 am Eastern Daylight Time (GMT-04:00) | 1 hour 0 minutes | Not started

Meeting link: https://fda1.webex.com/fda1/j.php?MTID=m2037415d800f23d93894e9ea3268001a

Meeting number: (b) (6)

Meeting password: (b) (6)

Audio connection:
+1-877-465-7975 US Toll Free
Global call-in numbers
Show toll-free dialing restrictions
Access (b) (6)
TIME CHANGE: Discussion: 5/7 Agenda

Attendees:
Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma
Meeting w/ Dr. Birx

Location: Roosevelt Room

Start: 5/1/2020 1:00:00 PM
End: 5/1/2020 2:00:00 PM
Show Time As: Busy

Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/17/2020 5:59:06 PM

Subject: Update
Location: WHSR
Start: 4/20/2020 2:00:00 PM
End: 4/20/2020 2:30:00 PM
Show Time As: Busy

Recurrence: (none)

Attendees:
Dr. Hahn
Dr. Redfield
Dr. Birx
Matt Pottinger
Chris Liddell
Confirmed - Dr. Birx call w/ ACOG/AAP Leadership

Dr. Birx office; 877-628-4681

American College of Obstetricians and Gynecologists (ACOG) participants:
Speaking: Maureen Phipps, MD, MPH, FACOG – CEO
Also on the line: Skye Perryman, JD – Chief Legal Officer and General Counsel
Rachel Tetlow, Federal Affairs Director

American Academy of Pediatrics (AAP) participants:
Speaking: Mark DelMonte, CEO
Also on the line: Tamar Haro, Senior Director, Federal and State Advocacy

ACOG/ AAP Agenda:

1. Opening and thanks
2. Healthy moms and babies
3. HHS funding for physicians
4. Conversation
5. Closing
From: ovp.eop.gov
Sent: 5/11/2020 2:07:34 PM

Subject: UPDATED DIAL IN Confirmed - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: 1-866-617-3597;; Participant Passcode: (b) (5)

Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Busy

Recurrence: (none)

Dial-In Information
Toll-Free #1-866-617-3597
Participant Passcode: (b) (6)
Leader Passcode: (b) (6)

Attendees:
Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@EOP]  
Sent: 5/26/2020 4:54:34 PM  
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@EOP], Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-FYDIBOHF23SPDLT/cn=Recipients/cn=0f1ab650905f424381ffbad983419fcd-HHS-olx1-cd]; McGuffee, Tyler Ann A. EOP/OVP [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43f78a049-HHS-conradp]; Gershman, Lynn E (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=466fe715fb22432e9dce605736dced8777-HHS-veu4-cd]  
Subject: Confirmed - Follow up discussion  
Location: Dr. Birx office  
Start: 5/27/2020 3:30:00 PM  
End: 5/27/2020 5:00:00 PM  
Show Time As: Busy  
Recurrence: (none)  

Attendees:  
Dr. Birx [confirmed in-person]  
Dr. Redfield [confirmed in-person]  
Dr. Hahn [confirmed in-person]  
Dr. Fauci [confirmed in-person]
Subject: Meeting

Location: WHSR JFK

Start: 5/4/2020 1:15:00 PM
End: 5/4/2020 2:15:00 PM
Show Time As: Tentative

Recurrence: (none)

**There will be no dial-in option**
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]

Sent: 4/24/2020 3:10:17 PM

To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@who.eop.gov]; Cytryn, Jen B. EOP/WHO [Jen.B.Cytryn@who.eop.gov]; Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@who.eop.gov]; Fauci, Anthony S. (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2a83b77989d40cc3-HHS]; Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30cd6224eb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith [CMS] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]; CMS/0 [Jeeh; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0ca3c49891383e38a036e9f-Stephen.Hah]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@who.eop.gov]; Pottinger, Matthew F. EOP/WHO [Matthew.F.Pottinger@who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@who.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [Kellogg.Joseph.K.Jr@who.eop.gov]; Williams, Teresa [CDC] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=32e463e6c48413a9e21cb26f99251b-HHS-c004-cd]; Redfield, Robert [CDC] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0faa85985f42381ffbd983419fcd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [Campana.AlexandraD@who.eop.gov]; DeValliere, Ian C. EOP/WHO [Ian.C.DeValliere@who.eop.gov]; Williams, Michael B. EOP/WHO [Michael.B.Williams@who.eop.gov]

Subject: HOLD

Location: WHSR

Start: 4/29/2020 2:00:00 PM

End: 4/29/2020 2:50:00 PM

Show Time As: Tentative

Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
Vought, Russell T. EOP/OMB [b6]; Bruno, Grace A. EOP/OMB [b6]; D'Angelo, Gregory B. EOP/OMB [b6]; Cytryn, Jen B. EOP/WHO [b6]; Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [b6]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@b6]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2b8c378998443fd78a049-HHS-conradp]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOBOHF23SPDLT)/cn=Recipients/cn=5e6154b833b4cb87b01816905e1300-HHS-Meredith]; CMS [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOBOHF23SPDLT)/cn=Recipients/cn=f45a6c965c274724a1be5970eb648ff7-JSheehy]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOBOHF23SPDLT)/cn=Recipients/cn=a0facf0ca3c4b881383ee38a636e9f-Stephen.Hahl]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@b6]; Pottinger, Matthew F. EOP/WHO [b6]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@b6]; Kellogg, Joseph Keith K. Jr. EOP/OVP [b6]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOBOHF23SPDLT)/cn=Recipients/cn=c82be6386c48413a9e21cb26f9a9251b-HHS-coo4-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOBOHF23SPDLT)/cn=Recipients/cn=01ab650905f424381ffbbd983419fcd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [b6]; DeValliere, Ian C. EOP/WHO [b6]; Williams, Michael B. EOP/WHO [b6]

Subject: HOLD

Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Tentative
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Conant, Ann M. EOP/OMB [b (6)]; Bruno, Grace A. EOP/OMB [b (6)]; D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@b (6)]; Cytryn, Jen B. EOP/WHO [b (6)]; Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [b (6)]; Bixr, Deborah L. EOP/NSC [Deborah.L.Bixr@b (6)]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2b83b77989d40cc3-HHS-CONRAD-b (6)]; Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43f78a049-HHS-conradp]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]; CMS [b (6)]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a66e96f52747241be593e648f7-JSheehy]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@b (6)]; Pottinger, Matthew F. EOP/WHO [b (6)]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@b (6)]; Kellogg, Joseph Keith K. Jr. EOP/OVP [b (6)]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fe9251b-HHS-coo4-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [b (6)]; DeValliere, Ian C. EOP/WHO [b (6)]; Williams, Michael B. EOP/WHO [b (6)]

Subject: HOLD [b (5)]
Location: WHSR
Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Tentative

-----Original Appointment-----
From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Friday, April 24, 2020 1:43 PM
To: Grogan, Joseph J. EOP/WHO; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Bixr, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH); Good-Cohn, Meredith (CMS); CMS; Sheehy, Janice; Hahn, Stephen; Holt, Brandon T. EOP/NSC; Pottinger, Matthew F. EOP/WHO; Ferro, Phil J. EOP/NSC; Kellogg, Joseph Keith K. Jr. EOP/OVP; Williams, Teresa (CDC); Redfield, Robert R (CDC); Campana, Alexandra D. EOP/WHO; DeValliere, Ian C. EOP/WHO; Williams, Michael B. EOP/WHO

Subject: HOLD
When: Monday, April 27, 2020 2:00 PM-2:50 PM (UTC-05:00) Eastern Time (US & Canada).
Where: WHSR
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@o.eop.gov]
Sent: 4/30/2020 4:31:01 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@o.eop.gov], McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee@o.eop.gov], Marks, Peter [/o=ExchangeLabs/ou=Exchange Administrative Group {FYDIBOHF23SPDLT}/cn=Recipients/cn=6bc2b5bd38445cb9c9adca3f72df53a-MarksP]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group {FYDIBOHF23SPDLT}/cn=Recipients/cn=a0afadcaf3c4b98913833e38a036e9f-Stephen.Hah]

Subject: Meeting w/ Dr. Birx
Location: Dr. Birx suite
Start: 5/1/2020 1:00:00 PM
End: 5/1/2020 2:00:00 PM
Show Time As: Tentative
Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]

Sent: 4/24/2020 3:10:17 PM

To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB

(b) (6) Vought, Russell T. EOP/OMB (b) (6) Bruno, Grace A. EOP/OMB (b) (6) D’Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@who.eop.gov]; Miller, Stephen EOP/WHO (Stephen.Miller@who.eop.gov); McGuffee, Tyler Ann A. EOP/OVP (b) (6) Birx, Deborah L. EOP/NSC (b) (6) Fauci, Anthony S (NIH) (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77898d40cc3-HHS-(b) (6) Conrad, Patricia L (NIH) (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224abeb49c795844f43fd78a049-HHS-conradp); Good-Cohn, Meredith (CMS) (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit); Sheehy, Janice (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy); Hahn, Stephen (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah); Holt, Brandon T. EOP/NSC (Brandon.T.Holt@who.eop.gov); Pottinger, Matthew F. EOP/WHO (b) (6) Ferro, Phil J. EOP/NSC (Philip.J.Ferro@who.eop.gov); Kellogg, Joseph Keith K. Jr. EOP/OVP (b) (6) Williams, Teresa (CDC) (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26f5a9251b-HHS-coo4-cd); Redfield, Robert R (CDC) (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbed983419fcd-HHS-olx1-cd); Campana, Alexandra D. EOP/WHO (b) (6) Williams, Michael B. EOP/WHO (b) (6) Mango, Paul (OS) (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932ca0f249d2a0c6a5f58b2c9ee5-HHS-Paul.Maj); Troye, Olivia EOP/NSC (Olivia.Troye@who.eop.gov); Marks, Peter (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ddb2b2b5db38445cb9c9adca3f72df53a-MarksP); Woodcock, Janet (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a363f3d-Janet.Woodc); OS/IOS (b) (6) HHS.GOV

CC: Bonner, Maria K. EOP/WHO (b) (6) Marks, Peter (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ddb2b2b5db38445cb9c9adca3f72df53a-MarksP); Woodcock, Janet (/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a363f3d-Janet.Woodc); OS/IOS (b) (6) HHS.GOV

Subject:

Attachments:

Location: WHSR JFK

Start: 4/29/2020 1:45:00 PM

End: 4/29/2020 2:30:00 PM

Show Time As: Tentative

Recurrence: (none)

*Please note the new start time of 1:45 PM due to conflicts in the WHSR*

(b) (6)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/17/2020 5:59:06 PM

Subject: Update
Location: WHSR

Start: 4/20/2020 2:00:00 PM
End: 4/20/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:
Dr. Hahn
Dr. Redfield
Dr. Birx
Matt Pottinger
Chris Liddell
From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@o[6]6]
Sent: 4/30/2020 10:52:54 AM
[6][6]o@ExchangeLabs/ou=Exchange Administrative Group
(FYDIOHOF23PDILT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[6][6]Redfield, Robert R
(CDC) [6][6]o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIOHOF23PDILT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fcd-HHS-olx1-cd]; Hahn, Stephen
[o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIOHOF23PDILT)/cn=Recipients/cn=a0afac0cfa3c4b9893c83e38a036e9f-Stephen.Hah]

Subject: Confirmed - Dr. Birx call w/ ACOG/AAP Leadership
Location: Dr. Birx office; 877-628-4681
Start: 4/30/2020 2:15:00 PM
End: 4/30/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Dial In: 877-628-4681
Participant:

ACOG participants:
Maureen Phipps, MD, MPH, FACOG – CEO
Skye Perryman, JD – Chief Legal Officer and General Counsel
Rachel Tetlow, Federal Affairs Director

AAP participants:
Mark DelMonte, CEO
Tamar Haro, Senior Director, Federal and State Advocacy

ACOG/AAP Agenda:
- Opening and thanks (Mark and Maureen)
- HHS funding for physicians and hospitals – concerns with distribution (Mark and Maureen)
- Immunization rates (Mark)
- Continued concerns regarding home birth/birth settings (Maureen and Mark)
- Opportunity to partner in the lead up to Mother’s Day (Maureen)
- PPE & Testing shortages (Maureen and Mark)
- Prioritization of L&D for rapid response testing
Meeting

WHSR JFK

5/4/2020 1:15:00 PM

2:15:00 PM

Busy

**There will be no dial-in option**
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
   EOP/OMB [Ann.M.Conant@who.eop.gov]; Bruno, Grace A. EOP/OMB [Grace.A.Bruno@who.eop.gov]; Vought, Russell T. EOP/OMB [Russell.T.Vought@who.eop.gov]; Cytryn, Jen B. EOP/WHO [Jen.B.Cytryn@who.eop.gov]; Miller, Stephen EOP/WHO
   [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@who.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIHOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2b83778988d40cc3-HHS-1]
   [Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIHOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIHOHF23SPDLT)/cn=Recipients/cn=5e06154b833bb4cb8a7b01816905e1300-HHS-Meredith]; CMS [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIHOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648f7-JSheehy]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIHOHF23SPDLT)/cn=Recipients/cn=e0fac6c0ca3c4b98913833e38e036e9f-Stephen.Hah]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@who.eop.gov]; Pottinger, Matthew F. EOP/WHO [Matthew.F.Pottinger@who.eop.gov]; Ferro, Phil J. EOP/NSC [Phil.J.Ferro@who.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [Joseph.K.Kellogg@ovp.eop.gov]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIHOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb2b1f9251b-HHS-c004-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIHOHF23SPDLT)/cn=Recipients/cn=01ab650905f42438fbd983419fcd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana@who.eop.gov]; DeValliere, Ian C. EOP/WHO [Ian.C.DeValliere@who.eop.gov]; Williams, Michael B. EOP/WHO [Michael.B.Williams@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIHOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]
Subject: (b) (5)
Location: WHSR
Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Busy
Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
Vought, Russell T. EOP/OMB [Russell.T.Vought@who.eop.gov]; Bruno, Grace A. EOP/OMB [Grace.A.Bruno@who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@who.eop.gov]; Cytryn, Jen B. EOP/WHO [Jen.B.Cytryn@who.eop.gov]; Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@who.eop.gov]; Fauci, Anthony S (NIH) [Anthony.S.Fauci@nih.gov]; Conrad, Patricia L (NIH) [Patricia.L.Conrad@nih.gov]; Good-Cohn, Meredith (CMS) [Meredith.Good-Cohn@hhs.gov]; CMS [CMS@hhs.gov]; Sheehy, Janice [Jsheehy@exchange.nhi.gov]; Hahn, Stephen [Stephen.Hahn@exchange.nhi.gov]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@who.eop.gov]; Pottinger, Matthew F. EOP/WHO [Matthew.F.Pottinger@who.eop.gov]; Ferro, Phil J. EOP/NSC [Phil.J.Ferro@who.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [Joseph.Kellogg@who.eop.gov]; Williams, Teresa (CDC) [Teresa.Williams@cdc.gov]; Redfield, Robert R (CDC) [Robert.R.Redfield@cdc.gov]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana@who.eop.gov]; DeValiere, Ian C. EOP/WHO [Ian.C.DeValiere@who.eop.gov]; Williams, Michael B. EOP/WHO [Michael.B.Williams@who.eop.gov]
Subject: HOLD
Location: WHSR
Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Busy
Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D’Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@who.eop.gov]; Cytryn, Jen B. EOP/WHO [Jen.B.Cytryn@who.eop.gov]; McGuﬀee, Tyler Ann A. EOP/OVP [Tyler.A.McGuﬀee@o vp.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@who.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-374752]; Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224eb49c795844fd43d78a049-HHS-conradp]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]; CMS-50 [Jim.C.Mitchel@ms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0fac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@who.eop.gov]; Pottinger, Matthew F. EOP/WHO [Matthew.F.Pottinger@who.eop.gov]; Ferro, Phil J. EOP/NSC [Phil.J.Ferro@who.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [Joseph.Kellogg@o vp.eop.gov]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=32e463e6c4841a9e21cb26f9a9251b-HHS-coo4-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=01ab650905f4243818b9d983419fcd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana@who.eop.gov]; DeValliere, Ian C. EOP/WHO [Ian.C.DeValliere@who.eop.gov]; Williams, Michael B. EOP/WHO [Michael.B.Williams@who.eop.gov]

Subject: HOLD

Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM

Show Time As: Busy
-----Original Appointment-----

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Friday, April 24, 2020 1:43 PM
To: Grogan, Joseph J. EOP/WHO; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Birch, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH)

Subject: HOLD

Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Busy

-----Original Appointment-----

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Friday, April 24, 2020 1:43 PM
To: Grogan, Joseph J. EOP/WHO; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Birch, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH); Good-Cohn, Meredith (CMS); Sheehy, Janice; Holt, Brandon T. EOP/NSC; Ferro, Phil J. EOP/NSC; Williams, Teresa (CDC); Pottinger, Matthew F. EOP/WHO; Williams, Michael B. EOP/WHO

Subject: HOLD

Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Busy

-----Original Appointment-----

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Monday, April 20, 2020 2:43:09 PM
To: Grogan, Joseph J. EOP/WHO; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOBF23SPDLT)/cn=Recipients/cn=a0fac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D’Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Birch, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH)

Subject: HOLD

Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Busy

-----Original Appointment-----

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Monday, April 20, 2020 2:43:09 PM
To: Grogan, Joseph J. EOP/WHO; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIOBF23SPDLT)/cn=Recipients/cn=a0fac0cfa3c4b98913833e38a036e9f-Stephen.Hahn]; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D’Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Birch, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH); Good-Cohn, Meredith (CMS); Sheehy, Janice; Holt, Brandon T. EOP/NSC; Pottinger, Matthew F. EOP/WHO; Ferro, Phil J. EOP/NSC; Williams, Teresa (CDC); Redfield, Robert R (CDC); Campana, Alexandra D. EOP/WHO; DeValliere, Ian C. EOP/WHO; Williams, Michael B. EOP/WHO

Subject: HOLD

Location: WHSR

Start: Monday, April 27, 2020 2:00 PM-2:50 PM (UTC-05:00) Eastern Time (US & Canada).
Where: WHSR
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Birx, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH)

Subject: HOLB
Location: WHSR
Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Tentative
Recurrence: (none)
Subject: (b) (5)

Location: WHSR JFK

Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM

Show Time As: Tentative

Recurrence: (none)
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@oep.eop.gov]; Cytryn, Jen B. EOP/WHO [Jen.B.Cytryn@who.eop.gov]; Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [b6@oep.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@oep.eop.gov]; Fauli, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b7989d40cc3-HHS-6]; Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224ebb49795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith CMS [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb42cb8a7b0161905e1300-HHS-Meredith]; CMS GU [b5@hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a5e5970eb648ff7-JSheehy]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b9891383e38a036e9f-Stephen.Hahn]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@oep.eop.gov]; Pottinger, Matthew F. EOP/WHO [b6@who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@oep.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [b6@oep.eop.gov]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=32e463e6e48413a9e21cb26fea9251b-HHS-c004-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbd983419fd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [b6@who.eop.gov]; DeValliere, Ian C. EOP/WHO [b6@who.eop.gov]; Williams, Michael B. EOP/WHO [b6@who.eop.gov]
Subject: HOLD
Location: WHSR
Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Tentative
Recurrence: (none)
Confirmed - Dr. Birx call w/ ACOG/AAP Leadership

Start: 4/30/2020 2:15:00 PM
End: 4/30/2020 2:30:00 PM
Show Time As: Tentative

Dial In: 877-628-4681
Participant: (b) (6)

ACOG participants:
Maureen Phipps, MD, MPH, FACOG – CEO
Skye Perryman, JD – Chief Legal Officer and General Counsel
Rachel Tetlow, Federal Affairs Director

AAP participants:
Mark DelMonte, CEO
Tamar Haro, Senior Director, Federal and State Advocacy

ACOG/AAP Agenda:

- Opening and thanks (Mark and Maureen)
- HHS funding for physicians and hospitals – concerns with distribution (Mark and Maureen)
- Immunization rates (Mark)
- Continued concerns regarding home birth/birth settings (Maureen and Mark)
- Opportunity to partner in the lead up to Mother’s Day (Maureen)
- PPE & Testing shortages (Maureen and Mark)
- Prioritization of L&D for rapid response testing
Meeting w/ Dr. Birx

Dr. Birx suite

5/1/2020 1:00:00 PM
5/1/2020 2:00:00 PM
Busy

(none)
Subject: Confirmed - Dr. Birx call w/ ACOG/AAP Leadership

Location: Dr. Birx office; 877-628-4681

Start: 4/30/2020 2:15:00 PM
End: 4/30/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Dial In: 877-628-4681

Participant: (b) (6)

ACOG participants:
Maureen Phipps, MD, MPH, FACOG – CEO
Skye Perryman, JD – Chief Legal Officer and General Counsel
Rachel Tetlow, Federal Affairs Director

AAP participants:
Mark DelMonte, CEO
Tamar Haro, Senior Director, Federal and State Advocacy

ACOG/AAP Agenda:
- Opening and thanks (Mark and Maureen)
- HHS funding for physicians and hospitals – concerns with distribution (Mark and Maureen)
- Immunization rates (Mark)
- Continued concerns regarding home birth/birth settings (Maureen and Mark)
- Opportunity to partner in the lead up to Mother’s Day (Maureen)
- PPE & Testing shortages (Maureen and Mark)
- Prioritization of L&D for rapid response testing
From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
(b) (6) Vought, Russell T. EOP/OMB [Russell.T.Vought@who.eop.gov]; Bruno, Grace A. EOP/OMB [Grace.A.Bruno@who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@who.eop.gov]; Cytryn, Jen B. EOP/WHO [Jen.B.Cytryn@who.eop.gov]; Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGehee, Tyler Ann A. EOP/OVP [Tyler.A.McGehee@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@who.eop.gov]; Fauci, Anthony S (NIH) [Anthony_S_Fauci@nih.gov]; Hahn, Stephen [Stephen.Hahn@nih.gov]; Williams, Teresa (CDC) [Teresa.Williams@cdc.gov]; Pottinger, Matthew F. EOP/WHO [Matthew.F.Pottinger@who.eop.gov]; Ferro, Phil J. EOP/NSC [Phil.J.Ferro@who.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [Joseph.Keith.K.Kellogg@who.eop.gov]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@who.eop.gov]; DeValliere, Ian C. EOP/WHO [Ian.C.Devalliere@who.eop.gov]; Mango, Paul (OS) [Paul.Mango@os.dhs.gov]; Williams, Michael B. EOP/WHO [Michael.B.Williams@who.eop.gov]; Troye, Olivia EOP/NSC [Olivia.T.Troye@who.eop.gov]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Marks, Peter [Peter.Marks@who.eop.gov]; Paddock, Christian EOP/WHO [Christian.Paddock@who.eop.gov]; Woodcock, Janet [Janet.Woodcock@fda.hhs.gov]; Williams, Michael B. EOP/WHO [Michael.B.Williams@who.eop.gov]; Mango, Paul (OS) [Paul.Mango@os.dhs.gov]; Woodcock, Janet [Janet.Woodcock@fda.hhs.gov]
Subject: [b] (6)
Attachments: [b] (6)
Location: WHSR JFK
Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM
Show Time As: Busy
Recurrence: (none)

*Please note the new start time of 1:45 PM due to conflicts in the WHSR*